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1. ACROMEGALY
Acromegaly is a rare disease caused by a growth hormone (GH) secreting 
pituitary adenoma and resulting in associated chronic elevated insulin-like growth 
factor I (IGF-I) levels, the mediator of most GH-activity (1). The disease presents 
either because of signs and symptoms due to GH hypersecretion, or mechanical 
compression by local space occupation or symptoms due to panhypopituitarism. 
Population based studies have reported that 9-17% of pituitary adenomas arose 
from somatotroph cells and cause excessive GH excretion (2-6), in 25% GH 
secreting pituitary adenomas co-secrete prolactin (7). Prevalence of acromegaly 
is between 40-70 cases per million inhabitants with an incidence rate of 3-4 new 
cases per million inhabitants a year (8-10). However, more recent studies report 
higher prevalence of the disease between 70-120 cases per million inhabitants and 
incidence rates between 7.7-11 new diagnosed acromegaly patients per million per 
year (2,3,11,12), indicating that acromegaly is likely of being underdiagnosed. Signs 
and symptoms develop slowly over time, causing a median delay in diagnosing the 
disease by 6 years (13). Acromegaly can be diagnosed at every age, however the 
majority is diagnosed between the age of 40-50 years (13).  
1.1. Anatomy 
The pituitary is located in the sella turcica below the hypothalamus, both structures 
are connected via the pituitary stalk. The optic chiasm (N. II) is situated between 
the hypothalamus and the pituitary. The nervus oculomotorius (III), trochlearis (IV) 
and abducens (VI) are also closely situated around the pituitary gland. Anatomical 
structures around the pituitary are depicted in Figure 1. The pituitary is the central 
endocrine gland, about the size of a pea, which coordinates (together with the 
hypothalamus and its releasing hormones) the peripheral endocrine glands via 
production of several hormones. The anterior lobe of the pituitary, connected to the 
hypothalamus via a capillary system, provides all hormones (GH, LH, FSH, TSH, ACTH 
and prolactin (PRL)) needed to control multiple processes in the human body such 
as growth, metabolism, control of the sex organs, the thyroid gland, the adrenals, 
physiology during pregnancy and nursing. The posterior lobe, connected to the 
hypothalamus via axons of hypothalamic neurons, is responsible for the secretion 
of oxytocin (important during childbirth) and vasopressin, which regulates blood 
pressure by reabsorption of water by the kidneys. The pituitary is highly vascularized 
by a portal system, which releases the hormones in the circulatory system. The 
central nervous system is separated from the circulatory system by the blood-brain 
barrier (BBB). However, the pituitary and many areas of the hypothalamus lack a 
BBB (14). 
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1.2. Growth hormone
GH promotes (bone/muscle) growth and influences metabolism which includes 
processes such as promoting protein synthesis, cell proliferation, gluconeogenesis, 
lipolysis and inhibition of glycogen storage and apoptosis. GH stimulates synthesis 
of IGF-I in peripheral tissues, predominantly in the liver. Many (but not all) effects 
of GH on peripheral tissues are physiologically mediated by IGF-I (15-17). Several 
studies have shown that the GH-IGF-I axis plays an important role during processes 
as longevity and ageing (18). It is hard to address the individual effects of GH and 
IGF-I in psychological conditions at the tissue level. What we know is that IGF-I 
and GH are both strong growth promoters as described previously. However, GH 
possesses anti-insulin or diabetogenic activity (19). On the other hand, insulin and 
IGF-I have similar actions, this clearly demonstrates that GH and IGF-I also exhibit 
different physiological actions. 
Once secreted and excreted by somatotroph cells in the pituitary, GH is entering 
the circulatory system by pulsatile-release. GH is released, particular, during stress, 
exercise and sleep. GH and IGF-I levels are high during adolescence, elevated during 
pregnancy and decline trough adult life. The IGF-I upper limit of normal, therefore, is 
age and sex dependent, which has to be taken into account during interpreting IGF-I 
values (20). GH-release is controlled by growth hormone releasing hormone (GHrH) 
which stimulates GH secretion/release, while endogenous somatotropin releasing-
Figure 1. A microadenoma in the pituitary 
Coronal cross-section of the head at the level of the pituitary gland depicting its relationship to the unharmed 
surrounded anatomy such as the optic chiasm above, the sphenoid sinus below, and the cavernous sinuses. 
This Figure is printed with permission from Mayfield Clinic.
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inhibiting factor (SRIF, also known as somatostatin) suppresses its release, both 
hormones are derived from the hypothalamus (21). Ghrelin, a hormone produced 
by the stomach, also promotes secretion of GH by the pituitary, and is influenced 
by food-intake (22). Additionally, negative feedback is also promoted by GH itself at 
the level of the hypothalamus. IGF-I has a negative feedback loop at the level of the 
hypothalamus and the pituitary, depicted in Figure 2. 
The binding of GH to its receptor stimulates Janus kinase 2 (JAK2) in signaling 
signal transducers and activators of transcription (STATs) to dimerize. The dimerized 
STATs translocate to the nucleus to regulate transcription of GH-target genes (23). 
A GH receptor (GHR) polymorphism common in the general population, which 
lacks exon 3 (d3-GHR), lead to greater stimulation of the intracellular JAK2-STAT5 
pathway in response to GH, and therefore results in increased transcription of these 
target genes. This enhanced signal transduction via the d3-GHR was first shown in 
vitro by transfection experiments (24). Thereafter, clinical studies were performed 
in GH deficient children and acromegaly patients. More about this topic is written 
in the outlines of this thesis, chapter 4 and 5. 
1.3 Pathophysiology of acromegaly
Acromegaly develops when somatotroph cells proliferate and together form a 
benign monoclonal adenoma, which hypersecrete GH that is released to the 
peripheral circulation. Based on the largest diameter of the adenoma on a magnetic 
resonance imaging (MRI), adenomas are subdivided in microadenomas (<1 cm) 
and macroadenomas (≥1 cm). The majority (78%) of the GH-secreting pituitary 
adenomas are macroadenomas (13). In chapter 2 of this thesis (Figure 2), the MRIs 
depict macroadenomas. Acromegaly is almost exclusively caused by a GH-secreting 
pituitary adenoma, however very rare acromegaly cases are described caused by 
extra-pituitary hypersecretion of GH in an ectopic pancreatic islet-cell tumor or 
non-Hodgkin’s lymphoma (25,26). Excessive production of GHrH could also induce 
acromegaly, via a central hypothalamic tumor or a peripheral neuroendocrine tumor 
mainly from pancreatic or bronchial origin (27). The vast majority of the GH-secreting 
pituitary adenomas occur sporadically, although reports are increasingly published 
about hereditary acromegaly cases including Multiple Endocrine Neoplasia 1, Carney 
complex, and McCune-Albright syndrome (28). Familial acromegaly without other 
syndromic features have also been described in literature. The majority (one fifth) of 
these familial cases show a mutation in the Aryl Hydrocarbon Receptor Interacting 
Protein (AIP) gene (29). Recently, a rare syndrome called X-linked acrogigantism 
(X-LAG) is discovered, which causes acromegaly in young children (30). 
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Figure 2. Feedback system of the GH-IGF-I axis 
Physiology of the GH-IGF-I axis by the hypothalamus, pituitary and the peripheral tissues, such as muscle, liver, 
bone and white adipose tissue. Somatostatin in this Figure is the same as endogenous somatotropin releasing-
inhibiting factor (SRIF).
GHrH: growth hormone releasing hormone, GH: growth hormone, IGF-I: insulin-like growth factor I. 
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1.4 Symptoms, co-morbidities and mortality 
Hypersecretion of GH and the associated elevated IGF-I levels result in increased 
morbidity and mortality (1). Symptoms associated with acromegaly are either 
caused by the GH/IGF-I hypersecretion itself and/or due to panhypopituitarism and/
or local tumor mass effects. Prolonged exposure to increased GH and IGF-I levels 
can cause an acromegalic phenotype. The disease is characterized by excessive 
skeletal growth, soft tissue enlargement and multiple other comorbidities, listed in 
Table 1 (1). Some GH-secreting pituitary adenomas cause serious symptoms, while 
others slowly cause non-specific complains or even remain symptomless and are 
diagnosed incidentally. Gigantism only arises in young acromegaly patients before 
fusion of epiphyseal growth plates of the bone. Mortality rates in acromegaly 
patients are approximately two to three times higher compared with age- and 
sex-matched controls (31), and are depending on how well GH/IGF-I levels are 
controlled. Cardiovascular, cerebrovascular and respiratory diseases are the major 
causes of death in acromegaly patients (31). 
  
1.5. Diagnosis 
The cornerstone of diagnosing acromegaly consists of IGF-I levels above the age-
adjusted normal value, and an insufficient GH suppression during oral glucose 
loading (32), both measurements depend on the upper limit of normal for the 
locally used assay. These biochemical measurements should be done in response to 
clinical parameters such as the patient’s (acromegalic) phenotype and/or coexisting 
comorbidities, described in Table 1. Following biochemical diagnosis of the disease, 
pituitary-imaging via an MRI scan is recommended in order to determine and 
visualize a GH-secreting adenoma and its size as well as its parasellar extent (32). 
2. TREATMENT MODALITIES
Treatment of acromegaly is aimed to reduce signs and symptoms, improve quality 
of life, and decrease morbidity and mortality. Depending on patient characteristics, 
pituitary adenoma size and localization, a treatment modality should be chosen. 
Available modalities are surgery, medical therapy, radiotherapy or a combination of 
these. Treatment mainly focuses on suppressing GH hypersecretion, normalization 
of IGF-I serum levels and tumor shrinkage or at least tumor size control (33). 
Treatment efficacy is monitored by GH/IGF-I serum levels and by an MRI to assess 
changes in tumor volume. Biochemical target goals are a random GH level of <1.0 g/l 
and an age-normalized serum IGF-I value, resulting in relief of signs and symptoms 
(32). Life expectancy in successfully treated acromegaly patients is approaching that 
of the general population (34,35). 
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2.1 Transsphenoidal adenectomy
Surgery is in general the first treatment modality and the only possibility to cure 
the disease, but is not always successful, as the majority of the patients have a 
macroadenoma (1). An urgent call for transsphenoidal adenectomy is visual field 
deficit, which needs direct pressure-relief of the tumor mass on the optic chiasm. 
The reported cure rates of transsphenoidal surgery vary widely, mainly depending 
on tumor size, tumor invasiveness and the experience of the neurosurgeon (36). 
Surgery of microadenomas (<1 cm in diameter) has an average cure rate of 78%, 
whereas with macroadenomas (≥1 cm in diameter) the average cure rate is 
≤50% (36). More recent data from daily practice was shown in a study with data 
gathered from the UK National Acromegaly Registry. This study reported cure rates 
between 20 and 40% (37). Complications of transsphenoidal surgery are meningitis, 
bleeding, spinal fluid leakage, diabetes insipidus and (partial) panhypopituitarism. 
Table 1. Symptoms and comorbidities of acromegaly
Symptoms: Comorbidities:
Fatigue Hypertension
Headache Hypertriglyceridemia 
Visual field defects Cardiomyopathy
Dysfunction cerebral nerves (sporadically) Diabetes mellitus type II
Snoring Sleeping apnea
Deepening of the voice Carpal tunnel syndrome
Excessive sweating Osteoarthrosis
Oily skin Colon polyps
Skin tags Organomegaly i.e.:
Thickness of soft tissue hands/feet Hepatomegaly
Arthropathy Splenomegaly
Facial changes i.e.: Dolichocolon
Frontal skull bossing Panhypopituitarism i.e.:
Enlargement of facial features Erectile dysfunction in men
Prognathism Menstrual cycle dysfunction in
womenMacrognathia
Diastema Secondary thyroid deficiency
Macroglossia Secondary adrenal deficiency
Chapter 1
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Major events as visual field loss and carotid artery injury occur, albeit rarely (38,39). 
Curation is determined by an oral glucose tolerance test with a GH level <1 g/l 
(32). The recurrence rate of patients who initially were cured after transsphenoidal 
surgery is 19%, in which the vast majority presents disease recurrence within the 
first 5 years of follow-up (40). 
2.2 Radiotherapy
First-line treatment in acromegaly remains surgery and/or medical treatment, but 
when biochemical control is not possible and the patient has an aggressive adenoma 
radiotherapy could be proposed. Conventional radiotherapy is administered in 20-
30 fractions, eventually resulting in a total dose of 45-50 Gray (41). The GH-decline 
during the first two years after radiotherapy are ranging between 50-70% of the 
initial value, thereafter characterized by a prolonged slow GH decrease over 10-
20 years (41). Disadvantages of radiotherapy are the delayed time to control the 
disease compared to surgery and medical treatment, apart from the unneglectable 
risk of adverse events. Hypopituitarism occurs in the vast majority over time (42-
44). Other severe side effects are rare such as visual field deficits, radiation-induced 
cerebral tumors and vascular injuries (41), but have to be taken into account when 
considering this treatment modality. A relatively new irradiation technique is 
the gamma-knife, in which a more precise stereotactically mapped region could 
be administered by one single high dose of radiotherapy, also called stereotactic 
radiosurgery. This results in a lower dose on the healthy surrounding tissue and 
probably a lower incidence of adverse events. Stereotactical radiotherapy can 
be used in the same cases as conventional radiotherapy, although this technique 
requires a well-defined target adenoma, restraining its applicability. In addition, it 
must be taken into account that especially long-term safety data are lacking, and 
final conclusions cannot be drawn about these new irradiation techniques. 
2.3 Medical treatment  
2.3.1 Somatostatin analogues
GH-secreting pituitary adenomas express different subtypes of somatostatin 
receptors (SSTRs), predominantly SSTR subtypes 2 and 5 (45), these receptors play 
a major role in reducing GH and IGF-I levels. Long-acting somatostatin analogues 
(LA-SSAs) have high-binding affinity for SSTR2 and a moderate affinity for SSTR5. 
According to current guidelines, LA-SSAs are considered to be the first line medical 
treatment modality after unsuccessful surgery as well as primary treatment option 
in selected cases (32,33). Meta-analyses of clinical trials showed that LA-SSAs 
alone normalize GH and IGF-I levels in about half of the patients (46). However, 
due to selection bias this efficacy rate is probably an overestimation. In unselected 
15
General introduction
1treatment-naive patients an LA-SSA efficacy rate of 40% seems to be more common (47). An additional advantage of LA-SSA treatment is its capacity to reduce tumor 
volume. Recent prospective multicenter clinical trial observed tumor shrinkage 
in 63% of primary treated patients with 120 mg Lanreotide Autogel administered 
every 28 days (48). Tumor shrinkage was defined as clinically significant when 
≥20% tumor volume reduction was observed after 48 weeks of Lanreotide Autogel 
administration. No differences between Lanreotide SR and Octreotide LAR were 
observed regarding tumor shrinkage and normalization of IGF-I levels (49). Most 
side effects of LA-SSA-treatment are transient and of mild-to-moderate intensity, 
most commonly are injection-site discomfort/erythema and gastrointestinal 
symptoms such as nausea, vomiting, abdominal pain, biliary sludge or gallstones 
and diarrhea (50).
2.3.2 Dopamine agonists
Dopamine agonists (DAs) suppress GH hypersecretion in patients with acromegaly, 
not only in mixed PRL-GH-secreting pituitary adenomas but also on pure GH-
secreting pituitary adenomas (51-54). Cabergoline (CAB) is more effective and 
tolerated than bromocriptine, however less effective than LA-SSA, but cheaper 
and can be taken orally (55). A meta-analysis concluded that CAB as monotherapy 
normalizes IGF-I levels in one third of patients with acromegaly (55). When CAB was 
added to LA-SSA, which fails to control acromegaly as monotherapy, IGF-I levels 
normalized in about half of the patients (55). An advantage of DAs is that the drug 
is given orally in 1-3 weekly doses. Side effects are headache, dizziness and nausea. 
2.3.3 Pegvisomant 
Pegvisomant (PEGV) is a PEGylated recombinant analogue of GH and thereby 
functions as a GH antagonist. The molecule contains, similar like human GH, 
191 amino acids and harbors several amino acid changes with respect to human 
GH. Most significantly is the replacement of glycine by lysine at the position 120 
corresponding with binding site 2 of the drug, which leads to a lack of function 
of GH signal transduction (56,57), depicted by Figure 3. Additional mutations 
corresponding with binding site 1 increase the affinity of PEGV with the GHR. 
Besides these changes, the drug is modified by the addition of five polyethylene-
glycol polymer chains, which is performed to prolong the half-life of the molecule, 
and improves its clinical applicability (58). PEGV is a competitive blocker of the GHR, 
pharmacology dictates that in principle it should be possible to control IGF-I levels in 
virtually every patient with acromegaly, provided that the appropriate PEGV dose is 
used (59). Monotherapy of PEGV requires a high cumulative weekly dose of around 
130-140 mg to achieve a 89-97% normalization rate (59,60). 
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PEGV-treatment is generally well tolerated and is increasingly considered to be 
safe (61,62). More data is available where it comes to medical treatment of LA-SSA 
and DA, as PEGV has only been commercially available since 2003. Lipohypertrophy 
(3-14%) and hepatotoxicity (4-14%) are the most frequently reported adverse events 
during long-term PEGV monotherapy (63-66). Lipohypertrophy is an increased 
subcutaneous fat deposition around the injection sites of PEGV and appeared to 
be reversible by a more frequent rotation of the injection-site in the majority of the 
patients (64). It is suggested that the blockade of GHRs causes unopposed insulin 
effects and, therefore, promotes lipogenesis (67). The PEGV-induced hepatocellular 
elevated enzymes are usually mild and self-limiting (63,64). These transient elevated 
transaminases (TET) are defined as alanine transaminase (ALT) and/or aspartate 
transaminase (AST) levels of more than three times the upper limit of normal. 
As PEGV systemically blocks GHRs, and does not prevent tumor growth of the 
pituitary adenoma, concerns were previously raised whether PEGV might induce 
growth of the pituitary adenoma. Despite the fact that in a few cases an increase 
in tumor size during PEGV therapy was reported, data indicates that its incidence 
is extremely rare and these concerns are conceived as being unfounded (61,68). 
However, more long-term data is needed to confirm these findings. 
Figure 3. Binding site 1 and 2 of growth hormone and pegvisomant 
A) Illustrative picture of growth hormone binding to its dimerized receptor resulting in activation of a downstream 
signal transduction, which eventually will lead to transcription of GH-target genes. 
B) Illustrative picture of pegvisomant binding to the dimerized GH receptor. Binding site 1 of pegvisomant improve 
binding to the GH receptor. Binding site 2 contains the replacement of glycine by lysine at the position 120 
substitution that blocks the conformational change of the GH receptor and thereby inhibits downstream signal 
transduction.
A B
site 1 site 2
PegvisomantGrowthhormone
Extracellular
space
 Cell membrane
Intracellular
space
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13. COMBINATION TREATMENT OF LA-SSA AND PEGV
An attractive way to biochemically control disease activity in acromegaly patients 
who are uncontrolled by LA-SSA treatment alone, is to add PEGV because of the 
two different modes of action. LA-SSA reduces hypersecretion of GH by binding to 
SSTRs on the cell surface of the pituitary adenoma and has the capacity to reduce 
tumor volume. While, PEGV acts by reducing excessive GH actions in peripheral 
tissues and blocks the increased production of IGF-I by the liver. LA-SSA combined 
with PEGV is suitable for adjuvant treatment and primary medical treatment. 
However, in the current guidelines combination treatment is only recommended 
for acromegaly patients who are not controlled by LA-SSA monotherapy (33). LA-
SSA in combination with PEGV as pre-surgical treatment to reduce morbidity is very 
questionable, as there is no supporting data yet.
3.1 Efficacy and dose reduction
As stated in the paragraph about PEGV monotherapy, PEGV in principle should be 
able to biochemically control disease activity, provided that the appropriate PEGV 
dose is used. Several studies have reported similar normalization rates of LA-SSA 
combined with PEGV, ranging between 67-100% and cumulative weekly PEGV 
doses range between 60-140 mg depending on disease activity, depicted in Table 
2 (63,66,69-71). Co-administration of the highest dose of LA-SSA on top of PEGV 
monotherapy appears to reduce the necessary mean PEGV dose by 50% (70), 
although with a high individual variability (72). Analysis of eight patients whose 
mean IGF-I levels were similar during PEGV monotherapy and on at least one 
moment during the co-administration of LA-SSA, showed that these patients were 
able to reduce their PEGV dose from 131.3 +/-36.2 to 62.5 +/-16.7  mg/week (70). 
Besides the LA-SSA-induced decrease in GH secretion of the adenoma, LA-SSAs 
also have direct and indirect effects that result in a GH-independent decrease of 
the IGF-I production (73,74), which will be further explained in the next paragraph. 
Moreover, a Danish study reported that PEGV serum levels increase by 20% when 
combined with LA-SSA (75). PEGV dose reduction during combination treatment 
might improve cost-effectiveness of medical treatment in acromegaly and may 
reduce injection frequency for patients. However, there are no direct studies 
comparing cost-effectiveness of the median required weekly PEGV dose during 
mono- and combination treatment.
3.2 Quality of life
Physicians tend to be mainly focused on biochemical parameters as GH and IGF-I 
levels during treatment of acromegaly. These parameters are definitely linked to 
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a better outcome and a lower risk of morbidity and mortality (35,76). However, 
normalized serum GH and IGF-I levels do not necessarily result in complete 
resolution of signs and symptoms (77,78). Neggers et al. reported on the results of 
a prospective, double blind, placebo controlled crossover study and demonstrated 
improved quality of life (QoL) in patients using LA-SSA combined with low-dose 
PEGV (78). QoL was assessed by two acromegaly specific QoL-questionnaires, the 
AcroQoL and the PASQ. Improved QoL was observed without significant changes 
in IGF-I levels after addition of PEGV to LA-SSA therapy in patients with normalized 
IGF-I levels during monotherapy of LA-SSA. An explanation for the observed 
improvement in QoL by the addition of low-dose PEGV could be a persistent 
systemic acromegaly disease activity during monotherapy of LA-SSA that has been 
hypothesized and was called ‘extra-hepatic acromegaly’ (79). LA-SSA treatment 
Table 2. Summary of studies reporting on combination treatment
First author, 
year, (REF) Design Aim of study
N. of 
patients
Disease 
control 
PEGV 
dose
Duration 
study*
Van der Lely 
2001 (71) Case report IGF-I normalization 1 100 280 18
Neggers
2007 (69) 
Retrospective 
observational 
study
IGF-I normalization 
and AEs 32 100 60 35**
Trainer 
2009 (66)
Randomized 
controlled 
trial
Primary: AEs, 
secondary: IGF-I 
normalization
29 73 105 9
Van der Lely 
2011 (70)
Prospective 
observational 
study
IGF-I normalization 
and AEs 57 79 60 7
Bianchi 
2013 (63)
Retrospective 
observational 
study
IGF-I normalization 
and AEs 27 67 140 30**
Summary of studies reporting on LA-SSA combined with PEGV (mg/week) and the percentage of disease control 
(%) (normalization of IGF-I levels) and the required PEGV dose in order to control IGF-I levels. The ACROSTUDYTM is 
not included in this table as it includes patients with monotherapy of PEGV and various other medical combinations 
with PEGV. 
REF: reference, LA-SSA: long-acting somatostatin analogues, PEGV: pegvisomant, IGF-I: insulin-like growth factor I, 
AEs: adverse events.
* in months
** median
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1selectively decreases hepatic IGF-I production by approximatly 20% via direct and indirect mechanisms (73,74,80). This might lead to an overestimation of the efficacy 
of LA-SSAs to normalize IGF-I via a reduction in the pathological GH secretion 
because of this GH-independent reduction of IGF-I levels. Therefore, GH actions 
on extra-hepatic tissues can remain elevated despite normalization of serum IGF-I 
levels. LA-SSA reduces portal insulin levels which only decreases hepatic GHR 
expression (80). This results in a relatively hyper-GH-sensitive state of the other 
tissues. Patients report these still excessive GH actions on non-hepatic tissues such 
as edema, fatigue and headaches comparable to the side-effects of high-dose GH 
replacement therapy in GH deficient subjects. A clinical example is a Danish study 
which observed, despite similarly normalized IGF-I levels, that LA-SSA treatment 
compared with neurosurgery alone was associated with less suppressed GH levels 
and less symptom relief (81). Blocking non-hepatic GH actions by low-dose PEGV 
could therefore be useful in treating this ‘extra-hepatic acromegaly’ (79). Moreover, 
PEGV has also been shown to improve insulin resistance by several mechanisms 
(82-87), since these are beneficial in the presence of LA-SSAs, which are known to 
reduce insulin secretion (88,89).
3.3 Safety aspects 
During combination treatment incidence of lipohypertrophy at the injection 
site occurred in 3% of the patients (63,90). TET >3x the upper limit of normal seems 
to occur more frequently during the combination of LA-SSA and PEGV, which was 
observed in 11-15% of the subjects in several studies (63,66,90). To the best of our 
knowledge, no study has reported a factor that predicts the elevated transaminases 
during PEGV-treatment, except for one Spanish study that observed that carriers 
of UGT1A1*28 polymorphism of Gilberts syndrome seem to have a higher risk 
of developing PEGV-induced TET (91). Another safety aspect is the stability of 
tumor volume during PEGV treatment. Several studies reported that combination 
treatment and PEGV monotherapy have similar incidence rates of increased tumor 
volume cases (63,66,90). In a significant number of patients treated with LA-SSA 
combined with PEGV, the tumor size even decreased (69,90). 
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OUTLINES OF THIS THESIS
The combination treatment of LA-SSA and PEGV is in the previous paragraphs 
described as an attractive treatment modality for severe acromegaly patients, in 
which transsphenoidal surgery and/or medical treatment were unsuccessful in 
controlling IGF-I levels. But the combination treatment may also be an option for 
less severe acromegaly patients regarding QoL-reasons, as stated in paragraph 3.2 
of this introduction. The use of PEGV alone or in combination with LA-SSA as a 
treatment option in acromegaly is increasing, although the drug has only been on 
the market since 2003. Therefore, long-term data on efficacy rates and safety issues 
is needed and highly important. This thesis focusses on the efficacy and safety of 
the combination treatment during the last decade. The Erasmus University Medical 
Center in Rotterdam currently has the largest single center cohort of acromegaly 
patients using the combination treatment of LA-SSA and PEGV. These acromegaly 
patients systematically visit our outpatient clinic, including standard performing 
of multiple measurements, and therefore is particularly suitable for observational 
research in a rare disease such as acromegaly. Apart from this rather descriptive 
clinical approach we focus on the question why some patients needed the addition 
of PEGV to LA-SSA in order to control their IGF-I levels. Therefore, we observed 
the SSTR expression on adenomas of patients using the combination treatment. 
The expression of SSTR2 on the GH-secreting pituitary adenoma cell membrane is 
significantly and positively correlated with the efficacy of LA-SSAs in suppressing GH 
and IGF-I levels in vitro, and is also associated with IGF-I normalization in acromegaly 
patients (92-96). A reduced expression of SSTR2 and/or SSTR5 in untreated GH-
secreting pituitary adenomas, might necessitate combination treatment because of 
(partial) resistance to LA-SSA treatment. Thereafter, we focus on the prediction of 
PEGV dosing, since PEGV doses vary widely among acromegaly patients, depending 
on disease activity and individual response to the drug (69,75,97,98). These 
individual differences might be attributed to a genetic factor, like the common GHR 
polymorphism lacking exon 3. In this thesis we aim to address the clinically-relevant 
question: Do clinicians have to take d3-GHR genotyping into account during PEGV 
dosing? To finish this thesis, a prediction model was created, incorporating several 
patient-, biochemical- and adenoma characteristics collected during the last years, 
in order to investigate whether we can individually predict the PEGV dose in addition 
to LA-SSA needed to control IGF-I levels. Hereafter, the chapters of this thesis are 
pointed out more in detail.
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1CHAPTER 2 
The combination treatment of LA-SSA and PEGV is used for almost a decade in the 
Rotterdam cohort, what can we tell about its efficacy parameters and safety profile? 
Efficacy parameters that are addressed in this chapter are; 1) normalization of IGF-I 
levels over time; 2) the required PEGV dose in order to normalize IGF-I levels and; 3) 
control of tumor volume. Safety aspects are focused on the two main side-effects of 
the combination treatment: lipohypertrophy and elevated transaminases. We also 
address whether carriers of the UGT1A1*28 polymorphism, causing the Gilbert’s 
syndrome, have a higher risk of developing PEGV-induced elevated transaminases.
CHAPTER 3
The expression of SSTR2 and SSTR5 on GH-secreting pituitary adenomas from 
acromegaly patients treated with PEGV (together with LA-SSAs) before surgery is 
currently unknown. In this chapter we address the following hypotheses; 1) various 
medical pre-treatment modalities can differently affect the SSTR2 and SSTR5 
expression on GH-secreting pituitary adenomas and; 2) the SSTR expression could 
affects postsurgical PEGV dosing in combination with LA-SSA. 
CHAPTER 4 AND 5  
The differences in individual PEGV dosing might be attributed to the d3-GHR 
polymorphism, which enhances signal transduction of GH by its receptor. Two main 
outcome parameters were used to address this hypothesis; 1) the lowest IGF-I level 
during PEGV-treatment and; 2) the required PEGV-dose to achieve the lowest IGF-I 
level. This was done in the Rotterdam combination treatment cohort (chapter 4), 
and subsequently pooled in a meta-analysis together with several other European 
acromegaly cohorts using PEGV (chapter 5).
CHAPTER 6  
The PEGV dose necessary to achieve disease control differs significantly between 
individual acromegaly patients. In this chapter, we identify predictors of PEGV 
dosing during PEGV monotherapy and in combination with LA-SSA. These predictors 
are used for the development of a multivariate regression model in order to predict 
the required PEGV dose by patient, biochemical and adenoma characteristics. This 
study is not designed to predict PEGV-overdosing, but should be considered as a 
useful clinical tool during PEGV dose titration. 
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ABSTRACT
Background: Treatment for acromegaly patients with long-acting somatostatin 
analogues (LA-SSA) often does not result in complete normalization of insulin-
like growth factor I (IGF-I). Addition of pegvisomant (PEGV), a GH receptor 
antagonist, could improve this; however, the literature has not described long-
term follow-up.
Objective: To assess long-term efficacy and safety of this combined treatment 
in the largest current single-center cohort of patients, from 2004-2013.
Design: Acromegaly patients were treated for at least 6 months with a high-
dose LA-SSA. To patients with persistently elevated IGF-I levels (>1.2 x the 
upper limit of normal (ULN)) or poor quality of life, PEGV was added as one 
weekly injection.
Results: The patients (n=141) were treated with PEGV and LA-SSA for a median 
period of 4.9 years [range: 0.5 – 9.2]. Efficacy, defined as the lowest measured 
IGF-I level during treatment, was 97.0%. The median PEGV dose to achieve 
this efficacy was 80 mg/week [interquartile range: 60 – 12]. Combination 
treatment-related adverse events were recorded in 26 subjects (18.4%). 
Pituitary tumor size increase was observed in one patient. Injection-site 
reactions were observed in four subjects. In 19 patients (13.5%), transiently 
elevated liver transaminases of more than three times the ULN were observed, 
of which 83% occurred within the first year of combination treatment. Eight 
patients died, at a mean age of 71 years; none of them were considered 
treatment-related.
Conclusions: The combination treatment with LA-SSAs and PEGV was effective 
in 97% of the patients, it appears to be a safe medical treatment and it reduces 
the required dose of PEGV.
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INTRODUCTION
Acromegaly is a rare disease that is almost exclusively caused by a growth hormone 
(GH)-secreting pituitary tumor that results in signs and symptoms and reduced 
life expectancy (1). Treatment is focused on improving life expectancy, reducing 
signs and symptoms, and thereby increasing the patient’s quality of life (QoL). 
These main objectives are considered to be accomplished when serum levels of 
IGF-I and GH are normalized. This is achieved in less than 60% of patients after 
surgery (2,3). Normalization after medical treatment occurs in 30% to over 90% of 
patients (4-7). Current medical treatment modalities focus on the normalization 
of IGF-I by targeting pituitary GH production or peripheral GH actions. In 1985, 
studies demonstrated that GH secretion by GH-secreting pituitary tumors could be 
inhibited by somatostatin analogues (8). Thereafter, many studies on the efficacy of 
LA-SSA to control pathological GH secretion reported an average normalization of 
IGF-I and GH (<2.5 µg/l) in 44% of patients treated with LA-SSAs (4).
More recently, PEGV was introduced (9). This drug is a genetically modified 
analogue of human GH; because it binds to but does not activate the GH receptor, 
it acts as a competitive GH receptor antagonist (9). The first report on its long-term 
efficacy and safety was published early this century (10). PEGV was approved in Europe 
in 2002, followed by the United States in 2003. Although PEGV clinical trials found 
efficacy rates of 90% (6,9,10), these were not confirmed by observational studies 
such as the ACROSTUDYTM and the German pegvisomant observational Study (7,11-
13). Nevertheless, phase IV non-interventional studies such as the ACROSTUDYTM 
are designed to gather additional medical information complementary to placebo-
controlled, randomized clinical trials (7,14), such as rare adverse events and atypical 
treatment reactions (15). Therefore, the ACROSTUDYTM is less suitable to assess 
efficacy. The adverse events reported during PEGV treatment seem relatively mild, 
the most frequent being transient elevated transaminases (TETs), followed by local 
lipohypertrophy at the injection site (6,7,16,17).
In 2005, the first study on the combined treatment of acromegaly with weekly 
PEGV and LA-SSAs reported high efficacy, as well as possible cost reductions due 
to the lower median required PEGV dose (18). Thereafter, long-term data on 
efficacy and safety showed an efficacy rate of 90% and the possibility of lowering 
the necessary dose of PEGV when combined with LA-SSAs (16,17,19). Combined 
treatment was also able to improve QoL in LA-SSA-controlled patients (20).
Because PEGV competitively blocks the GH receptors in all peripheral tissues, 
it does not prevent tumor growth of the pituitary adenoma (6). In previous 
studies with LA-SSAs and PEGV, tumor size increase was not observed, and in a 
significant number of patients (19%) the tumor size even decreased (16, 17). 
Although combination treatment and PEGV monotherapy appear to have similar 
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efficacies (6,7,16), side effects such as TETs seem to occur more frequently during 
combination therapy (7). No studies could detect any factor that predicts elevations 
of the liver enzyme alanine aminotransferase (ALT), except one that reported that 
carriers of UGT1A1*28 polymorphism of Gilbert’s syndrome seem to have a higher 
risk of developing PEGV-induced liver injury (21).
Combination therapy might be an attractive option for treating acromegaly, 
but the long-term effects outside of the clinical studies such as the ACROSTUDYTM 
remain uncertain. Here we report on the long-term efficacy and safety of combined 
treatment with PEGV and high-dose LA-SSA treatment for almost a decade in a 
single-center tertiary referral hospital.
METHODS
Data was collected from all consecutive patients who were treated with LA-SSA for 
at least 6 months (n=141) at our Pituitary Center Rotterdam between 2004 and 
2013. Permission from the Institutional Review Board of the Erasmus Medical 
Center Rotterdam was obtained for all the substudies involved, and all patients 
gave their written informed consent. All patients were initially started on LA-SSA 
monotherapy in a stable dose, after which PEGV was added by a weekly injection.
Results were derived from two data sets. The first contains data from 
acromegaly patients (n=112) with elevated IGF-I levels (>1.2 xULN), after at least 6 
months of high-dose LA-SSAs (Sandostatin LAR 30 mg or Lanreotide Autogel 120 mg 
every 28 days). This group is described in this article as the “uncontrolled group.” 
Acromegaly patients in the second group (n=29) were co-treated with PEGV to 
improve the QoL as add-on-therapy on top of LA-SSAs, which already had normalized 
their IGF-I levels. They are designated as the “QoL group.” In our analyses, this QoL 
group was only used for the assessment of safety aspects. 
In the uncontrolled group, 27 acromegaly patients started with 25 mg PEGV 
weekly as co-treatment, whereas another 18 started with 40 mg PEGV weekly, 
and the last 67 patients started with a variable dose of PEGV weekly, guided by 
their baseline IGF-I. The variable starting dose was based on one of our previous 
reports (17) (see Figure 2). The formula to calculate the PEGV dose is: 4 + (IGF-I 
z-score during treatment with highdose LA-SSA*16), which was derived from 
a method described previously (17). This formula can only be used when IGF-I 
is elevated after a period of at least 6 months of LA-SSA treatment. Intervals of 
dose adaptations were 6-8 weeks, until a controlled IGF-I level was achieved on 
two consecutive occasions. The subjects then visited our outpatient clinic every 
16 weeks. For the QoL group, methods were described previously (16). When the 
once-weekly PEGV dose exceeded 80 mg per injection, patients divided the dosage 
into two weekly injections. With weekly doses over 200 mg, subjects changed 
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administration intervals into daily injections or five injections per week. At each 
visit to our outpatient clinic, efficacy and safety parameters were assessed.
The efficacy parameter IGF-I was assessed using the Immulite 2000 assay 
(DPC Biermann GmbH/Siemens), a solid-phase, enzyme-labeled, chemiluminescent 
immunometric assay with an intra-assay variability of 2-5%, and an inter-assay 
variability of 3-7%. The IGF-I age- and sex-adjusted reference ranges were used 
from an article by Elmlinger et al (22). PEGV serum levels were assessed in Aarhus, 
as described in a previous report (23).
Safety assessments included: electrocardiogram, serum concentrations 
of ALT, aspartate aminotransferase (AST), alkaline phosphatase (Alk phos), 
 γ-glutamyltranspeptidase (γ-GT), total bilirubin (bili), and lactate dehydrogenase. 
Magnetic resonance imaging (MRI) assessed changes in pituitary tumor volume at 
least annually. Decrease of tumor size was determined by one radiologist, who was 
blinded for the outcome. Decrease was defined as more than a 20% reduction of 
the largest diameter of the tumor during combination treatment compared with 
the largest diameter of the last MRI before the addition of PEGV. 
Genomic DNA was isolated from peripheral blood leukocytes. A 324 11bp 
fragment of the UGT1A1 gene promoter, which includes the TATA box, was 
PCR-amplified by using forward (5’-GAGTATGAAATTCCAGCCAG-3’) and reverse 
(5’-GGATCAACAGTATCTTCCC-3’) primers and platinum Taq Mix (invitrogen). Cycle 
conditions were 95°C for 5 minutes, followed by 35 cycles of 95°C for 30 seconds, 
60°C for 30 seconds, 72°C for 30 seconds, and 72°C for 7 minutes. The results were 
ascertained on the 3500 Genetic analyzer (Applied Biosystems). Gilbert’s syndrome 
was characterized by an additional TA repeat in the TATA sequence of the UGT1A1 
promoter region, i.e., A(TA)7 TAA instead of A(TA)6 TAA. Results were first published 
by Bosma et al (24).
Somatostatin receptor type 2 (SSTR2) mRNA expression was performed in 
one patient’s tumor sample, described in the results. Real-time quantitative PCR 
was performed as previously published (25). Sequences and concentrations of 
the SSTR2 primerprobe pairs and of the hypoxanthine phosphoribosyltransferase 
(HPRT) are described in the same previously published report (25). We used the 
ABI Prism 7900 Sequence Detection System (Applied Biosystems) to measure the 
samples and compared it with the housekeeping gene HPRT.
Statistical methods
Data are expressed as median [interquartile range [IQR]] unless otherwise specified. 
Differences between two or more independent subgroups were analyzed using the 
Mann-Whitney U test and the one-way ANOVA (multiple comparison), respectively.
Paired data were analyzed with the Wilcoxons signed rank test. Nominal variables 
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were analyzed using the χ2-test. P-values <0.05 (two-tailed) are considered 
statistically significant. Statistical analyses were performed with SPSS version 20 and 
GraphPad Prism version 6 for Windows (IBM SPSS Statistics for Windows, Armonk, 
NY, USA and GraphPad Software, San Diego, CA, USA).
RESULTS 
Efficacy 
Patient characteristics are depicted in Table 1. The median duration of PEGV 
treatment was 4.9 years [range: 0.5 – 9.2]. Normalization of IGF-I for age and sex, 
defined as the lowest IGF-I during treatment, was observed in 97.3% of the subjects. 
The absolute median IGF-I level was 18.0 nmol/l [IQR: 13.4 – 23.6], 0.56 xULN of 
IGF-I [IQR: 0.43 – 0.74], or expressed as SD score (SDS), -0.16 [IQR: -1.27 – 0.90]. 
All patients had a lowest IGF-I level below 1.2 xULN. The median weekly PEGV dose 
to achieve these lowest IGF-I levels was 80 mg [IQR: 60 – 120]. The IGF-I level at 
Sex – male % 58.0
Age – years 48.2 [39.0 – 59.1]
Tumor volume – macro % 81.3
Diabetes mellitus II – % 36.9
Gilbert’s polymorphism 
    Heterozygous – %                                       43.1
    Homozygous – % 11.5
Previous therapy
    Surgery – % 30.4
    Radiotherapy – % 0.9
    Surgery and Radiotherapy – % 10.7
IGF-I at start of PEGV – nmol/l 66.5 [46.4 – 87.9]
IGF-I xULN at start of PEGV 1.89 [1.48 – 2.56]
IGF-I expressed as SDS at start of PEGV 8.02 [5.10 – 11.13]
Table 1. Patient characteristics
Data are expressed as median [IQR] or percentage.
IGF-I: insulin-like growth factor I, PEGV: pegvisomant, ULN: upper limit of normal, SDS: standard deviation score.
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the last visit was 26.0 nmol/l [IQR: 20.0 – 34.4], 0.85 xULN [IQR: 0.67 – 1.09], or 
expressed as SDS 1.50 [IQR: 0.49 – 2.84]. The median necessary dose of PEGV to 
achieve this IGF-I level was 80 mg/week [IQR: 60 – 130]. There was no significant 
difference between the PEGV dose during the lowest IGF-I and the PEGV dose at the 
last visit (p=0.106).
The weighted median control of IGF-I levels (1.2 xULN) over years 1 to 9 was 
89.7%, with a median PEGV dose of 73.8 mg/week. The median control of IGF-I 
(1.0 xULN) over years 1 to 9 was 78.0%. The annual results from years 1 to 9 of the 
median IGF-I and PEGV levels are depicted in Figure 1. In Supplemental Figure 1, the 
normalization rate during the first year and the necessary PEGV dose are depicted. 
Supplemental materials can be found at the end of this chapter. A clinical tool is 
depicted in Supplemental Figure 2. This Figure shows the required dose of PEGV 
that is necessary to normalize the IGF-I level. 
Normalization rate, expressed as the lowest IGF-I level, was not significantly 
different between patients with (95.0%) or without (98.6%) diabetes mellitus type 
II (DM) (p=0.588). The necessary dose to achieve this was identical for non-DM 
and DM (p=0.281). Normalization of IGF-I levels was achieved in 95.7% of patients 
who had undergone prior pituitary surgery, which was comparable to the outcome 
in patients receiving primary medical treatment (98.5%; p=0.604) and with no 
difference between the two groups in the PEGV dose (p=0.518). This was also the 
Figure 1. IGF-I serum levels <1.2 xULN years 1-9
Percentage of patients who ar normalized with an IGF-I <1.2 xULN and the median PEGV dose (gray line) are shown 
in this figure for every individual year during the 9 years of treatment. Cumulative numbers of the included patients 
at each treatment year are depicted at the bottom of every bar. All patients (n=112) were treated for at least one 
year, 17 patients were treated for the maximal 9 years of follow up.
IGF-I: insulin-like growth factor I, PEGV: pegvisomant, ULN: upper limit of normal.
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case when radiotherapy was excluded from the analysis (p=0.901).
No significant differences in normalization rate and PEGV dose necessary 
to control IGF-I were observed between sexes (p=0.997, p=0.225, respectively), 
microadenomas vs macroadenomas (p=0.711, p=0.809, respectively), or carriers vs 
non-carriers of Gilbert’s polymorphism (p=1.000, p=0.789, respectively).
In 11 patients, surgery was performed during combination therapy. In 
Supplemental Table 1, the reasons for surgery are depicted. The PEGV dose before 
operation was 120 mg [IQR: 80 – 160]. One patient was cured after transsphenoidal 
surgery (TSS). Six patients could discontinue PEGV and continued with a high dose 
of LA-SSAs after significant tumor debulking. The other five patients continued with 
80 mg [IQR: 80 – 100] PEGV weekly.
Safety 
Liver tests
ALT and AST were normal at baseline in all patients. TETs of more than 3 xULN 
were observed in 22 patients (15.6%; Table 2). All cases were transient without 
adaptation of PEGV dose or discontinuation, except for one patient with TET 26.1 
xULN, who was previously reported (26) and developed a second period of TET 2 
xULN after re-exposure to PEGV monotherapy. The development of TET was not 
influenced by the PEGV dose (p=0.803). Obstruction of the biliary tract could be 
an explanation for three of these cases, therefore in 19 patients (13.5%) TET could 
be linked to PEGV treatment. Re-exposure to PEGV after discontinuation resulted 
in a second period of TET >3 xULN in two patients during combination therapy. 
TET >3 xULN occurred after a median period of 5.2 months [IQR: 3.2 – 13.3] (see 
Supplemental Figure 3A). In a median period of 5.5 months [IQR: 3.0 – 14.0], TET 
normalized again (see Supplemental Figure 3B).
Gilbert’s polymorphism
Gilbert’s polymorphism (UGT1A1*28) was assessed in 131 (93%) of the 141 
patients. No blood could be obtained from 10 patients. UGT1A1*28 was observed 
in 71 (54.2%) of patients, 11.5% homozygous and 42.7% heterozygous. Of the 22 
TET cases, four (18.2%) were homozygous and eight (36.4%) were heterozygous. No 
association between UGT1A1*28 and TET was found in patients with heterozygous 
(p=1.000) or homozygous polymorphism (p=0.827). The same lack of association 
applied to heterozygous UGT1A1*28 compared to homozygous (p=0.752). Neither 
sex (p=0.393) nor DM (p=0.956) was associated with TET.
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Table 2. TET patients during pegvisomant treatment of acromegaly
Peak TET (xULN)
Patient 
number Sex
PEGV dose  
during TET 
(mg/week) Bili
Alk. 
phos. ɣ-GT AST ALT DM
Gilbert’s  
Polymorphism Clinical features
1 M 30 0.7 0.6 2 4.0 4.7 - Normal
2 M 300 - 1.0 1.8 5.0 5.5 - Normal
3 M 40 0.4 1.2 0.9 4.3 7.0 - Normal
4 M 160 0.4 1.2 1.8 4.6 6.5 + Normal
5 M 80 1.1 0.5 2 3.5 3.9 - Heterozygous
6 M 60 2.3 2.9 16.7 16.7 25.8 + Homozygous MRCP:  Cholecystolithiasis
7 M 60 0.6 0.8 1.8 2.4 3.6 - Heterozygous
8 M 40 5.3 0.9 5.1 4.9 8.0 - Homozygous Ultra-sound: Cholecystolithiasis
9 M 80 - 0.9 0.8 3.1 1.2 + Heterozygous
10 M 40 1.6 1.1 4.6 3.1 4.3 - ND
11 M 40 2.0 1.4 8.8 9.5 8.3 - Homozygous
12 M 60 0.9 1.2 4.8 6.3 13.2 - Normal
13 M 80 1.3 2.6 11.8 5.6 3.7 - Heterozygous Ultra-sound:  Cholecystolithiasis
14 M 60 1.3 1.3 6.9 13.7 26.1 + Heterozygous
15 F 80 0.8 0.8 1.5 2.9 4.5 + Normal
16 F 20 1.0 0.6 0.9 7.5 10.0 - Heterozygous
17 F 60 0.7 0.7 2.7 2.8 4.0 - Heterozygous
18 F 60 - - 3.9 - 4.6 - Homozygous
19 F 160 - 1.1 4.1 2.4 3.7 - Normal
20 F 20 - 0.9 2.3 2.8 3.7 + Normal
21 F 40 1.3 0.7 1.3 8.4 11.7 - Normal
22 F 60 - 1.0 1.5 4.0 4.8 - Heterozygous
Second period of TET
16 F 40 - 0.5 0.5 6.1 7.1 - Heterozygous
20 F 60 - 2.0 9.9 2.4 4.0 + Normal
TET: transient elevated transaminases, PEGV: pegvisomant, xULN: times upper limit of normal, Bili: total bilirubin, 
Alk. Phos: alkaline phosphatase, γ-GT: γ-glutamyltranspeptidase, AST: aspartate aminotransaminase, ALT: alanine 
aminotransferase, DM: diabetes mellitus type II, M: male, F: female, ND: not determined, MRCP: magnetic 
resonance cholangiopancreatography.
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Pituitary tumor size
Decrease in tumor size, defined as a decrease of more than 20% during 
combination treatment, was observed in 13 patients (16.9%), whereas size could 
not be determined in patients with the presence of an empty sella (n=8) or in 
whom radiotherapy was performed (n=13). During combined treatment, pituitary 
apoplexy occurred in two patients without a necessity for surgical intervention. 
In one patient, surgery was needed due to true tumor size increase. This case is 
described at the end of the Results, Two exceptional patients (tumor growth). 
Injection-site reactions
Injection-site reactions were observed in four subjects (2.8%). In three patients, 
lipohypertrophy appeared to be reversible by a more frequent rotation of the 
injection site. Nevertheless, one of these patients decided for TSS (see Supplemental 
Table 1) in order to be able to stop PEGV treatment. After TSS, the patient was able 
to stop the PEGV and to lower the LA-SSA dose. One patient underwent cosmetic 
surgery due to lipohypertrophy.
Mortality 
During the 9 years of follow-up, eight patients died (5.6%). All deaths were considered 
to be unrelated to the treatment. In Supplemental Table 2, the causes of death are 
listed. The average age of the patients who died was 71 years [range: 51 – 86]. 
All patients had significant comorbidities such as cardiovascular, cerebrovascular, 
malignant, or pulmonary disease.
Two exceptional patients 
Tumor growth
The first patient, a 25-year-old female, showed significant tumor growth during the 
combination therapy. In 2011, the patient presented with bitemporal hemianopia; 
therefore, TSS was performed. Retrospectively, her symptoms were presented 
2 years before the diagnosis. Before surgery, the IGF-I level was 127 nmol/l (2.9 
xULN). After surgery, the bitemporal hemianopia resolved, and other pituitary axes 
remained unaffected. Octreotide LAR 20 mg monthly was started, and the IGF-I 
level dropped to 67 nmol/l (1.6 xULN) 5 months after surgery. Octreotide LAR was 
increased to 30 mg every 3 weeks because IGF-I was still elevated. Despite the 
change in dose, the IGF-I level rose to 100 nmol/l (2.3 xULN). Pituitary MRIs (Figure 
2, A-C) performed 3 and 8 months after surgery showed a large tumor remnant. 
After 11 months, the LA-SSA IGF-I level was 87 nmol/l (2.0 xULN), and GH was 
105 g/l; at this stage, the patient was transferred to our hospital. IGF-I normalized 
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with Sandostatin LAR 30 mg and PEGV 80 mg twice weekly. Seven months after 
the addition of PEGV, an increase in tumor size was observed (Figure 2D) and a 
second TSS was needed, which was followed by radiotherapy. PEGV was restarted 
after surgery in combination with Sandostatin LAR 30 mg. A weekly dose of 100 mg 
of PEGV normalized the IGF-I level. To date, IGF-I remains normal, and the tumor 
size is stable. The pathology report after the first surgery revealed a GH-secreting 
adenoma with a Ki-67 index of 1%. After the second surgery, the pathology reported 
A
C
B
D
Figure 2. Magnetic resonance images of first patient (tumor growth)
A) At diagnosis.
B) Three months after the 1st surgery, no medical treatment.
C) Eight months after the 1st surgery, Sandosatin Lar 20 mg every 4 weeks.
D) Seven months after the addition of PEGV, Sandostatin Lar 30 mg every 4 weeks + PEGV 160 mg/week.
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sparsely granulated GH-secreting adenoma with a Ki-67 index of 1-2%; additionally, 
receptor expression was determined on the tumor specimen (Figure 3A). SSTR2 
mRNA expression could be demonstrated (0.3; expressed as relative expression of 
HPRT), as well as SSTR1 and SSTR5 mRNA expression. Incubation of primary cultures 
of dispersed somatotroph tumor cells of this patient with octreotide resulted in 
significant reduction of GH secretion (15.5%; p<0.01; Figure 3B). 
Increasing demand for pegvisomant 
The second patient, a 29-year-old male, started combination therapy in 2007 after 
TSS and transfrontal surgery. Normalization of IGF-I was achieved after 9 months 
with a PEGV dose of 210 mg/week (Figure 4). Eight months after normalization, the 
IGF-I increased again above the ULN. In the subsequent 3 years (2008-2010), the 
IGF-I level continued to increase despite a stepwise doubling of the PEGV dose to 420 
mg/week. PEGV was still given in combination with a high-dose LA-SSA (Lanreotide 
Autogel, 120 mg every 3 weeks). At the end of 2010, the combination therapy was 
sufficient to decrease the IGF-I below the ULN for 2 years, but the IGF-I level rose 
again in 2012. During these periods of IGF-I increase, additional MRIs were assessed 
but did not show any tumor size increase. PEGV injections were supervised at the 
hospital on several occasions in order to check the administration procedures and 
compliance. Retrospectively, PEGV levels were measured (Figure 4). GH levels did 
not increase significantly, and no PEGV antibodies were detected. Serum PEGV level 
in relation to injected doses and IGF-I levels are depicted in Figure 4.
Figure 3. Tumoral mRNA receptor expression
A) Tumoral SSTR2 mRNA expression is 0.3, expressed as relative to the expression of HPRT. 
B) Incubated primary cultures of dispersed somatrotroph tumor cells with octreotide. Tumor cells were available 
after transspenoidal surgery, because of tumor growth in a patient during combination therapy. Shown here a 
significant decrease of GH secretion by 15.5%. 
SSTR: somatostatin receptor, CON: control, OCT: octreotide (10 nM), * p<0.001.
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DISCUSSION 
Combined treatment has a high efficacy, similar to the clinical registration trials, and 
seems to be safe. Almost all of the adverse events occurred within the first year and 
were transient. 
The efficacy and safety of the combination therapy that we report here are 
based on data that we obtained from a single tertiary referral center. All patients 
attended the outpatient clinic on a regular basis, under the supervision of 
experienced pituitary endocrinologists. This approach could explain the superior 
outcome as compared to the results reported in the ACROSTUDYTM, which contains 
patients treated at centers with less experience. Recent reports suggest that the 
efficacy of PEGV treatment (7,13) is not as high as reported by the clinical trials using 
mono-therapy of PEGV (9,10). Our data, however, show that PEGV in combination 
with LA-SSA is as effective as in clinical trials, provided that optimal dosing is applied. 
In our opinion, rare diseases should be treated in dedicated expert centers 
only. This has been clearly shown for neurosurgery in acromegaly (27). Therefore, 
it would make sense that medication indicated for the treatment of acromegaly 
is restricted to specialized centers. The large number of PEGV-treated acromegaly 
patients in our center has brought about more experience and a more structural 
approach, which might explain in part the higher efficacy that we achieved compared 
to more recent literature (7). However, dosing strategies could be suboptimal, even 
in highly experienced centers, due to local legislation or reimbursement issues.
Figure 4. IGF-I serum level and PEGV serum level during time
IGF-I serum levels expressed as upper limit of normal and PEGV serum levels (µg/l) of one patient during years of 
combination treatment. The arrows show the moment of PEGV dose increase (mg/week).
IGF-I: insulin-like growth factor I, PEGV: pegvisomant, ULN: upper limit of normal.
2007 2008 2009 2010 2011 2012 2013 2014
0
1
2
3
0
6000
8000
10000
12000
14000
IG
F1
/U
LN
Pegv
serum
level
(µ
g
/
L)
60 80 210
420
560 weekly Pegv
dose
Years
PEG
V
 serum
 level (µ
g/l)
60 80 210
420
22 20 20 201
weekly 
PEGV dose
IG
F-
I x
U
LN
560
Chapter 2
44
Studies in the field have used different criteria for the assessment of IGF-I 
levels. Some use the lowest IGF-I and end-of-study IGF-I, and others the lowest 
annual IGF-I. The current data underline the fact that efficacy numbers are a matter 
of definition. The cotreatment study of PEGV with Lanreotide Autogel used end-of-
study and lowest IGF-I, and efficacy was 58 and 79%, respectively (28). The initial 
registration studies (10) and our combined treatment study (6) used the lowest 
IGF-I, and the efficacy rates were over 90%. With the current data set, a similar 
efficacy of 97.3% is observed, assessing lowest IGF-I recorded during treatment in 
a specialized center with standardized methods and not from a clinical trial with 
irregular follow-up.
Surgery before combined treatment did not significantly reduce the required 
dose of PEGV to normalize IGF-I. This is in line with our previous observations 
(6,16,17). In the current study, 11 patients underwent surgery during combined 
treatment. In five patients, the pre- and post-surgery PEGV doses were more or less 
similar. The decision to perform surgery in such cases therefore remains difficult. 
The incidence of TETs and local effects of PEGV at the injection site have been 
previously reported by several groups (7,10,11,13,17,29,30). The incidence of TET 
during combination therapy seems to be higher compared to PEGV monotherapy. 
Reported incidences during combination therapy range from 11-15% when an ALT 
cutoff of 2 xULN or 3 xULN is used (16,28). During PEGV monotherapy, an incidence 
of elevated transaminases was reported to be 5.2% (13). In the ACROSTUDYTM, only 
30 patients (2.5%) had an AST or ALT above 3 xULN (7). Most of the patients with 
TET were on combination treatment (7). However, the real frequency of PEGV-
related TET during monotherapy in this cohort might be underestimated. Elevated 
transaminases are usually transient, patients are usually not seen in a systematic, 
repetitive way, and therefore TET will go unnoticed. This can explain part of the 
difference in TET between our 15% and the 2.5% in the ACROSTUDYTM. Our data 
support the notion that TET seems to occur more frequently during combined 
treatment. We recommend careful monitoring of patients with TET 3 xULN. 
Cholelithiasis must be excluded by an ultrasound of the liver. In patients with TET 
10 xULN, we also recommend doing a liver biopsy and discontinuing PEGV in case 
of drug-induced hepatitis. 
We found an association between DM and TET in 2007 (17), but it was not 
found in a more recent study (16) or in the current evaluation of the long-term 
treatment data. A few years later, a Spanish group observed an association between 
a common polymorphism (UGTA1A*28) of Gilbert’s syndrome and male sex and 
TET (21). In our large single-center cohort, we detected this polymorphism in 
54.2% of our patients. However, we could not find a dose effect between wild-type 
and homo- or heterozygous carriers of this polymorphism of Gilbert’s syndrome. 
Moreover, we could not confirm any association with TET and the polymorphism. 
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No other association for TET could be observed in this database. Therefore, there is 
still no explanation for TET during PEGV treatment, except for the hypothesis that 
combined LA-SSA and PEGV increases the intrahepatic lipid content assessed by 
MRI that could lead to TET (31).
From the current data, it is clear that combined treatment usually stabilizes 
or decreases pituitary tumor size, which is in line with our previous observations 
(16). In some patients, tumor size decrease was observed; however, in one patient 
tumor size was increased. This was an exceptional patient with a short duration 
of symptoms before diagnosis and a significant SSTR2 expression, but only an 
octreotide-mediated GH decrease in vitro of 15.5%. In most GH-adenomacultures 
with similar SSTR2 expression, GH secretion decreases 50% or more after treatment 
with a similar dose of octreotide (32). Therefore, it is likely that a postreceptor 
defect was present in this tumor, explaining the lack of biochemical control during 
LA-SSA alone and tumor size control during combined treatment.
During long-term control of IGF-I with combination therapy, PEGV dose does 
not increase. In one exceptional case, dose adaptation was needed to treat the 
escape in IGF-I levels over time, without any change in tumor volume. PEGV injection 
instruction was repeated several times, as was supervised injections. We could 
not observe any aberrant injection pattern at any of these supervised moments. 
The single Dutch pharmacist who provides PEGV throughout The Netherlands was 
asked to review the amount of delivered PEGV. The pharmacist could not find any 
disparity between the amount of PEGV delivered to the patient and the amount 
prescribed. Certain studies report large interindividual differences in PEGV serum 
levels with similar PEGV dose administrations (23,33). However, there is only limited 
data on serum PEGV levels during long-term use. The patient from our series who 
needed a very high PEGV dose to obtain disease control also exhibited very high 
serum PEGV levels, suggesting adequate compliance and no obvious evidence of 
increased clearance of the drug.
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CONCLUSION
Combined treatment for acromegaly for almost a decade appears highly effective 
and comparable to the original registration trials, providing that the proper PEGV 
dose is used. Side effects were mild and transient, and we could not confirm Gilbert’s 
polymorphism as a cause of the observed transient elevated liver enzymes. Tumor 
size decrease was observed in 16.9% of the patients. However, one patient had 
continued growth of the pituitary adenoma despite normalization of IGF-I. The only 
way to identify these patients is to continue periodic monitoring by radiological 
imaging 
We found that in combination with high-dose LA-SSAs, the median dose of 
PEGV necessary to normalize IGF-I levels (80 mg/week) was considerably less than 
the dose of PEGV in those patients in the ACROSTUDYTM who did not normalize their 
IGF-I during long-term treatment with PEGV only (140 mg/week). This suggests 
that, for a significant number of patients, the combination of PEGV and LA-SSAs 
could be considerably less expensive. However, in one patient, dose increments of 
PEGV were required over time.
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SUPPLEMENTAL MATERIALS 
Supplemental Figure 1. IGF-I serum levels <1.2 ULN during the first year
Percentages of patients with IGF-I normalization (<1.2 xULN) an median PEGV doses in mg/week (gray line) are 
shown for the first year of treatment.
IGF-I: insulin-like growth factor I, PEGV: pegvisomant.
Supplemental Figure 2. A clinical tool for PEGV dosing
This is a clinical tool to calculate the required dose of PEGV to normalize the IGF-I level based on the IGF-I level 
before the start of PEGV. Formula of the required PEGV dose = 37.28 + (29.11* (IGF-I expressed in ULN)), (p<0.001).
This formula can only be used when IGF-I is elevated after a period of at least 6 months of LA-SSA treatment. This 
Figure can only be used if the IGF-I level is measured by the Immulite 2000 assay, as was done in this article (DPC 
Biermann GmbH/Siemens, Fernwald, Germany).
IGF-I: insulin-like growth factor I, PEGV: pegvisomant, xULN: x the upper limit of normal.
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Supplemental Table 1. Surgical patients during combination therapy
Indication for transsphenoidal surgery Curation
1 Request patient for debulking -
2 Tumor volume reduction due to LA-SSA, candidate for curation/debulking
-
3 Request patient for debulking -
4 Request patient for debulking -
5 Request patient for debulking -
6 Request patient for debulking -
7 Request patient for debulking -
8 Candidate for curation +
9 Side effect of PEGV (lipohypertrophy) -
10 Tumor growth and visual field loss -
11 Request patient for debulking -
Supplemental Figure 3.
PEGV: pegvisomant, TET: transient elevated transaminases.
M
on
th
s
A) Time to TET in months after start of PEGV B) Normalization of TET in months
 PEGV: pegvisomant.
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Cause of death Number of  
patients
Percentage
Cardiovascular failure 3 37.5
Sepsis 2 25.0
Malignancy 2 25.0
Pulmonary failure 1 12.5
Total 8 100.0
In the total cohort 5.6% of the subjects deceased. 
Supplemental Table 2. Cause of death during combination treatment
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ABSTRACT
Background: Growth hormone secreting pituitary adenomas (somatotroph 
adenoma) predominantly express somatostatin receptors (SSTRs) subtypes 2 
and 5. Higher SSTR2 expression on somatotroph adenomas results in a better 
response to somatostatin analogues (SSAs), which preferentially bind, but also 
downregulate, SSTR2. The effect of the combined treatment with SSAs and 
the growth hormone (GH) receptor antagonist pegvisomant (PEGV) on SSTR 
expression in somatotroph adenomas is currently unknown. 
Objective: To assess SSTR2 and SSTR5 expression in three groups of somatotroph 
adenomas: drug-naive, treated with long-acting (LA) SSA monotherapy, 
or LA-SSA and PEGV combination therapy before surgery. Additionally, we 
evaluated the required PEGV dose to achieve insulin-like growth factor I (IGF-I) 
normalization in relation to the SSTR expression. 
Design: At our Pituitary Center Rotterdam, we selected acromegaly patients 
who underwent transsphenoidal neurosurgery. All patients were eventually 
treated with LA-SSA and PEGV combination therapy during their medical 
history. SSTR2 and SSTR5 expression in somatotroph adenomas tissues was 
determined using immunohistochemistry. 
Results: Out of 39 somatotroph adenoma tissue samples, 23 were drug-naive, 
9 received pre-treatment with LA-SSA and 7 LA-SSA and PEGV combined 
treatment. SSTR2 expression was significantly higher in treatment-naive 
compared to combined treatment somatotroph adenomas (p=0.048), while 
SSTR5 expression did not differ. Noteworthy, SSTR2 expression in naive 
somatotroph adenoma tissues was inversely correlated to the required PEGV 
dose to achieve insulin-like growth factor I (IGF-I) normalization during post-
surgical medical treatment (ρ=-0.538, p=0.024).
Conclusions: In our specific cohort, the SSTR2 expression is lower in patients 
pre-treated with LA-SSA and PEGV compared to the drug-naive acromegaly 
patients. Additionally, the SSTR2 expression in treatment naive somatotroph 
adenoma tissues was inversely correlated with the required PEGV dose to 
achieve IGF-I normalization. 
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INTRODUCTION
Somatotroph adenomas express different SSTR subtypes, predominantly SSTR 
subtypes 2 and 5 (1), which play a major role in reducing GH secretion and thereby 
IGF-I levels. LA-SSAs have high-binding affinity for SSTR2 and a moderate affinity 
for SSTR5. According to current guidelines, LA-SSAs are considered to be the first 
line medical treatment modality after unsuccessful surgery as well as primary 
treatment option in selected cases (2,3). However, a number of studies published 
on the efficacy of LA-SSAs in acromegaly, show that LA-SSA treatment alone fails 
to reach complete normalization of IGF-I levels in about 50% of the cases. A recent 
meta-analysis reported an average control rate of 56 and 55% for GH and IGF-I 
normalization, respectively, during monotherapy with LA-SSA (4). However, due 
to selection bias this efficacy rate is probably an overestimation. In unselected 
treatment-naive patients an LA-SSA efficacy rate of 40% seems to be more common 
(5,6). Tumor shrinkage with LA-SSA was observed in 63-75% of these primary 
treated patients (6).
The expression of SSTR2 on somatotroph adenomas cell membrane is 
significantly and positively correlated with the efficacy of LA-SSAs in suppressing 
GH and IGF-I levels in vitro, and it is also associated with IGF-I normalization in 
acromegaly patients (7-11). In this light, a recent study from our group showed that 
a SSTR2 immunoreactivity score (IRS) of at least 5 had a sensitivity of 86% and a 
specificity of 91% in predicting IGF-I control during adjuvant LA-SSA treatment (9). 
Additionally, SSTR2 expression and tumor volume reduction after LA-SSA treatment 
are positively correlated (11,12). Moreover, partial- and non-responder tumors 
to monotherapy with LA-SSAs seem to have lower SSTR2 mRNA expression and 
higher SSTR5 mRNA expression compared to full-responders on LA-SSAs (13). An 
effective treatment option to normalize IGF-I levels in partial-responder patients 
is the addition of the GH receptor antagonist PEGV to first-line medical treatment 
with LA-SSA (14,15). To the best of our knowledge, the expression of SSTR2 and 
SSTR5 on somatotroph adenomas tissues from acromegaly patients treated with 
PEGV (together with LA-SSAs) before surgery is currently unknown.
Based on the finding that the response to LA-SSA treatment is mainly 
driven by the expression of SSTR2, a reduced expression of SSTR2 in untreated 
somatotroph adenomas at baseline, probably necessitates combined treatment 
because of (partial) resistance to LA-SSA treatment. However, we cannot exclude 
feedback mechanisms like the drop in IGF-I levels during medical treatment and an 
associated increase in hypothalamic growth hormone releasing hormone (GHrH) 
levels, which theoretically also can influence the expression of SSTR2 and SSTR5 
on the somatotroph adenoma cell membrane. To investigate the effects of the 
addition of PEGV to LA-SSAs on SSTR expression, we assessed the expression of 
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SSTR subtypes 2 and 5 in three groups of acromegaly patients: drug-naive (naive 
group), treated with LA-SSA monotherapy (mono LA-SSA group) before surgery, and 
treated with LA-SSA and PEGV (combined group) before surgery. Since all patients 
included in the present study received LA-SSA and PEGV combined treatment during 
their clinical history, we were able to assess the required PEGV dose (added to LA-
SSAs) needed after surgery to achieve the normalization of IGF-I levels. Therefore, 
we additionally evaluated the required PEGV dose in relation to the expression of 
SSTR2 and SSTR5, in order to observe indirectly the partial-resistance to LA-SSA. 
The underlying hypotheses are; 1) various medical pre-treatment modalities can 
differently affect the SSTR2 and SSTR5 expression on somatotroph adenomas and; 
2) the SSTR expression can affect post-surgical PEGV dosing in combination with 
LA-SSA. 
METHODS
Patient and somatotroph adenoma tissue selection
Data collection of acromegaly patients was performed at our Rotterdam Pituitary 
Center and a retrospective evaluation was carried out. We used a database 
including acromegaly patients which were all eventually treated with PEGV in 
combination with LA-SSA (n=141), and we selected those patients who underwent 
transsphenoidal neurosurgery (n=66), representing a total of 71 transsphenoidal 
surgeries. Five patients underwent a second surgery, of these patients we only 
included the tissue samples of the first surgery. Besides medical history data, a 
somatotroph adenoma paraffin-embedded tissue sample in order to perform 
immunohistochemistry, had to be available. We selected 39 somatotroph adenoma 
tissues obtained from 39 patients. A flowchart representing the selection procedure 
of the somatotroph adenoma tissues for our study is depicted in Figure 1. No patient 
underwent radiotherapy before surgery. Three groups of different medical pre-
treatment modalities before surgery were identified: drug-naive patients, patients 
on monotherapy with LA-SSAs and patients treated with LA-SSAs in combination 
with PEGV. Table 1 shows patient characteristics of the three pre-treatment groups 
before surgery. The mono LA-SSA group was treated with LA-SSAs for a median of 
6 months, the combined group was treated for a median of 20 months with LA-
SSAs and for a median of 13 months with PEGV before surgery. PEGV treatment 
was added to the highest dose of LA-SSA by weekly injections. For starting doses 
of PEGV and the protocol of PEGV dose titration to achieve normal IGF-I levels see 
Franck & Neggers et al. (14). Magnetic resonance imaging was used to assess tumor 
volume as macro vs. micro adenomas at time of diagnosis.
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Moment of surgery 
regarding medical 
pre-treatment 
All patients 
eventually were 
treated with 
LA-SSA + PEGV
Naive
n=23
LA-SSA
n=9
LA-SSA + PEGV
n=7
Figure 1. Flowchart depicting tissue selection
Flowchart of this study selection procedure. Patients who underwent transsphenoidal surgery and eventually were 
treated with LA-SSA in combination with PEGV, were selected and tissues were collected. N is the number of 
tissues, which represents the number of patients, as we excluded tissues from a second surgery. 
DA: dopamine agonist, Naive: no previous medical treatment, LA-SSA: long-acting somatostatin analogues, PEGV: 
pegvisomant. 
Surgery 1988-2013
n=71
Included in this study:
n=39
Excluded from this study:
- No tissue available
- Tissue sample too small 
- Tissue of a second surgery 
- DA before surgery
- Medical treatment unknown
- Histological diagnosis inconclusive 
n=13
n=8
n=5
n=3
n=2
n=1
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All patients selected for this study were eventually treated with LA-SSA in 
combination with PEGV after surgery, and were subdivided in partial- and full-
responder to monotherapy with LA-SSAs. Most of the patients included in this 
study were partial-responders to LA-SSAs (n=31) and were considered to have a 
minimal decrease of 15% in their GH and IGF-I levels and still have elevated IGF-I 
serum levels (>1.2x upper limit of normal (ULN)) after at least six months on the 
highest dose of LA-SSAs (Sandostatin LAR 30 mg or Lanreotide Autogel 120 mg 
every 28 days). These patients required PEGV in combination with LA-SSA in order 
to achieve normalized IGF-I levels. Partial-responders had a median IGF-I decrease 
of -28.4% [IQR: -21.2 – -43.4] after LA-SSA monotherapy. Full-responders to LA-SSAs 
(n=8) achieved normal IGF-I levels during monotherapy with LA-SSAs and received 
PEGV during a clinical trial aimed to investigate aspects of quality of life (16). Full-
responders had a median IGF-I decrease of -61.9% [IQR: -53.5 – -67.3] after LA-
SSA monotherapy. The response to monotherapy with LA-SSA in order to subdivide 
the total cohort in partial- and full-responder patients, could have been evaluated 
before or after surgery. Table 2 provides general, biochemical and somatotroph 
adenoma characteristics of partial- and full-responder patients to monotherapy of 
LA-SSAs. When investigating the required PEGV dose to achieve normalization of 
IGF-I in relation with the SSTR2 expression, we included only the partial-responder 
patients, not pre-treated before surgery, in order to achieve a more clear indication 
from a homogeneous cohort. Permission from the Institutional Review Board of the 
Erasmus Medical Center Rotterdam was obtained and all patients gave their written 
informed consent.
Hormone assays
Serum IGF-I levels were measured with a Radioimmunoassay (Medgenix Diagnostics, 
Fleurus, Belgium, intra-assay coefficient of variation (CV) 6.1%, inter-assay CV 9.9%), 
an Immunoradiometric assay (Diagnostic Systems Laboratories, Webster, Texas, 
USA, intra-assay CV 3.9%, inter-assay CV 4.2%), and the Immulite 2000 assay, a solid-
phase, enzyme-labelled chemiluminescent immunometric assay (DPC Biermann 
GmbH/Siemens, Fernwald, Germany, intra-assay variability of 2-5%, inter-assay 
variability of 3-7%). IGF-I age-adjusted reference ranges were used in accordance 
with an earlier report (17). IGF-I levels were evaluated just before surgery, during 
monotherapy of LA-SSA and after surgery when every patient eventually was treated 
with LA-SSA in combination with PEGV. Over time, IGF-I assays were replaced by 
one another. We therefore chose to express IGF-I levels only as ULN and not by the 
absolute values. 
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Immunohistochemistry
Thirty-nine somatotroph adenoma tissues were available for haematoxylin staining 
and immunostaining of SSTR2 and SSTR5. Formalin-fixed paraffin-embedded tumor 
samples were cut into sequential 4 µm thick sections, deparaffinized and stained 
using a fully automated Ventana BenchMark ULTRA Stainer (Ventana, Tucson Arizona, 
USA) according to manufacturers’ instructions at the pathology department. Binding 
of peroxidase-coupled antibodies was detected using 3,39-diaminobenzidine as 
a substrate and the sections were counterstained with haematoxylin. The rabbit 
monoclonal anti-SSTR2 antibody (BioTrend, Köln, Germany) was used at a dilution 
of 1:25, whereas the rabbit monoclonal anti-SSTR5 (Abcam, Cambridge, UK) 
antibody at a dilution of 1:50. 
Normal pancreatic tissue served as a positive control for both SSTR2 and SSTR5 
staining. For negative controls, the primary antibody was omitted. Immunostaining 
Figure 2. Immunohistochemical expression patterns of SSTR2 and SSTR5
Heterogeneous expression patterns of SSTR2 and SSTR5 on somatotroph adenomas, scored by the immunoreactivity 
score (IRS). IRS 3 represents a low, IRS 6 represents an intermediate and IRS 12 represents an high SSTR2 and SSTR5 
expression pattern. Photography was performed during magnification of 200x. 
HE: haematoxylin, SSTR2: somatostatin receptor subtype 2, SSTR5: somatostatin receptor subtype 5. 
HE
SS
TR
2
SS
TR
5
IRS 3 IRS 6 IRS 12
Chapter 3
62
of the somatotroph adenoma tissues was scored by a semi-quantitative IRS (18), 
and is the product of the percentage of positive stained cells (0: no positive cells; 
1: <10%; 2: 10-50%; 3: 51-80%; 4: 80%) and the staining intensity (0: no staining; 1: 
weak staining; 2: moderate staining; 3: strong staining), shown in Figure 2. The IRS 
ranges between 0 and 12. The somatotroph adenoma tissue scoring was performed 
by two independent investigators (S.E.F and F.G.), who were blinded for each other’s 
findings, for patient characteristics and their treatment regimes.
Statistical methods
Data are expressed as median [interquartile range [IQR]]. Differences between two 
subgroups were analysed using an unpaired t-test or the Mann-Whitney U test (in 
case of non-parametric data). Differences between three independent subgroups 
were analysed using one-way ANOVA or Kruskal-Wallis test (in case of non-
parametric data). Nominal variables were analysed using Fisher’s exact test. Results 
of correlation analyses are expressed as Spearman’s rank correlation coefficients 
(rho). P-values <0.05 (two-tailed) are considered statistically significant. Statistical 
analyses were performed with SPSS version 20 and GraphPad Prism version 6 
for Windows (IBM SPSS Statistics for Windows, Armonk, NY, USA and GraphPad 
Software, San Diego, CA, USA).
RESULTS
Patient characteristics before surgery
Patient characteristics before surgery are presented in Table 1. Out of the 39 
evaluated somatotroph adenoma tissue samples, 23 were collected during a drug-
naive state, 9 during mono LA-SSA treatment and 7 during LA-SSAs combined with 
PEGV therapy. No significant differences were present between the three medical 
pre-treatment groups before surgery when considering: sex, tumor volume assessed 
as macro vs. micro adenomas, IGF-I levels at diagnosis, age at time of surgery, IGF-I 
levels before surgery and the duration of LA-SSA treatment before surgery. IGF-I 
levels are expressed as xULN. 
Expression of SSTR2 and SSTR5 after different medical pre-
treatment options
The SSTR2 IRS in the naive group has a median of 6.0 [IQR: 2.0 – 12.0], the mono 
LA-SSA group has a median of 6.0 [IQR: 6.0 – 12.0], and the group pre-treated with 
LA-SSA and PEGV has a median of 2.0 [IQR: 1.0 – 4.5], depicted in Figure 3A. A 
pairwise comparison showed that the median SSTR2 IRS on somatotroph adenomas 
was statistically significant higher in the treatment naive group compared to the 
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Figure 3. SSTR2 and SSTR5 expression per medical pre-treatment group
A) The SSTR2 IRS is significantly lower in the combination group compared to the naive group.
B) The SSTR5 IRS is not significantly different between the different medical pre-treatment groups. SSTR IRS is 
expressed as median [interquartile range]. Pre-treatment groups before surgery were tested reciprocally with the 
Mann-Whitney U test (Naive: n=23; Mono LA-SSA: n=9; LA-SSA + PEGV: n=7). 
Naive: no previous medical treatment, LA-SSA: long-acting somatostatin analogues, PEGV: pegvisomant, 
IGF-I: insulin-like growth factor I, ULN: upper limit of normal, SSTR2: somatostatin receptor subtype 2, SSTR5: 
somatostatin receptor subtype 5, IRS: immunoreactivity score. 
A) SSTR2
B) SSTR5
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combined group (p=0.048). We did not find any statistically significant difference 
for the SSTR2 IRS between treatment naive and the mono LA-SSA group. However, 
a trend for a lower median SSTR2 IRS was observed in the combined group when 
compared to the mono LA-SSA group (p=0.055).
The SSTR5 IRS in the naive group has a median of 12.0 [IQR: 7.0 – 12.0], the 
mono LA-SSA group has a median of 12.0 [IQR: 6.0 – 12.0], and the group pre-
treated with LA-SSA and PEGV has a median of 9.0 [IQR: 9.0 – 12.0]. The SSTR5 IRS 
did not significantly differ between LA-SSA and PEGV treatment and the other two 
groups, depicted in Figure 3B. 
Partial- and full-responder patients to monotherapy with LA-SSAs
All patients selected for this study were eventually treated with LA-SSAs combined 
with PEGV after surgery, and were subdivided in partial- and full-responder to 
monotherapy with LA-SSAs. Partial-responder patients have elevated serum IGF-I 
levels after at least six months on LA-SSAs, and needed PEGV in combination with LA-
SSAs in order to achieve normalized IGF-I levels. Full-responders to LA-SSA achieved 
normal IGF-I levels during monotherapy with LA-SSA. Patient characteristics of 
partial- (n=31) and full-responders (n=8) to monotherapy with LA-SSA are presented 
in Table 2. No major differences were observed between partial- and the full-
responders to monotherapy with LA-SSAs, regarding sex, age at time of surgery, 
tumor volume assessed as macro vs. micro adenomas, medical pre-treatment 
before surgery and IGF-I xULN at time of surgery. IGF-I xULN during monotherapy 
with LA-SSA was significantly different, as we selected for this variable. As for the 
SSTR expression at time of surgery, when only partial-responder patients were 
included, we observed that the SSTR2 and SSTR5 IRS followed a similar distribution 
between the medical pre-treatment groups as the one showed in the previous 
paragraph. However, possibly due to the loss of statistical power (eight patients 
less were included in the analysis), the difference of the SSTR2 IRS between the 
naive and the combined group was not significant anymore (p=0.135), depicted in 
Supplemental Figure 1A and B. Supplemental materials can be found at the end of 
this chapter.
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IGF-I levels and PEGV dosing in relation to the SSTR2 and SSTR5 
expression
IGF-I levels (xULN) during monotherapy with the highest approved dose of LA-SSAs 
were inversely correlated with the SSTR2 expression (ρ=-0.495, p=0.002, n=39, 
Figure 4). The SSTR5 expression was not correlated with the IGF-I (xULN) during 
monotherapy with LA-SSA (ρ=0.145, p=0.405, n=39). As mentioned in the methods 
section, when observing the required PEGV dose to achieve normalization of IGF-I 
in relation with the SSTR2 and SSTR5 expression, we included only the partial-
responder patients, not pre-treated before surgery (drug-naive status). In this 
context, we observed that the required PEGV dose was inversely correlated to the 
SSTR2 expression (ρ=-0.538, p=0.024, n=16, Figure 5A), while it did not correlate 
to the SSTR5 expression (ρ=-0.071, p=0.792, n=16, Figure 5B). Correlation analyses 
tested in the medical pre-treatment groups before surgery; monotherapy with LA-
SSA (n=9) and LA-SSA in combination with PEGV (n=7), as described in the first part 
of this results section, were not statistically significant between the required PEGV 
dose and the SSTR2 and SSTR5 expression. 
Partial-LA- 
SSA-responders
Full-LA- 
SSA-responders
p-value
No. of tissues – n (%) 31 (79.5) 8 (20.5)
Males – n (%) 19 (61.3) 5 (62.5) 0.640
Age at time of surgery – years 43.2 [30.7 – 49.9] 43.5 [42.1 – 49.7] 0.306
Tumor volume – macro-n (%) 30 (96.8) 8 (87.5) 0.372
Medical pre-treatment before surgery:
    Naive – n (%) 16 (51.6) 7 (87.5)
    Mono LA-SSA – n (%) 8 (25.8) 1 (12.5) 0.225
    LA-SSA + PEGV – n (%) 7 (22.8) 0
IGF-I xULN before surgery 2.3 [1.8 – 3.2] 2.8 [2.4 – 3.2] 0.853
IGF-I xULN during mono LA-SSAa 2.0 [1.5 – 2.3] 0.7 [0.5 – 0.8] ≤0.001
Table 2. Patient characteristics; partial- and full-responders during monotherapy 
with LA-SSA
Partial-responders to LA-SSA were considered to have elevated serum IGF-I levels after at least six months on the 
highest dose of LA-SSAs and needed PEGV for disease control. Full-responders to LA-SSA achieve normal IGF-I 
levels during monotherapy of LA-SSA and PEGV was added because of quality of life reasons during a clinical trial. 
Monotherapy of LA-SSA could have been administered to the patient before or after surgery. Numerical data are 
expressed as median [interquartile range]. 
Naive: no previous medical treatment, LA-SSA: long-acting somatostatin analogues, PEGV: pegvisomant, IGF-I: 
insulin-like growth factor I, ULN: upper limit of normal.
a. The response of IGF-I levels to monotherapy with LA-SSA in order to subdivide the total cohort in partial- and 
full-responder patients, could have been evaluated before or after surgery.
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DISCUSSION
This is the first study aimed to investigate the expression of SSTR2 and SSTR5 in 
somatotroph adenoma tissues of acromegaly patients treated with LA-SSAs in 
combination with PEGV. In our specific cohort, the combined group (LA-SSA and 
PEGV) at time of surgery showed a lower median SSTR2 IRS compared to the 
drug-naive group, while the IRS of the SSTR5 was not different between the pre-
treated groups. Additionally, we observed that the required PEGV dose to achieve 
normalization of IGF-I levels was inversely correlated with the SSTR2 expression, 
but not with the IRS of SSTR5 in drug-naive acromegaly patients. In the following 
discussion, we focus on all the possible explanations for the finding that in our 
cohort the SSTR2 expression is lower in the combined group compared with 
the naive group. The most likely explanation for this finding is that somatotroph 
adenomas (partial) resistant to LA-SSA, that need combined treatment, have lower 
SSTR2 expression at baseline. However, we cannot exclude that other factors, such 
as feedback mechanisms of the GH-IGF-I axis and the down-regulation of SSTR2 due 
to prior LA-SSA treatment could affect the SSTR expression as well. 
As far as the GH-IGF-I axis feedback mechanisms play a possible role in the 
Figure 4. IGF-I during monotherapy with LA-SSA is inversely correlated with the 
SSTR2 expression
IGF-I xULN during the highest dose of monotherapy with LA-SSA is inversely correlated with the SSTR2 expression 
(Spearman correlation analyses). 
LA-SSA: long-acting somatostatin analogues, IGF-I: insulin-like growth factor I, ULN: upper limit of normal, SSTR2: 
somatostatin receptor subtype 2, IRS: immunoreactivity score.
IG
F-
I x
U
LN
SSTR2 IRS
ρ=-0.495
p=0.002
n=39
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Figure 5. The PEGV dose in combination with LA-SSA is inversely correlated with 
the SSTR2 expression
The required PEGV dose (mg/week) in combination with the highest dose of LA-SSA needed to control IGF-I levels 
is inversely correlated with the expression of SSTR2 (Spearman correlation analyses) and was not correlated with 
the SSTR5 expression. This Figure only contains partial-responders to monotherapy with LA-SSA and the SSTR 
expression was estimated during a drug-naive state (n=16). 
PEGV: pegvisomant, LA-SSA: long-acting somatostatin analogues, SSTR2: somatostatin receptor subtype 2, SSTR5: 
somatostatin receptor subtype 5, IRS: immunoreactivity score.
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modulation of SSTR expression, we assume that GH itself does not have a direct 
effect on the modulation of SSTRs at the pituitary level during combination 
treatment, since PEGV blocks GH receptors (GHRs) also at the level of the pituitary 
(19). More complex is the prediction of growth hormone releasing hormone (GHrH) 
levels via the hypothalamus in presence of PEGV-treatment. PEGV generally causes 
a further elevation of serum GH levels (20), which could result in a decrease of 
GHrH via some areas in the hypothalamus and might consequently result in down-
regulation of SSTR2. On the other hand, the drop of IGF-I and the associated increase 
in hypothalamic GHrH levels might have an influence on the expression of SSTR2 
and SSTR5 at the level of the somatotroph adenoma as well. In our study IGF-I levels 
of patients treated with LA-SSA in combination with PEGV were relatively lower 
compared to the naive group. However, Park et al. reported that in spontaneous 
dwarf rats the expression of all SSTR subtypes was not directly influenced by 
exogenous IGF-I treatment (21). Moreover, in the same study the authors observed 
that GHrH has a direct stimulatory effect on SSTR2 expression, both in vivo and in 
vitro. If these observations can be extrapolated to humans, we could speculate that 
the decrease of IGF-I levels probably does not play a major role in the explanation 
of the observed decrease of SSTR2 expression during the combination treatment, 
while the modulation of GHrH levels seems to be more involved. However, based 
on the current knowledge, our results demonstrating a lower SSTR2 expression in 
the combined group compared to the naive group, cannot clearly be explained by 
the effect of PEGV on the modulation of the GH-IGF-I-pituitary-hypothalamus axis. 
Finally, to the best of our knowledge, a direct effect of PEGV on SSTR expression has 
not been reported, although it cannot be excluded a priori.
The down-regulation of cell surface SSTR2 by endogenous somatostatin and 
LA-SSA treatment has been reported in several studies (7,22,23), possibly through 
ligand-induced receptor internalization. Casar-Borota & Heck et al. demonstrated 
this down-regulation of SSTR2 expression by LA-SSA therapy also in a randomized 
subset of acromegaly patients (n=13 mono LA-SSA, n=13 direct surgery), to exclude 
a possible clinical selection bias (7). However, we did not observe a statistically 
significant difference in our acromegaly cohort between the naive and mono LA-SSA 
pre-treatment group regarding SSTR2 expression (p=0.828). A possible explanation 
for this finding may reside in the selection of our patient group. Indeed, our cohort 
is most likely represented by acromegaly patients with more disease activity, since 
they were all referred to us as a tertiary referral hospital and, most importantly, 
the majority of these patients needed PEGV in addition to LA-SSAs to normalize 
IGF-I levels (n=31). In this light, as shown in the result section, even the drug-naive 
group showed a relatively low SSTR2 IRS (median IRS 6, which means about 50% 
moderately stained cells) compared to staining observed in a previous study using 
comparable techniques and scoring system (median IRS 9) (7). This finding may 
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result in a lower down-regulation of SSTR2 after LA-SSA treatment alone, and/or 
contribute to “mask” the down-regulation of a receptor pattern already relatively 
low at baseline. However, considering all these limitations we observed that the 
combined treatment group in our study had a lower SSTR2 IRS compared to the 
naive group. Noteworthy, the SSTR2 IRS between the mono LA-SSA and combined 
group was almost significantly different (p=0.055). Furthermore, the duration of 
LA-SSA treatment was remarkably shorter in the mono LA-SSA group compared to 
the combined treatment group by a median difference of 14 months, however this 
difference did not reach statistical significance. This difference could be a possible 
explanation (besides the concomitant treatment with PEGV) for the observed lower 
expression of SSTR2 in the combined treatment group compared to the mono LA-
SSA and naive group. In conclusion, the lower expression of SSTR2 in somatotroph 
adenomas in the combined treatment group could simply be related to the fact that 
these patients necessitate combined treatment due to their (partial) resistance to 
LA-SSA treatment. Therefore, we can hypothesize that these partial responders to 
monotherapy with LA-SSA have already lower SSTR2 expression at baseline, which 
could be the reason these patients need PEGV in addition to LA-SSA for disease 
control. Previously, it was already reported that full-responders to LA-SSA showed 
significant higher SSTR2 expression compared to the partial LA-SSA responders (9, 
12). Furthermore, for the first time, we observed that in drug-naive somatotroph 
adenomas a lower SSTR2 expression correlates with a higher required PEGV dose 
in order to achieve normalized IGF-I levels, which also reflects more severe disease 
activity. This observation may have clinical implications for the postoperative 
treatment in acromegaly patients and, therefore, represents an important finding 
of our study.
The main limitations of this study are; 1) the retrospective design; 2) the 
relative small sample size and; 3) the peculiar patient group in which the study has 
been conducted (all treated with combination medical therapy during their clinical 
history). However, this can be expected by the rarity of acromegaly as well as the 
fact that only a subset of the patients is treated with LA-SSA in combination with 
PEGV. These limitations of the present study could be overcome in the future by 
the design of a large prospective randomized study aimed to evaluate the impact 
of different treatment modalities on SSTR expression. Furthermore, assessment 
of IGF-I and GH levels can also be improved, and, in particular, GH measurement 
should be assessed by a non-commercial assay in order to distinguish between 
endogenous GH and PEGV, which is recently introduced in our clinical practice. 
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CONCLUSION
This is the first study that assessed the effect of the combined medical treatment 
with LA-SSAs and PEGV on SSTR expression in somatotroph adenoma tissue of 
acromegaly patients. In our specific cohort, SSTR2 expression is lower in patients pre-
treated with LA-SSA and PEGV compared to the drug-naive acromegaly patients. This 
finding is in line with the evidence that LA-SSA and PEGV-treated patients are usually 
(partial) resistant to LA-SSA treatment alone (dependent on SSTR2 expression). 
Moreover, we observed that patients with a lower SSTR2 expression need a higher 
required PEGV dose in combination with LA-SSA to achieve normalized IGF-I levels 
after surgery, when assessed in drug-naive somatotroph adenoma tissues. 
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Sublemental Figure 1A and 1B. SSTR2 and SSTR5 expression per medical pre-
treatment group in partial-responders to LA-SSA
SSTR2 IRS (A) and SSTR5 IRS (B) per medical pre-treatment group in only partial-responders to LA-SSA. SSTR2 IRS 
and SSTR5 IRS were not statistically significant different when medical pre-treatment groups before surgery were 
tested reciprocally with the Mann-Whitney U test (Naive: n=16; Mono LA-SSA: n=8; LA-SSA + PEGV: n=7). SSTR IRS 
is expressed as median[interquartile range]. 
Naive: no previous medical treatment, LA-SSA: long-acting somatostatin analogues, PEGV: pegvisomant, 
IGF-I: insulin-like growth factor I, ULN: upper limit of normal, SSTR2: somatostatin receptor subtype 2, SSTR5: 
somatostatin receptor subtype 5, IRS: immunoreactivity score. 
A) SSTR2
B) SSTR5
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ABSTRACT
Background: Doses of the growth hormone receptor (GHR) antagonist 
pegvisomant (PEGV) that normalize insulin like growth factor I (IGF-I) levels 
vary widely among acromegaly patients. Predictors for PEGV response are 
baseline IGF-I levels, sex, body weight, and previous radiotherapy. A GHR 
polymorphism lacking exon 3 (d3-GHR) is frequent in the general population. 
The influence of d3-GHR on PEGV responsiveness in acromegaly is unclear.
Objective: To assess the influence of d3-GHR on IGF-I levels and PEGV 
responsiveness in acromegaly patients using combined PEGV and  long-acting 
somatostatin analogues (LA-SSA) treatment.
Design: Data was collected at the Rotterdam Pituitary Centre between 2004 
and 2013. Patients with elevated IGF-I levels (>1.2 upper limit of normal (ULN); 
n=112) and over 6 months of high-dose LA-SSA treatment were co-treated 
with PEGV. GHR genotype was assessed using genomic DNA in 104 patients.
Results: D3-GHR was observed in 51 (49.0%) of the patients (7.7% homozygous, 
41.3% heterozygous) and was in Hardy-Weinberg equilibrium (p=0.859). 
Baseline characteristics were similar in d3-GHR and full-length (fl)-GHR 
genotypes. During PEGV and LA-SSA treatment IGF-I levels were not different 
between d3-carriers and non-carriers. Similarly, no difference in PEGV 
dose required to normalize IGF-I (p=0.337) or PEGV serum levels (p=0.433) 
was observed between the two groups. However, adenoma size decreased 
significantly (>20% of largest diameter) in 25.6% of the fl-GHR genotype but 
only in 7.5% of d3-carriers (p=0.034, OR: 4.6 [CI: 1.1 – 18.9]).
Conclusions: GHR genotype does not predict the IGF-I normalizing dose of 
PEGV in acromegaly patients using PEGV in combination with LA-SSA. However, 
fewer d3-carriers showed significant reductions in adenoma size.
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INTRODUCTION
Disease activity and phenotype is diverse among patients with acromegaly. 
Comorbidities such as hypertension, cardiomyopathy, diabetes mellitus type II, 
sleep apnea and osteoarthritis are influenced by the severity and the duration 
of GH hypersecretion (1). PEGV is a competitive GHR antagonist that is used in 
the treatment of acromegaly (2). The required dose of PEGV to achieve disease 
control as assessed by the normalization of IGF-I levels differs significantly between 
individual patients (2). Baseline IGF-I appears to be a predictor for the required dose 
(3). Other factors known to influence the required dose are sex, body weight and 
previous radiotherapy (4). However, GHR polymorphisms seem to have an influence 
as well (5,6).
A polymorphism of the GHR that lacks exon 3 during splicing is common in 
the general population. About half of the population is homozygous for the fl-GHR, 
30-40% is heterozygous for d3-GHR and 10-20% is homozygous for this deletion 
(7,8,9). It has been reported that the d3-GHR polymorphism shows a comparable 
distribution between different cohorts of acromegaly patients (6,10,11,12). Multiple 
studies show that the fl-GHR and d3-GHR have comparable binding properties, and 
that internalization of fl-GHR is as effective as d3-GHR (13,14,15). However, Dos 
Santos et al. (8) showed in transfection experiments that the lack of exon 3 results in 
an enhanced signal transduction by the STAT-5-dependent pathway, which increases 
the expression of IGF-I and other GH-dependent genes. Scientific attention on d3-
GHR was in the beginning focused on the outcome of recombinant GH replacement 
therapy in GH-deficient children and later in adults, in which the studies often show 
different conclusions (16,17,18). Thereafter research was focused on the severity of 
acromegaly regarding the GHR-genotype.
Previous research showed that d3-GHR carriers with acromegaly have a more 
severe clinical and biochemical phenotype, however, inconsistent results have 
also been reported. For example, Wassenaar et al. (19) reported an increased 
prevalence of osteoarthritis, dolichocolon and adenomatous colonic polyps in d3-
GHR carriers with acromegaly, but no difference in cardiovascular risk and bone 
mineral density. Mercado et al. (11) observed that diabetes mellitus type II was 
more prevalent in patients with the d3-GHR genotype apart, whereas several 
other phenotypical features were independent of GHR genotype. The authors also 
observed a significantly higher serum IGF-I concentration after treatment (surgery, 
radiotherapy and/or pharmacological therapy) in d3-GHR carriers (11). Cinar et al. 
(20) reported that d3-GHR genotype did not have an effect on clinical features nor 
on comorbidities in acromegaly patients.
A meta-analysis on GH-deficiency concluded that the presence of d3-GHR 
increases the response to recombinant GH treatment in GH-deficient children (21). 
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This pharmacogenetic phenomenon could be important for PEGV treatment in 
acromegaly. In theory, carriers of d3-GHR might need less PEGV than non-carriers 
to reach a comparable decrease in IGF-I levels. Indeed, two studies reported that 
the required PEGV dose for normalization of IGF-I levels was significantly lower 
in acromegaly patients with a d3-GHR genotype (5,6). A later study, however, did 
not observe a better response of d3-GHR carriers during monotherapy PEGV nor 
during combination treatment with PEGV and somatostatin analogues (10). These 
inconsistent findings indicate that larger cohorts of acromegaly patients are needed 
to investigate whether the response to PEGV differs between d3-GHR and fl-GHR 
genotypes. We, therefore, examined whether there were differences in the clinical 
and biochemical responses during PEGV treatment between both genotypes in our 
cohort of 104 patients using somatostatin analogues combined with PEGV.
METHODS
Patients
Data of acromegaly patients was collected at our Rotterdam Pituitary Centre 
between 2004 and 2013. Inclusion criteria were; 1) elevated serum IGF-I levels (>1.2 
xULN) after at least 6 months on the highest dose of LA-SSAs (Sandostatin LAR 30 
mg or Lanreotide Autogel 120 mg every 28 days) and; 2) genomic DNA could be 
obtained (n=104). After the initial start with monotherapy of LA-SSA, co-treatment 
with PEGV was added by weekly injections. For starting doses of PEGV and the 
protocol of PEGV dose titration to achieve normal IGF-I levels, see Franck & Neggers 
et al. (22). All patients gave their written informed consent. The study was approved 
by the local Institutional Review Board.
Hormone assays
Serum levels of IGF-I and GH were measured with the Immulite 2000 assay (DPC 
Biermann GmbH/Siemens, Fernwald, Germany), a solid-phase, enzyme-labeled 
chemiluminescent immunometric assay, with an intra-assay variability of 2-5%, and 
an inter-assay variability of 3-7%. The IGF-I age-adjusted reference ranges were 
used in accordance with earlier reports (23). PEGV serum levels were assessed in 
Aarhus, as described previously (24).
Assessment of side effects included serum concentrations of alanine 
aminotransferase (ALT), aspartate aminotransaminase (AST), alkaline phosphatase, 
γ-glutamyltranspeptidase and total bilirubin. Magnetic resonance imaging (MRI) 
was used to assess changes in pituitary tumor volume at least every 2 years. 
Changes in tumor size were assessed by a single radiologist who was blinded for 
patient characteristics and treatment regimens. A ‘significant decrease’ was defined 
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as a reduction of more than 20% of the largest diameter of the tumor during 
combination treatment compared with the largest diameter of the last MRI before 
the addition of PEGV.
Q-PCR of GHR deletion of exon 3
The exon 3-deleted GHR polymorphism could be assessed in 104 patients. Genomic 
DNA was extracted from peripheral blood leukocytes by standard procedures. 
Analysis of the d3-GHR polymorphism was carried out using quantitative PCR (Q-PCR) 
as previously described (5). Briefly, primer/probe sets binding to exons 3 and 10 of 
the human GHR gene were added to the DNA samples. GHR exon 10 served as an 
internal positive control. Q-PCR was performed in triplicate 384-wells plates with 20 
ng genomic DNA in a volume of 5 µl using 1x Taqman Universal PCR Master Mix (Life 
Technologies), 3 µM GHR exon 3 primers/probe and 9 µM GHR exon 10 primers/
probe. Amplification was performed using a real-time Taqman 7900 HT instrument 
(Applied Biosystems) with the following cycle conditions: 50°C for 2 min, 95°C for 10 
min followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min. Differences in cycle 
threshold (ΔCt) between exon 3 and exon 10 amplicons were used to determine 
the exon 3 copy number for each sample. A ΔCt value of 1 indicates two exon 3 
copies (genotype fl/fl), a ΔCt value of 2 indicates one exon 3 copy (genotype fl/d3) 
and no signal for exon 3 in the presence of a normal exon 10 signal indicates an 
absent exon 3 (genotype d3/d3). To validate the genotyping accuracy, 25 samples 
were randomly selected to determine the GHR exon 3 polymorphism for a second 
time using a multiplex PCR assay (7). No discrepancies were found between the 
genotypes obtained by either method.
Statistical analysis
Data are expressed as medians [interquartile range [IQR]] unless otherwise specified. 
Nominal variables were analyzed using the χ2-test. Differences between two or 
more independent subgroups were analyzed using the Mann-Whitney U test or 
the Kruskal-Wallis ANOVA respectively. Hardy-Weinberg equilibrium was analyzed 
with the χ2-test via the observed and expected genotype frequencies. Results of 
correlation analyses are expressed as Spearman’s rank correlation coefficient. 
P-values <0.05 (two-tailed) are considered statistically significant. Statistical analyses 
were performed with SPSS version 20 and GraphPad Prism version 6 for Windows 
(SPSS software, Chicago, IL, USA and GraphPad Software, San Diego, CA, USA).
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RESULTS
Patient characteristics 
Characteristics of the 104 patients are presented in Table 1. The median age of 
all patients at time of diagnosis was 45.4 years and the majority of the patients 
were male. The median time between the diagnosis and the start of PEGV was 1.4 
years. The median duration of PEGV treatment was 5 years. The majority of the 
patients had a macroadenoma. Diabetes mellitus type II was present in one-third of 
subjects. Previous therapies were surgery (42.3%) and radiotherapy (12.5%). Before 
the start of PEGV in combination with LA-SSAs, the median absolute IGF-I level was 
63.8 nmol/l or 1.81 expressed as times the ULN of IGF-I. The median GH level at the 
start of PEGV was 4.0 µg/l. For 18 patients, GH levels were missing at the start of 
PEGV.
Table 1. Patient characteristics of fl-GHR and d3-GHR genotypes
Expressed as median [interquartile range]. 
ULN: upper limit of normal, PEGV: pegvisomant, IGF-I: insulin-like growth factor I, GHR: growth hormone receptor, 
d3-GHR: growth hormone receptor polymorphism lacking exon 3, fl-GHR: full-length growth hormone receptor.
a. fl/fl genotype vs d3 genotype (fl/d3 and d3/d3).
GHR genotype
All patients fl-GHR All d3-carriers p-valuea
n – (%) 104 53 (51.0) 51 (49.0)
Males – % 58.7 54.7 62.7 0.432
Age at diagnosis – years 45.4 [35.4 – 56.0] 43.0 [35.4 – 52.7] 46.8 [36.8 – 56.2] 0.400
Time between diagnosis and 
start of PEGV – years 1.4 [0.9 – 3.5] 1.4 [0.9 – 4.1] 1.6 [0.9 – 3.5] 0.995
Age at start PEGV – years 47.8 [37.8 – 59.2] 46.8 [37.2 – 59.0] 48.9 [40.1 – 59.2] 0.309
Years of PEGV treatment 5.0 [2.4 – 6.3] 4.2 [2.0 – 7.4] 5.2 [3.2 – 7.2] 0.181
Tumor volume – macro % 81.7 79.2 84.3 0.614
Diabetes mellitus type II – % 36.5 30.2 43.1 0.222
Previous therapy:
     Surgery – % 42.3 43.4 41.2 0.845
     Radiotherapy – % 12.5 7.5 17.6 0.146
GH at start of PEGV – µg/l 4.0 [2.3 – 10.3] 4.5 [2.5 – 10.2] 3.5 [2.2 – 7.3] 0.206
IGF-I at start of PEGV  
 –  nmol/l 63.8 [46.5 – 86.6] 68.8 [46.1 – 94.0] 62.6 [48.9 – 78.3] 0.558
IGF-I xULN at start of PEGV 1.81 [1.48 – 2.50] 2.03 [1.47 – 2.72] 1.77 [1.52 – 2.31] 0.521
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Patient characteristics and GHR genotype
The d3-GHR polymorphism assessed in 104 (92.9%) of the 112 patients. The 8 
patients, from whom genomic DNA was not retrieved, did not exhibit phenotypical 
features different from the genotyped patients (data not shown). D3-GHR was 
observed in 51 (49.0%) of the patients, of which 7.7% were homozygous and 
41.3% were heterozygous. This distribution of the d3-GHR genotype followed the 
Hardy-Weinberg equilibrium (p=0.859). Patient characteristics for both groups are 
depicted in Table 1. No statistically significant differences were present at baseline 
between the GHR genotypes, regarding age at diagnosis and at start of PEGV, years 
of treatment, sex, tumor volume assessed as macro- vs. microadenomas, presence 
of diabetes mellitus type II, kind of previous therapy, and GH and IGF-I levels before 
start of PEGV. 
Clinical and biochemical response during treatment
IGF-I levels
Normalization of IGF-I corrected for age, defined as a dichotomous variable based 
on the lowest IGF-I during treatment, was observed in almost all fl-GHR patients and 
d3-GHR carriers, and was not significantly different between the groups (p=0.587, 
Table 2). The lowest median absolute IGF-I level during treatment (18.0 nmol/l) 
in the fl-GHR genotype was not significantly different from that in the d3-GHR 
genotype (18.4 nmol/l, p=0.592). Furthermore, IGF-I xULN and decrease of IGF-I 
during treatment was not different between d3-carriers and non-carriers (p=0.780 
and 0.728, respectively, Figure 1). 
Figure 1. Decrease of IGF-I during PEGV treatment
Data is expressed as median. Decrease of IGF-I is based on the IGF-I leven before the start of PEGV and the lowest 
IGF-I during PEGV treatment. 
PEGV: pegvisomant, IGF-I: insulin-like growth factor I, GHR: growth hormone receptor, d3-GHR: growth hormone 
receptor polymorphism lacking exon 3, fl-GHR: full-length growth hormone receptor.
a. fl/fl genotype vs d3 genotype (fl/d3 and d3/d3).
fl/fl d3/fl d3/d3
IG
F-
I (
nm
ol
/l
)
before PEGV
during PEGV
p=0.728a
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Table 2. Clinical and biochemical response during treatment of fl-GHR and d3-GHR 
genotypes
Expressed as median [interquartile range]. 
ULN: upper limit of normal, PEGV: pegvisomant, IGF-I: insulin-like growth factor I, GHR: growth hormone receptor, 
d3-GHR: growth hormone receptor polymorphism lacking exon 3, fl-GHR: full-length growth hormone receptor.
a. fl/fl genotype vs d3 genotype (fl/d3 and d3/d3).
b. Dichotomous variable based on the lowest IGF-I during treatment period.
c. Difference between IGF-I before the start of PEGV and Lowest IGF-I during combination treatment.
d. Required PEGV dose to achieve normalization of the IGF-I level.
e. More than 20% volume reduction.
f. Patients with an empty sella were not included in the analyses, as decrease and increase are not applicable.
g. Tested by logistic regression, correction for radiotherapy did not influence the significance.
h. Tested by Fisher’s exact test.
GHR genotype
All patients fl-GHR All d3-carriers p-valuea
n – (%) 104 53 (51.0) 51 (49.0)
Normalization of IGF-I  
<1.0 xULNb – % 97.1 96.2 98.0 0.587
Lowest IGF-I during  
treatment – nmol/l
18.5  
[14.5 – 23.5]
18.0  
[14.7 – 24.3]
18.4  
[12.1 – 23.1] 0.592
Lowest IGF-I xULN  
during treatment
0.57  
[0.43 – 0.75]
0.56  
[0.43 – 0.76]
0.56  
[0.40 – 0.71] 0.780
Decrease IGF-Ic – % 69.5  [59.6 – 78.3]
75.4  
[59.6 – 79.7]
72.0  
[63.5 – 78.1] 0.728
PEGV dosed – mg/week 80.0  [60.0 – 120.0]
80.0  
[60.0 – 110.0]
80.0  
[60.0 – 140.0] 0.337
PEGV dose – mg/kg/week 0.90  [0.66 – 1.28]
0.82  
[0.59 – 1.24]
0.91  
[0.66 – 1.40] 0.655
PEGV serum level – µg/l 4625  [2975 – 11962]
4913  
[3025 – 12500]
4625  
[2925 – 8025] 0.433
Ratio PEGV serum/dose
63.0  
[38.5 – 100.0]
68.0  
[39.0 – 99.0]
56.0  
[36.0 – 93.0] 0.293
Transient elevated  
transaminases – % 16.3 15.1 17.6 0.725
Decrease of tumor sizee,f  
during treatment – % 16.5 25.6 7.5 0.034
g
OR: 4.6  
[CI: 1.1 – 18.9]
Change in tumor size during treatmentf
Decrease of tumor sizee – n (%) 13 (12.5) 10 (18.9) 3 (5.9)
No change of tumor size – n (%) 66 (63.5) 29 (54.7) 37 (72.5) 0.036h
Increase of tumor size – n (%) 1 (1.0) 1 (1.9) 0
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PEGV dose and PEGV serum level 
The median required PEGV dose to achieve the lowest IGF-I level was 80.0 mg/
week [60.0 – 110.0] for non-carriers and 80.0 mg/week [60.0 – 140.0] for the d3-
GHR genotype. No significant difference between the two groups was found for 
the PEGV dose (p=0.337), as presented in Figure 2. Correlation analysis showed a 
positive correlation between the decrease in IGF-I level and the PEGV dose (ρ=0.211, 
p=0.030), depicted in Figure 3. The median required PEGV dose between men 
and women was not significantly different (p=0.650). Weight correlated positively 
with the PEGV dose (ρ=0.265, p=0.007). The PEGV dose in mg/kg/week was not 
Figure 2. Required PEGV dose for normalization of IGF-I
Expressed as median [interquartile range].
a. fl/fl genotype vs d3 genotype (fl/d3 and d3/d3).
PEGV: pegvisomant, IGF-I: insulin-like growth factor I, GHR: growth hormone receptor, d3-GHR: growth hormone 
receptor polymorphism lacking exon 3, fl-GHR: full-length growth hormone receptor.
Figure 3. Correlation between IGF-I and PEGV dose
The decrease of IGF-I between the start of PEGV and the lowest IGF-I level during treatment of the total acromegaly 
cohort during combination treatment. PEGV dose is the required dose to achieve this lowest IGF-I level during 
treatment. Adjustment for GHR variant, age and sex did not influence correlation analysis. 
PEGV: pegvisomant, IGF-I: insulin-like growth factor I.
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significantly different between fl-GHR and d3-GHR (p=0.655). 
The PEGV serum levels (n=83, genotyped cohort), measured during the end 
of the inclusion period of this study, were also not significantly different between 
the two genotypes (p=0.433), as shown in Figure 4. PEGV serum levels were 4913 
µg/l [IQR: 3025 – 12500] for non-carriers and 4625 µg/l [IQR: 2925 – 8025] for 
Figure 5. Correlation between IGF-I and PEGV serum level 
The decrease of IGF-I between the start of PEGV and the lowest IGF-I level during combination treatment. PEGV 
serum levels were measured during the end of the inclusion period of this study. Adjustment for GHR variant, age 
and sex did not influence correlation analysis.
PEGV: pegvisomant, IGF-I: insulin-like growth factor I.
Figure 4. PEGV serum levels
PEGV serum levels were measured during the end of the inclusion period of this study. Expressed as median 
[interquartile range]. 
PEGV: pegvisomant, IGF-I: insulin-like growth factor I, GHR: growth hormone receptor, d3-GHR: growth hormone 
receptor polymorphism lacking exon 3, fl-GHR: full-length growth hormone receptor.
a. fl/fl genotype vs d3 genotype (fl/d3 and d3/d3).
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the d3-GHR carriers. Correlation analysis showed a positive correlation between 
the decrease of IGF-I and the PEGV serum level (n=86 (total cohort), ρ=0.225, 
p=0.041, Figure 5). The median PEGV serum levels were not different between men 
and women (n=86, p=0.870). Weight was not correlated to the PEGV serum level 
(n=79, ρ=-0.027, p=0.814). The ratio of PEGV serum levels over the PEGV dose was 
not significantly different between the d3-GHR carriers and non-carriers (n=83, 
p=0.293). Samples of 29 patients (25.9%) were not available for the assessment 
of PEGV concentrations. In 7.8% of the samples, a PEGV serum level of 0 mg/l was 
measured during PEGV treatment and was left out of the analysis.
Tumor shrinkage and liver enzyme tests
A significant reduction of the adenoma size was observed in 25.6% of the fl-GHR 
genotype and in 7.5% of the d3-carriers, which is a significant difference between 
the groups (p=0.034, OR: 4.6 [CI: 1.1 – 18.9] tested by logistic regression). When 
tested by Fisher’s exact test, p-value was 0.036. Of the d3-carriers, 17.6% had 
transiently elevated transaminases (TET), the most common side effect of the 
combination treatment with PEGV and LA-SSA, compared to 15.1% of patients with 
the fl-GHR genotype (p=0.725).
DISCUSSION
The results of our study did not show a significant difference in patient characteristics 
or treatment response to PEGV between fl-GHR and d3-GHR genotypes in patients 
with acromegaly. Carrying the d3-GHR polymorphism did not affect the PEGV 
dose nor the PEGV serum levels during treatment. However, a significantly larger 
reduction in tumor volume during treatment was observed in patients with the fl-
GHR genotype compared to d3-carriers (p=0.034). 
Transfection studies have shown that the lack of exon 3 in the GHR 
enhances GH signal transduction (8) and there are clinical data to suggest that 
this polymorphism confers a better response to GH replacement therapy and also 
impacts on patients with acromegaly (5,6,25,26). The group of acromegaly patients 
in our study is suitable to further analyze the clinical relevance of the d3-GHR 
genotype for two reasons. First, acromegaly patients using LA-SSAs and PEGV have 
a more severe disease activity, as LA-SSA monotherapy was not effective enough to 
normalize IGF-I. Secondly, d3-GHR carriers, having a higher GHR signal transduction, 
are considered to respond better to PEGV compared to patients with the fl-GHR. 
Therefore, the d3-GHR carriers can be hypothesized to need a lower dose of PEGV 
to achieve disease control. Indeed, studies during PEGV monotherapy by Bianchi et 
al. (6) (n=19) and Bernabeu et al. (5) (n=44) revealed that the required PEGV dose 
to normalize IGF-I levels was significantly lower in acromegaly patients with d3-GHR 
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genotype. However, Filopanti et al. (10) studied two groups of acromegaly patients 
using monotherapy PEGV (n=64) and LA-SSAs in combination with PEGV (n=63) and 
could not confirm the superior treatment response of d3-GHR carriers in either 
group. It could be argued that the sample sizes of these two cohorts in the last 
negative study were too small to observe an effect. However, in our current study, 
with a reasonable sample size, an effect of the d3-GHR was also not observed.
In our cohort of acromegaly patients, the d3-GHR polymorphism was 
observed in 49% of the patients and followed the Hardy-Weinberg equilibrium. 
This demonstrates the absence of a selection benefit in our acromegaly cohort 
using combination therapy. Acromegaly cohorts in the studies of Bernabeu et al. 
and Filopanti et al. did not follow the Hardy-Weinberg equilibrium. The latter study 
suggested an association between d3-GHR genotype and a more severe phenotype 
of acromegaly patients.
In our study, we measured PEGV serum levels to investigate whether a 
discrepancy might exist between the PEGV dose and the serum levels of PEGV 
between the genotypes. For both PEGV serum levels and PEGV doses, we could not 
detect a significant difference between the two genotypes. PEGV serum levels of 
0 µg/l (n=5) measured during PEGV treatment were left out of the analysis. These 
undetectable PEGV serum levels could be explained by a false negative error of 
the assay, noncompliance of the patient in taking the drug or the absence of PEGV 
due to the half-life of the drug (T1/2el=74-172 h (27)). Although the half-life of the 
drug is probably increased during combination treatment, since PEGV serum levels 
increase by 20% (24,28), in our opinion it is the loss of PEGV from the circulation 
that is the most likely explanation for the undetectable PEGV serum levels. The 
majority of patients with undetectable PEGV serum levels were using a low PEGV 
dose, between 10 and 60 mg once weekly. 
Apart from differences in sample sizes, the discrepancies between our data and 
those previously published could be due to an IGF-I-independent pathway. Binder 
et al. (25,26) published two studies on the use of recombinant human GH (rhGH) 
in children short for gestational age with remarkable outcomes. They observed a 
higher growth velocity in d3-GHR carriers during rhGH therapy, although this was 
not reflected by increases in IGF-I levels, and may allow cautious speculation about 
an IGF-I-independent pathway. If this perspective held true, our study and previous 
research may not have been suitable to assess the influence of d3-GHR genotype on 
IGF-I levels during PEGV treatment in acromegaly patients.
We could not find a significant difference in baseline characteristics, clinical 
or biochemical response between fl-GHR and d3-GHR carriers. However, we did 
observe a difference between the decrease in adenoma volume during treatment 
between patients with fl-GHR genotype and the d3-carriers. An explanation for the 
higher decrease in the fl-GHR group is not readily available as PEGV dose and PEGV 
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serum levels were not significantly different between carriers and non-carriers. 
Moreover, Veldhuis et al. (29) observed that PEGV does not cross the human blood-
brain barrier. However, many areas of the hypothalamus and the pituitary lack a 
blood-brain barrier (30,31). A direct effect of PEGV on the difference between fl-
GHR and d3-GHR genotype in tumor shrinkage is thus difficult to estimate. LA-SSAs 
are more likely to have influence on the different rates of tumor shrinkage between 
the two genotypes. A meta-analysis by Giustina et al. (32) reported that LA-SSAs 
induced relevant tumor shrinkage in more than half of the acromegaly patients 
studied. Predictors of tumor shrinkage by LA-SSAs are age, decrease of GH and IGF-I 
levels, treatment-naive patients and duration of LA-SSA-treatment (32,33,34). Age at 
diagnosis, age at start of PEGV, decrease of IGF-I levels during treatment and previous 
therapy (such as neurosurgery and radiotherapy) were not significantly different 
in our study between fl-GHR and d3-GHR genotype. The other studies about d3-
GHR and PEGV treatment (Bianchi, Bernabeu and Filopanti) did not describe tumor 
shrinkage (5,6,10). Bernabeu et al. did report two cases of tumor increase during 
PEGV monotherapy, but genotypes were not specified. Filopanti et al. reported four 
cases of tumor increase in the PEGV monotherapy group, of which one patient had 
the fl-GHR genotype and three patients were carriers of d3-GHR. In a single-center 
study in Mexico City (11), the authors observed more severe disease activity with 
lower efficacy of treatment (radiotherapy, surgery and/or pharmacological therapy) 
in acromegaly subjects with the d3-GHR genotype. Therefore, it might be expected 
that carriers of the d3-GHR have less tumor regression, since biochemical response 
and tumor regression seem to be linked.
CONCLUSION
The clinical data in our study do not support a role for GHR genotype in the 
treatment response to PEGV combined with LA-SSA in patients with acromegaly. 
Our observation that the reduction in pituitary tumor volume during combination 
therapy was smaller in d3-carriers was unexpected and merits further attention.
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ABSTRACT
Background: The common exon 3 deletion polymorphism of the growth 
hormone receptor (d3-GHR) is associated with disease severity in acromegaly 
patients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating 
severe acromegaly. Response to PEGV treatment seems to be influenced 
by d3-GHR and appears to be more responsive to PEGV, although available 
results remain conflicting.
Objective: To assess the influence of d3-GHR on the responsiveness of 
acromegaly patients to PEGV by compiling the evidence derived from the 
largest available studies.
Design: A systematic review of the literature identified three published studies 
and one conference abstract. Acromegaly patients (n=324, 49.7% d3-GHR 
carriers) were treated with either PEGV monotherapy or PEGV combined with 
long-acting somatostatin analogues (LA-SSA) and/or cabergoline. A meta-
analysis of raw data from these studies was performed.
Results: No significant effect of the d3-GHR was observed while bringing 
insulin-like growth factor I (IGF-I) levels below the upper limit of normal with 
PEGV, which was defined as the lowest IGF-I level during PEGV-treatment 
(mean difference: -2.3%; 95% CI: -6.5 – 1.8%, p=0.270). The PEGV dose 
required to achieve the lowest IGF-I levels was also not significantly influenced 
by individuals carrying d3-GHR (mean difference: 4.1 mg/week; 95% CI: -5.1 
– 13.2, p=0.385). For both outcomes, separate analysis of PEGV monotherapy 
and combination treatment gave similar results.
Conclusions: Our findings suggest that the d3-GHR polymorphism has no 
effect on biochemical disease control in acromegaly, as it is not of added value 
for either the prediction of PEGV responsiveness or the determination of the 
required PEGV dose. 
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INTRODUCTION
Acromegaly is a rare disease characterized by excessive secretion of growth 
hormone (GH) resulting in a diversified clinical presentation. The disease is almost 
exclusively caused by a GH-secreting pituitary adenoma (1). These elevated GH 
levels subsequently increase IGF-I production, predominantly by the liver, although 
other tissues also synthesize IGF-I (2). If untreated, the disease is associated with 
an increase in morbidity and mortality (2). Control of disease activity results in 
mortality rates similar to the general population (3). Although transsphenoidal 
surgery remains the first line treatment in most countries (4), it is often unsuccessful 
for macroadenomas, making additional treatment modalities necessary when GH 
and IGF-I levels remain elevated. However, primary medical treatment is becoming 
more and more popular, starting with LA-SSAs with an average efficacy rate in 
normalizing GH and IGF-I levels in treatment naive patients of 44% (5). A highly 
effective alternative for patients who are not normalized by LA-SSA monotherapy 
is the addition of PEGV to LA-SSA, or even PEGV monotherapy, provided that the 
appropriate PEGV dose is used (6-8). 
PEGV is a PEGylated recombinant GH analogue that acts as a competitive GH 
receptor antagonist in all tissues except the brain, most importantly suppressing 
GH-dependent production of IGF-I by the liver (9). The PEGV dose required for 
normalization of IGF-I levels in acromegaly is variable, depending on disease 
activity and individual response to the drug (6,10). Likewise, a wide inter-individual 
variation in PEGV serum levels is observed despite identical PEGV dosing (11,12). 
These differences in individual responses have been partly attributed to a common 
polymorphism in the GH receptor gene characterized by deletion of exon 3. This 
in-frame deletion causes loss of 22 amino acids from the extracellular domain. In 
about half of the general population the polymorphism is homozygous for the full-
length GHR (fl/fl-GHR), with the remaining half carrying the d3-GHR polymorphism; 
30-40% being heterozygous and 10-20% homozygous for this deletion (13-15). A 
similar distribution of this GHR variant in cohorts of acromegaly patients has been 
described in the literature (16-20).
The deletion of exon 3 in GHR is caused by retrovirus-mediated alternative 
splicing, which results in skipping of coding exons (15). This alternative splicing 
pattern is human-specific (15). Evolutionary conservation of this GHR variant suggests 
beneficial effects. Transfections experiments by Dos Santos et al. have shown that 
the lack of exon 3 in the GHR enhances GH signal transduction by approximately 
30% (14). More specifically, the deletion of exon 3 leads to greater stimulation of 
the intracellular JAK-STAT pathway in response to GH, which results in increased 
transcription of GH-target-genes. Following the report of Dos Santos et al., several 
studies primarily focused on assessing the role of the d3-GHR polymorphism during 
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recombinant GH treatment of GH-deficient and non-GH-deficient pre-pubertal 
children with short stature. Carrying one or more d3-GHR alleles was found to be 
associated with increased baseline height and growth response to GH, according to 
a meta-analysis by Wassenaar et al. (21). Thereafter, subsequent studies evaluated 
the influence of d3-GHR on the severity of acromegaly. 
Several studies have addressed the influence of the d3-GHR polymorphism 
on GH and IGF-I levels. The first study included 44 untreated active acromegaly 
patients, in which a higher baseline GH was observed in d3-GHR carriers whereas 
IGF-I levels were similar across the three genotypes (22). However, a more recent 
study in 105 patients with untreated acromegaly could not confirm these findings 
(18). The impact of the GHR variant on comorbidities was assessed in 86 acromegaly 
patients during long-term disease control (23). The presence of d3-GHR was 
associated with an increased prevalence of irreversible long-term complications, 
such as osteoarthritis, dolichocolon, and adenomatous colonic polyps. However, 
d3-GHR was not associated with other comorbidities such as metabolic syndrome, 
diabetes mellitus type II, and vertebral and non-vertebral fractures. A recent Turkish 
study (n=118) observed no effect of the GHR variant on either clinical features nor 
comorbidities, but suggested that the polymorphism might play a role in GH/IGF-I 
level discordance. Posttreatment biochemical characteristics were also assessed by 
an Italian cohort study, suggesting that more discordant GH/IGF-I levels (high IGF-I 
and GH ≤2 ng/ml) were observed in d3-GHR carriers, and that this discordance in 
levels was enhanced after initiation of somatostatin analogue treatment (16). 
A previously cited meta-analysis observed an association with increased 
growth velocity in recombinant human (rh)GH treated GH-deficient children carrying 
d3-GHR (21). Subsequently, the question emerged whether d3-GHR influences 
pharmacodynamics of PEGV in acromegaly as carriers of d3-GHR might need less 
PEGV to normalize IGF-I levels than patients with the fl/fl-GHR genotype in order to 
normalize IGF-I levels. PEGV directly antagonizes the GHR, and therefore could have 
a greater impact on exon 3-deleted GHRs. Two studies, indeed, reported a lower 
required PEGV dose during disease control in acromegaly patients with the d3-GHR 
genotype (16,24). However, more recent studies in larger acromegaly cohorts could 
not confirm these findings (25,26). These contradictory reports on the influence 
of d3-GHR in acromegaly patients regarding PEGV-treatment responses and the 
PEGV doses required to normalize IGF-I levels, motivated us to conduct a systematic 
review of the literature to identify studies examining this question and to perform 
a meta-analysis. The aim of this study is to address the clinically-relevant question: 
Do clinicians have to take d3-GHR genotyping into account during PEGV dosing? 
99
D3-GHR meta-analysis
5
MATERIALS & METHODS
Inclusion criteria
The two main outcome parameters used by us were; 1) Lowest IGF-I level expressed 
as upper limit of normal (xULN) during PEGV-treatment and; 2) the required PEGV-
dose to achieve the lowest IGF-I level. Studies reporting these main outcomes in 
acromegaly cohorts concerning the influence of d3-GHR were included. In these 
studies the exon 3-deleted GHR polymorphism has been reported as fl/fl-GHR, d3/
fl-GHR, d3/d3-GHR, and/or d3-GHR, in which d3-GHR could be a combination of the 
d3/fl-GHR and d3/d3-GHR genotype. 
Search strategy
The online literature databases: Embase.com, Medline (OvidSP), Pubmed Publisher, 
Web of Science, Google Scholar, and the Cochrane Library were used for this 
systemic search of studies reporting the influence of d3-GHR on the outcome in 
response to PEGV treatment in acromegaly patients. This was performed under the 
guidance of a research librarian. The performed search strategy was: (d3GHR OR d3-
GHR OR “d3-growth hormone receptor” OR “exon 3” OR d3 OR “exon 3-deleted” OR 
“exon 3 deletion”) AND (GHR OR “GH receptor” OR “growth hormone receptor” OR 
GHRs OR “GH receptors” OR “growth hormone receptors”) AND (Polymorphism OR 
polymorphisms OR isoform OR isoforms OR genotype OR genotypes OR variant OR 
variants) AND Acromegaly AND (Pegvisomant OR somavert OR “growth hormone 
receptor antagonist” OR “GH receptor antagonist” OR “GHR antagonist”). The 
searches were performed on the 9th of September 2014. Thereafter, the references 
of relevant articles were revised for additional studies. 
Data review and data collection
Data selection was independently assessed by the investigators S.E. Franck and 
S.J.C.M.M. Neggers. Besides our own cohort, two articles and one conference 
abstract met our selection criteria. The study of Bianchi et al. from 2009 (n=19) 
was excluded from this meta-analysis as the vast majority of the patients was also 
included in a larger cohort (n=127) published by the same author-group in 2012 
(16, 25). We contacted the principal investigators of these three research groups, in 
order to collect raw data from these acromegaly cohorts. We were able to obtain 
from all three selected articles the variables needed to perform the meta-analysis: 
genotype coded as fl/fl, d3/fl or d3/d3, sex, age at diagnosis, PEGV monotherapy 
vs. PEGV combined with LA-SSA and/or cabergoline (CAB) (combination treatment), 
lowest IGF-I levels during PEGV treatment and required PEGV-dose to achieve this 
lowest IGF-I level. In total 135 patients were treated with PEGV monotherapy and 
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189 with combination treatment. Medical ethics committees from each hospital 
approved the protocol, and a written informed consent was obtained from all 
patients. The paragraph ‘Included study characteristics’ in the results section 
describes this approach in more detail. 
Statistical analysis
Raw data from each cohort was used to calculate betas (βs) and standard errors 
(SEs) by linear regression analysis. βs and SEs were calculated per cohort and 
medication group (PEGV monotherapy, combination treatment and total cohort: 
monotherapy + combination treatment). The variable lowest IGF-I during PEGV 
treatment was corrected for sex, age and required PEGV-dose to achieve the lowest 
IGF-I level. This latter variable itself was corrected for sex and age, when used for 
meta-analysis individually. Hardy-Weinberg equilibrium was analyzed with the χ2-
test via the observed and expected genotype frequencies.
Statistical analyses were performed with SPSS version 20 (SPSS software, 
Chicago, IL, USA) and GraphPad Prism version 6 for Windows (GraphPad Software, 
San Diego, CA, USA). Potential effects of the genotype GHR deletion of exon 3 were 
calculated by an inverse-variance meta-analyses in R, version 3.2.1 (27). Fixed 
effects meta-analyses were performed as implemented in the R package ‘rmeta’ 
(28). As we test two independent medical treatment variants (PEGV monotherapy 
and combination treatment) as well as the total cohort, we set the significance 
threshold of our one-sided p-value’s at 0.025 in order to correct for multiple testing 
(Bonferroni correction).
RESULTS
Literature search
We identified 511 potentially relevant studies by a literature search in Embase, 
Medline, Pubmed, Web of Science, Google Scholar, and the Cochrane Library, 
depicted in Figure 1. Of these studies 497 were found not to meet the inclusion 
criteria on the basis of title and abstract. Fourteen papers were relevant for 
more detailed examination, of which nine were excluded for different reasons: 
four papers presented a description/citation of an included study in our meta-
analysis in a book, three papers presented an abstract of an included study in our 
meta-analysis, and two studies did not report original data. One original study 
(16) was excluded as the majority of the patients were included in a larger more 
recent study, which was already included in this meta-analysis (25). Finally, we 
included three published original studies and one conference abstract describing 
one relevant acromegaly cohort (24-26,29). All four selected papers included 
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data of both requested outcomes; 1) Lowest IGF-I level expressed as ULN during 
PEGV-treatment and; 2) the required PEGV-dose to achieve the lowest IGF-I level. 
Included study characteristics
Characteristics of the four included studies are summarized in Table 1. The reports 
were published between 2010 and 2015, and the range of the number of included 
patients varied between 44 and 127. All reports included only acromegaly patients 
with elevated IGF-I levels after at least 6 months of the maximum tolerated dose of 
LA-SSA. Kamenický et al. included 53 patients, of which one patient was excluded 
because LA-SSA pre-treatment was not administered, and GHR genotype was not 
available in three patients, resulting in 49 acromegaly patients relevant for analysis 
(29). 
511 studies were iden  fi ed 
from online literature databases 
3 studies and 1 abstract 
were included  
14 studies were relevant for 
more detailed ex  on
497 studies were excluded on the basis of  tle and abstract
   1 study was exc  ents had 
   been included in a larger more recent cohort, which is 
   included in this meta-anlysis (Filopant et al. JCEM 2012)
   9 studies were excluded on the basis of: 
   n=4; Descrip  on /cit  on of an included study in a book
   n=3; Abstract of an included study
   n=1; Review
   n=1; Special feature editorial
Figure 1. Flow diagram of study selection and exclusion stages
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In total 135 patients were treated with PEGV monotherapy and 189 with 
combination treatment (177 PEGV + LA-SSA, 8 PEGV + CAB, 4 PEGV + LA-SSA 
+ CAB). Treatment modalities were different per study. Bernabeu et al. (n=44) 
and Kamenický et al. (n=49) predominantly included patients treated with PEGV 
monotherapy (Bernabeu: 29 PEGV alone; 7 PEGV + LA-SSA; 7 PEGV + CAB; 1 PEGV + 
LA-SSA + CAB, Kamenický: 42 PEGV alone; 3 PEGV + LA-SSA; 1 PEGV + CAB; 3 PEGV + 
LA-SSA + CAB). Filopanti et al. (n=127) included an almost equal number of patients 
treated with PEGV monotherapy and combination treatment (64 PEGV alone, 63 
PEGV + LA-SSA). Franck et al. (n=104) included only patients treated with LA-SSA in 
combination with PEGV. 
The frequency distribution of the d3-GHR genotype showed some variation 
between studies and ranged between 46.5% in the cohort of Filopanti et al. to 59.1% 
in the cohort of Bernabeu et al, shown in Table 1. The total sample of this meta-
analysis included the following genotypes: fl/fl: 163 (50.3%); d3/fl: 122 (37.7%); 
d3/d3: 39 (12.0%). With the exception of Franck et al. (p=0.859), none of the 
included cohorts had genotype frequencies following Hardy-Weinberg equilibrium 
(HWE) proportions. When all cohorts (n=324) were pooled together the genotype 
distribution was not in accordance with HWE (p=0.034). 
In one of the four studies, an effect of d3-GHR was observed on the duration 
of successful PEGV treatment, as carriers required less time to reach IGF-I 
normalization (24). However, no difference was observed in genotype distribution 
between normalized and non-normalized patients regarding IGF-I levels during 
PEGV treatment. Meanwhile, the required PEGV dose per kg bodyweight was 
approximately 20% lower in d3-GHR carriers (24). The other three studies did not 
report an influence of the genotype on PEGV-treated acromegaly patients regarding 
either IGF-I levels or the required PEGV dose. 
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META-ANALYSIS
Lowest IGF-I during PEGV treatment
The effects of d3-GHR on the lowest IGF-I during PEGV treatment could be assessed 
in all four cohorts using the raw data sets obtained from the principal investigators 
and the individual effects of the studies are summarized in Table 2. The mean 
difference in lowest IGF-I (xULN) between d3-GHR carriers and fl/fl-GHR in the total 
cohort was -2.3% [95% CI: -6.5 – 1.8%], which reflects a small negative effect in 
d3-GHR carriers when compared with fl/fl-GHR in combined data from the four 
studies. However, this effect was not significant (p=0.270, heterogeneity p=0.535, 
Figure 2). Similar results were observed when the total cohort was subdivided into 
patients using either PEGV monotherapy or combination treatment and analyses 
were performed separately (PEGV monotherapy; mean difference: -0.2%, 95% CI: 
-0.07 – 0.07, p=0.961 and combination treatment; mean difference: -2.2%, 95% CI: 
-0.07 – 0.03, p=0.417; heterogeneity both not significant). 
Effect
−0.3 −0.2 −0.1 0.0 0.1 0.2
Bernabeu 2010 (Spain)
Kamenicky 2011 (France)
Filopan 2012 (Italy)
Franck 2015 (The Netherlands)
Summary
Mean difference: -2.3% (95% CI: -6.5 – 1.8) p=0.270
Figure 2. Forest plot of meta-analysis: effect of d3-GHR on IGF-I during PEGV
The summary effect of d3-GHR genotype with respect to fl/fl-GHR on lowest IGF-I xULN during PEGV treatment 
in patients treated with PEGV alone or in combination with LA-SSA and/or CAB (n=43) has a mean difference of 
-2.3% relative to the ULN of IGF-I [95% CI: -6.5 – 1.8%], p=0.270. 
GHR: growth hormone receptor, fl: full-length, d3: deletion of exon 3, IGF-I: insulin-like growth factor I, ULN: 
upper limit of normal, PEGV: pegvisomant, LA-SSA: long-acting somatostatin analogues, CAB: cabergoline, CI: 
confidence interval.
Mean differ nce: -2.3% [95% CI: -6.5 – 1.8] p=0.270
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Table 2. Effect of d3-GHR on the lowest IGF-I xULN during PEGV treatment
First author, year β of ULN SE of β p-value
Heterogeneity 
p-value
PEGV monotherapy 
   Bernabeu 2010  0.017 0.147 0.907
   Kamenický 2011 -0.052 0.060 0.393
   Filopanti 2012  0.026 0.046 0.576
Meta-analysis PEGV monotherapy -0.002 0.035 0.961 0.582
Combination treatment
   Bernabeu 2010 -0.193 0.309 0.547
   Kamenický 2011 -0.185 0.193 0.439
   Filopanti 2012  0.025 0.062 0.684
   Franck 2015 -0.027 0.030 0.371
Meta-analysis combination treatment -0.022 0.027 0.417 0.654
Total cohort
   Bernabeu 2010 -0.059 0.120 0.626
   Kamenický 2011 -0.077 0.052 0.145
   Filopanti 2012  0.015 0.038 0.702
   Franck 2015 -0.027 0.030 0.371
Meta-analysis total cohort -0.023 0.021 0.270 0.535
Meta-analyses of the effect of d3-GHR vs. fl-GHR on lowest IGF-I xULN during PEGV treatment in patients treated 
with PEGV alone, in combination with LA-SSA and/or CAB and in the total cohort (PEGV monotherapy + combination 
treatment). βs and SEs are corrected for sex, age at diagnosis and required PEGV dose. Effect indicates p≤0.025; no 
effect indicates p≥0.025; 
GHR: growth hormone receptor, fl: full-length, d3: deletion of exon 3, IGF-I: insulin-like growth factor I, SE: standard 
error, ULN: upper limit of normal, PEGV: pegvisomant, β: beta, SE: standard error. 
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Required PEGV dose to achieve the lowest IGF-I levels
The effect of d3-GHR on the required PEGV dose needed for the lowest IGF-I 
level during treatment and the individual effects of the studies are summarized in 
Table 3. The mean difference in required PEGV dose was 4.1 mg/week [95% CI: 
-5.1 – 13.2 mg/week], which suggests a small positive effect in d3-GHR carriers 
when compared with fl/fl-GHR in the total cohort from the four studies, however 
this effect was not significant (p=0.385, heterogeneity p=0.535, Figure 3). Similar 
results were observed when the total cohort was subdivided in patients using PEGV 
monotherapy or in combination with LA-SSA and analyses were perform separately 
Table 3. Effect of d3-GHR on the required PEGV dose
First author, year β of ULN SE of β p-value
Heterogeneity 
p-value
PEGV monotherapy 
   Bernabeu 2010  21.880 15.523 0.171
   Kamenický 2011 -22.323 19.305 0.255
   Filopanti 2012    9.213 7.424 0.219
Meta-analysis PEGV monotherapy    7.930 6.327 0.210 0.193
Combination treatment
   Bernabeu 2010 -73.166 26.187 0.017
   Kamenický 2011 -39.367 106.970 0.737
   Filopanti 2012    3.061 10.123 0.763
   Franck 2015    9.440 9.200 0.312
Meta-analysis combination treatment    1.350 6.577 0.837 0.029
Total cohort
   Bernabeu 2010 -10.624 15.288 0.419
   Kamenický 2011 -19.448 18.215 0.291
   Filopanti 2012    6.696 6.127 0.277
   Franck 2015 9.440 9.200 0.312
Meta-analysis total cohort 4.060 4.675 0.385 0.374
Meta-analyses of the effect of d3-GHR vs. fl-GHR on the required PEGV dose needed to achieve normalization of 
IGF-I levels in patients treated with PEGV alone, in combination with LA-SSA and/or CAB and in the total cohort 
(PEGV monotherapy + combination treatment). βs and SEs are corrected for sex and age. Effect indicates p≤0.025; 
no effect indicates p≥0.025.
GHR: growth hormone receptor, fl: full-length, d3: deletion of exon 3, IGF-I: insulin-like growth factor I, SE: standard 
error, ULN: upper limit of normal, PEGV: pegvisomant, β: beta, SE: standard error. 
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(PEGV monotherapy; mean difference: 7.9 mg/week, 95% CI: -4.5 – 20.3, p=0.210 
and combination treatment; mean difference: 1.4 mg/week, 95% CI: -11.5 – 14.2, 
p=0.837; heterogeneity both not significant). In a multivariate linear regression 
model, the required PEGV dose was not different between the three genotypes with 
adjustment for sex, age and the different cohorts included in this meta-analysis (β=-
0.5, SE=5.2, p=0.923). When the total cohort was subdivided in monotherapy PEGV 
or combination treatment with LA-SSA and separately analyzed for the required 
PEGV dose, the linear multivariate regression model showed similar results. 
Effect
−60 −40 −20 0 20
Bernabeu 2010 (Spain)
Kamenicky 2010 (France)
Filopan 2012 (Italy)
Franck 2015 (The Netherlands)
Summary 
40
Mean difference: 4.06 mg weekly (95% CI: -5.1 – 13.2) p=0.385
Figure 3. Forest plot of meta-analysis: effect of d3-GHR on the required PEGV dose
The summary effect of d3-GHR genotype with respect to fl/fl-GHR on the required PEGV dose needed to achieve 
normalization of IGF-I levels in patients treated with PEGV alone or in combination with LA-SSA and/or CAB 
(n=43) has a mean difference of 4.1 mg/week [95% CI: -5.1 – 13.2], p=0.385]. 
GHR: growth hormone receptor, fl: full-length, d3: deletion of exon 3, IGF-I: insulin-like growth factor I, ULN: 
upper limit of normal, PEGV: pegvisomant, LA-SSA: long-acting somatostatin analogues, CAB: cabergoline, CI: 
confidence interval.
 : .1 g/  [95% CI: -5.1 .2] p=0.385
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DISCUSSION
The aim of this meta-analysis was to answer the question whether clinicians should 
take into account d3-GHR genotyping during PEGV prescription, as previous studies 
of its function are contradictory. Our results indicate that d3-GHR does not influence 
the pharmacodynamics of PEGV in acromegaly, at least not clinically-relevant. No 
effect was observed concerning the response of PEGV treatment as the mean 
change in IGF-I levels was not significantly different between the GHR genotypes. 
Furthermore, the required PEGV dose to achieve normalization of IGF-I levels did 
not differ between carriers of the d3-GHR and the fl/fl-GHR genotypes. 
The first two published studies reporting the effect of d3-GHR genotype on 
PEGV-pharmacodynamics in acromegaly observed beneficial effects regarding d3-
GHR carriers. An Italian study (n=19) observed lower IGF-I levels in d3-GHR carriers 
compared to those with the fl/fl-GHR genotype after 3 and 6 months of PEGV (16). 
However, after 12 months of PEGV treatment this difference was lost, although 
the final PEGV dose was significantly lower in d3-GHR carriers compared to the 
fl/fl-GHR genotype. Similar results were observed in a Spanish cohort (n=44); no 
difference was observed in genotype distribution between IGF-I controlled and non-
controlled patients, but the required PEGV dose per kilogram of weight to normalize 
IGF-I levels was 20% lower (p=0.033) in patients with the d3-GHR polymorphism 
compared with the fl/fl-GHR genotype (24). The previous 19 Italian patients 
were later included in a larger cohort (n=127) in which the same research group 
reported that they could not confirm their previous results (25). Similarly, we did 
not observe a difference between the two genotypes regarding IGF-I levels during 
PEGV treatment. Concerning PEGV dosing, we only observed a significant difference 
in a subset of the patients undergoing combination treatment (n=15, Table 3). This 
effect was not observed in patients receiving PEGV monotherapy (n=29) or in the 
total cohort (monotherapy and combination treatment tested together). More 
recent studies, reporting larger cohorts (n=49, n=127, n=104), were also unable to 
confirm the beneficial effects on PEGV-pharmacodynamics in acromegaly patients 
carrying the d3-GHR polymorphism (25, 26, 29). This phenomenon could be due to 
the presence of a publication bias in the beginning of this publication series about 
the effect of d3-GHR in acromegaly, the so-called ‘winner’s curse’.
This meta-analysis included 324 acromegaly patients, the d3-GHR 
polymorphism was observed in 161 (49.7%) of the patients, of which 122 (37.7%) 
were heterozygous and 39 (12.0%) were homozygous. As previously mentioned, half 
of the general population is homozygous for the fl/fl-GHR; 30-40% is heterozygous 
for d3-GHR and 10-20% is homozygous for this deletion (13-15). A similar distribution 
of the d3-GHR polymorphism is reported in several acromegaly cohorts (16-20), 
including the total cohort in this meta-analysis, although the distribution was not 
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in accordance with HWE. When HWE was tested in the individual cohorts, only 
the Dutch cohort was in HWE. An explanation for this deviation from HWE in the 
smaller cohorts may indicate a possible random genetic drift related to the small 
sample size. The smaller French cohort (18) (n=49) has an increased prevalence of 
the d3/d3 genotype and a lower prevalence of the d3/fl genotype. When three d3/3 
patients are shifted to the d3/fl genotype the distribution is in HWE. Interestingly, 
when only these three French patients are shifted, the total cohort of 324 patients 
is also in accordance with the HWE. These three patients from a smaller cohort, that 
could explain the disbalance in the HWE distribution, are not expected to affect the 
results of this meta-analysis. In the larger cohort of Filopanti et al. the deviation 
from HWE could be explained by a genotyping error, however this seems to be 
unlikely as these data were obtained following the same methods and by the same 
laboratory analysts that found consistent distributions of the d3-GHR genotype 
following HWE in healthy individuals and several series of acromegaly patients (20), 
which was also additionally monitored and confirmed by an independent staff.  
Since acromegaly is a rare disease and patients treated with PEGV are limited, 
we could only include a relatively small number of large studies in this meta-
analysis. To date however, this is the largest dataset available for this specific group 
of acromegaly patients. Furthermore, GHR genotyping was done locally in several 
laboratories using multiplex and quantitative PCR techniques. Similarly, different 
assays were used to measure IGF-I levels, and therefore it was chosen to express 
the IGF-I level as the upper limit of normal. In addition, a comparison between fl/
fl-GHR and d3-GHR regarding baseline GH and IGF-I levels in untreated acromegaly 
patients is missing, which would have given a more complete overview. Especially, 
as there are data reporting an association between d3-GHR and discordant GH and 
IGF-I levels (high IGF-I vs. normal GH) (22,30), however conflicting data regarding 
this topic are also reported (31). Despite these limitations, we were able to obtain 
all the available raw data from the studies derived from our systematic literature 
search on d3-GHR and PEGV treatment. Moreover, data were all collected using 
similar definitions, as response to PEGV treatment was objectified by the lowest 
IGF-I level during the PEGV treatment period, as was the associated required PEGV 
dose linked to these IGF-I levels. Furthermore, PEGV monotherapy and combination 
therapies showed similar results for both the response to PEGV treatment and the 
required PEGV dose. If d3-GHR carriers were to exhibit greater biological activity 
of GH, a dose effect for PEGV per haplotype is also to be expected. In this meta-
analysis, we aimed to evaluate a dose effect regarding the required PEGV dose in 
a pairwise comparison between the three genotypes. No difference in PEGV dose 
was observed between the three genotypes either in the PEGV monotherapy or in 
the combination treatment group, making it highly unlikely that there is a clinically-
relevant effect of d3-GHR on the pharmacodynamics of PEGV in acromegaly. This 
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outcome leaves room for discussion about the effect of the d3-GHR polymorphism 
in healthy individuals. D3-GHR carriers present in the general population, should 
either maintain normal GH activity despite less circulating GH, and therefore have 
similar GH end-targets such as metabolic state, body composition and final height 
or exhibit an increase in these GH end-targets. In this respect, it is interesting to 
note that genome-wide association studies on final height (32,33) and metabolic 
state (34) did not report any association with the GHR locus in healthy individuals, 
corroborating our findings. In summary, we believe that our study demonstrates 
that the presence of the d3-GHR genotype in acromegaly patients has no impact on 
clinical practice. Moreover, we are convinced that this meta-analysis provides us a 
final conclusion regarding the d3-GHR polymorphism and its lack of effect on PEGV 
response and dosing in acromegaly.
CONCLUSION
In our meta-analysis of a combined group of 324 acromegaly patients obtained 
from four separate study cohorts, the presence of one or two copies of the d3-
GHR polymorphism had no significant effect on the lowest IGF-I levels during PEGV 
treatment nor on the required PEGV dose to achieve these levels. Similarly, no 
difference between subgroups of subjects that used PEGV either as monotherapy 
or in combination with LA-SSAs were observed. Our results indicate that there is 
no evidence supporting a role for the d3-GHR polymorphism in either predicting 
responses to PEGV therapy or determining PEGV dosing during treatment of 
acromegaly.
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ABSTRACT
Background: Effective treatment of acromegaly with pegvisomant (PEGV), a 
growth hormone receptor antagonist, requires an appropriate dose titration. 
PEGV doses vary widely among individual patients, and various covariates may 
affect its dosing and pharmacokinetics. 
Objective: To identify predictors of the PEGV dose required to normalize 
insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in 
combination with long-acting somatostatin analogues (LA-SSAs). 
Design: Two retrospective cohorts (Rotterdam + Liège acromegaly survey 
(LAS), total n=188) were meta-analysed as a form of external replication to 
study the predictors of PEGV dosing in addition to LA-SSA, the LAS (n=83) 
was used to study the predictors of PEGV monotherapy dosing. Multivariable 
regression models were used to identify predictors of the PEGV dose required 
to normalize IGF-I levels.
Results: For PEGV dosing in combination with LA-SSA, IGF-I levels, weight, 
height and age, were associated with the PEGV normalization dosage 
(p≤0.001, p≤0.001, p=0.028 and p=0.047, respectively). Taken together, these 
characteristics predicted the PEGV normalization dose correctly in 63.3% 
of all patients within a range of +/- 60 mg/week (21.3% within a range of +/- 
20 mg/week). For monotherapy, only weight was associated with the PEGV 
normalization dose (p≤0.001) and predicted this dosage correctly in 77.1% of 
all patients within a range of +/- 60 mg/week (31.3% within a range of +/- 20 
mg/week). 
Conclusions: In this study, we show that IGF-I levels, weight, height and age 
can contribute to define the optimal PEGV dose in order to normalize IGF-I 
levels in addition to LA-SSA. For PEGV monotherapy, only the patient’s weight 
was associated with the IGF-I normalization PEGV dosage. 
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INTRODUCTION
Acromegaly is a rare disease caused by excessive secretion of growth 
hormone (GH), and a subsequent increase in IGF-I production (1). The disease 
is almost exclusively caused by a GH-secreting pituitary adenoma (2). Severity 
and phenotype of the disease varies among acromegaly patients. Uncontrolled 
acromegaly is associated with an increase in morbidity and mortality (1). The 
control of IGF-I levels results in mortality rates similar to the general population 
(3). Although often unsuccessful in macroadenomas, transsphenoidal surgery 
generally is considered as the first treatment modality (4,5). Additional treatment 
after surgery is necessary when GH and IGF-I levels remain uncontrolled. LA-SSAs, 
as adjuvant medical treatment or as primary medical treatment, are regularly 
prescribed. Several studies addressed the response of LA-SSA, and show that LA-
SSA treatment alone reaches control of the disease in about 40% of the patients 
(6,7). A highly effective alternative for patients who are not normalized by LA-SSA 
monotherapy is the addition of PEGV to LA-SSA, or PEGV monotherapy, provided 
that the appropriate PEGV dose is given (8-12). PEGV is a PEGylated recombinant 
analogue of GH which competitively blocks the GH receptor, and thereby reduces 
the excessive GH actions in the liver and peripheral tissues (13,14). PEGV is slowly 
absorbed from the subcutaneous depot (T
max
 of 33-77 hours, T1/2 el 74-172 hours) 
(15). The mode of PEGV-clearance is still not understood. We do not know whether 
the kidneys and/or the liver metabolizes the drug.
The dose of PEGV required to achieve disease control, defined as normalization 
of IGF-I levels, differs between individual acromegaly patients, both during PEGV 
monotherapy and in combination with LA-SSA (8,12). PEGV doses range widely 
between 20-200 mg/week during combination treatment with LA-SSA (16). A study 
by Freda et al. observed that patients using PEGV monotherapy in the ACROSTUDYTM 
with persistently elevated IGF-I levels needed a higher mean PEGV dosage (17). 
Defining the optimal starting dose for PEGV is difficult as the pharmacokinetics 
remain to be elucidated and data on pre-treatment determinants of the PEGV 
dosage required for biochemical disease control is sparse. Currently, IGF-I levels are 
most commonly used during PEGV titration, which is in line with a previous study 
from our group reporting a positive correlation between baseline IGF-I levels and 
the PEGV dose required for normalization of IGF-I during combination treatment 
of LA-SSA and PEGV (8,18). Other predictors that have been reported are GH 
levels, sex, body weight and previous radiotherapy (19,20). Two studies previously 
reported about a GH receptor polymorphism lacking exon 3, which seemed to have 
an influence as well during PEGV dosing (21,22). However more recent studies in 
larger acromegaly cohorts clearly state that this polymorphism has no clinical effect 
on the PEGV response nor the determination of the required PEGV dose (23-25). 
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Given the importance of swift biochemical control in acromegaly but the lack 
of studies investigating pre-treatment predictors we aimed to develop a multivariate 
regression model for predicting the required PEGV dose to achieve normalization of 
IGF-I levels in acromegaly patients.
MATERIALS & METHODS
Cohorts description
Patients (n=271) were included from two retrospective cohorts; 1) the Rotterdam 
cohort and; 2) the Liège acromegaly survey (LAS) cohort (26). The Rotterdam 
cohort contains data from acromegaly patients using LA-SSA in combination with 
PEGV (n=112) collected in the Pituitary Center Rotterdam between 2004 and 2013, 
previously published in 2014 (8). The LAS cohort (n=3194 from 14 centers), was 
created using a software tool which enables hospitals throughout Europe to include 
acromegaly patients and report patient, biochemical and adenoma characteristics 
(26). For this study, only patients using PEGV monotherapy (n=83) or PEGV in 
combination with LA-SSA (n=76) were enrolled from 10 different centers. The 
inclusion period was between 2010 and 2015. 
Rotterdam cohort
Clinical and biochemical data were collected from acromegaly patients with 
elevated IGF-I levels (>1.2x upper limit of normal (ULN)), after at least 6 months 
of the highest dose of LA-SSAs (octreotide LAR 30 mg or lanreotide Autogel 120 
mg every 28 days). In this group, 27 acromegaly patients started with 25 mg PEGV 
weekly as co-treatment, while another 18 started with 40 mg PEGV weekly, and the 
last 67 patients started with a variable PEGV dose, guided by their baseline IGF-I 
levels. This variable PEGV starting dose was based on one of our previous reports 
(Figure 2, (18)). The formula to calculate the PEGV dose is 4 + (IGF-I z-score during 
treatment with high dose LA-SSA*16) and was deducted from a method described 
previously (18). This formula can only be used when IGF-I levels are elevated after a 
period of at least 6 months of LA-SSA treatment. Intervals of dose adaptations were 
6-8 weeks until a controlled IGF-I level was achieved on two consecutive occasions. 
The subjects then visited our outpatient clinic every 16 weeks. When the once 
weekly PEGV dose exceeded 80 mg per injection, patients divided the dosage to two 
weekly injections. With weekly doses over 200 mg, subjects changed administration 
intervals into daily injections or 5 injections per week. At each visit to our outpatient 
clinic, standard measurements were performed including assessments of IGF-I 
levels. Permission from the Institutional Review Board of the Erasmus Medical 
Center Rotterdam was obtained and all patients gave their written informed consent. 
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LAS cohort
Acromegaly patients from the LAS database treated with PEGV were selected and 
divided in two groups; PEGV in combination with LA-SSA and PEGV monotherapy. 
From the LAS-database, we were able to select 141 potential patients using the 
combination treatment. We excluded 65 patients, because of two reasons; 1) no 
IGF-I normalization during LA-SSA + PEGV treatment was achieved (n=16) and; 
2) follow-up data during LA-SSA and PEGV-treatment were missing (n=49). The 
remaining patients (n=76) were selected for this study. The same exclusion criteria 
applied for the PEGV monotherapy patients. We were able to select 122 potential 
patients using PEGV monotherapy. We excluded 39 patients (no IGF-I normalization 
during PEGV monotherapy was achieved (n=6) and follow-up data during PEGV-
treatment were missing (n=33)). The remaining patients (n=83) were selected 
for this study. The medical ethics committee from the Liège University hospital 
approved the protocol, and was covering the other European centers. 
Hormone assays
In the Rotterdam cohort, the GH and IGF-I level measurements were assessed with 
the Immulite 2000 assay (DPC Biermann GmbH/Siemens, Fernwald, Germany), 
a solid-phase, enzyme-labeled chemiluminescent immunometric assay, with an 
intra-assay variability of 6%, and an inter-assay variability of 5-6% for GH and with 
an intra-assay variability of 2-5%, and an inter-assay variability of 3-7% for IGF-I. 
The IGF-I age and sex-adjusted reference ranges were used from an article by 
Elmlinger et al. (27). In the LAS cohort, containing acromegaly patients from several 
European hospitals, the GH and IGF-I level measurements were assessed locally, 
and consequently performed with different assays. Therefore, the IGF-I levels 
were chosen to be expressed as the ULN of the reference ranges used in the local 
hospitals. In this study, GH levels were measured as a single random sample and 
expressed as absolute values. 
Candidate predictors
Variables that were considered as possible predictors for PEGV normalization 
dosage were selected based on the literature (8,18-20), biological plausibility, 
and availability of robust data ascertainment in both cohorts and included: age at 
diagnosis, sex, weight, height, tumor size (micro vs. macroadenoma at diagnosis), 
presence of diabetes mellitus type II, IGF-I levels (expressed as ULN), random GH 
levels and previous treatment modalities (transsphenoidal surgery, radiotherapy 
and the duration of LA-SSA monotherapy before the addition of PEGV). Weight, 
IGF-I levels (expressed as ULN) and random GH levels were collected between 
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6 months before and at the time of PEGV-addition. Other data was collected at 
baseline (as indicated), was fixed data in the patient’s record, or was established 
during disease process. 
Outcome
The outcome used in this study was the PEGV dose (mg/week) needed for the 
normalization of IGF-I levels either during the addition to LA-SSA (highest tolerable 
dose) or as PEGV monotherapy. 
Statistical analysis
Data are expressed as median [interquartile range]. Differences between two 
subgroups were analysed using an unpaired t-test or the Mann-Whitney U test 
(in case of non-parametric data). Nominal variables were analysed using Fisher’s 
exact test. For subjects in which PEGV was added to LA-SSA therapy, the distribution 
of the PEGV dose required for normalization of IGF-I levels was not comparable 
between the two cohorts, therefore we meta-analyzed the data as a form of external 
replication. For all regression models, log-transformation of the outcome variable 
(required PEGV dose) was performed to normalize residuals and non-linearity was 
assessed utilizing restricted cubic splines with 3-4 knots. We used univariable linear 
regression models to assess the association between each candidate predictor and 
the required PEGV dose. The decision for linear regression models instead of multiple 
models for the identification of predictors was based on Akaike information criterions 
and log-likelihood tests comparing multilevel models with random intercepts and/
or slope per cohort versus standard linear regression correcting for cohort. To allow 
for optimal generalizability of effect estimates that predict the required PEGV dose, 
we performed multivariable multilevel modelling with a random intercept per 
cohort for the final model. We selected useful predictors using backward selection 
based on the change in regression coefficients and residual explained variability of 
the model, with a p-value <0.20 as to keep predictors liberally in the model. Other 
p-values are considered statistically significant when lower than 0.05 (two-tailed). 
For subjects switching from LA-SSA to PEGV monotherapy, we used univariable linear 
regression models to assess the association between each potential predictor and 
the required PEGV dose. We subsequently calculated the predicted normalization 
dosage for each subject using the outcomes of the final (multivariable) regression 
models. In addition, we also calculated more conservative and more progressive 
models to cope with potential under or overtreatment by adding or subtracting the 
equivalent of 40 mg/week from the outcome of the regression formula. To cope with 
(differentially) missing values of the candidate predictors, missing data on candidate 
predictors were multiple imputed (five times). The imputation model included all 
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candidate predictor variables, the outcome variable and several relevant variables 
descriptive for the study subjects. There was no difference between the original or 
any of the imputed datasets. All analyses were performed in each of the completed 
datasets and final results were pooled. All statistical analyses were performed using 
Statistical Package of Social Sciences version 20.0 for Windows (SPSS Inc. Chicago, 
IL, USA) or using R statistical software version 3.2.43 (packages rms, MASS and lm4).
RESULTS
Cohort characteristics
Patient characteristics and previous treatment modalities of the two combination 
treatment cohorts and the PEGV monotherapy cohort are depicted in Table 1. 
Acromegaly patients treated with the combination treatment included in the LAS-
database are younger (39.0 vs. 45.5 years), more likely to be diagnosed with a 
macroadenoma (90.8 vs. 81.3%) and suffered from diabetes mellitus type II more 
frequently (43.4 vs. 36.6%). Patients from the Rotterdam cohort are taller (178 vs. 
170 cm). Patients who were included in the LAS-database needed higher PEGV doses 
in order to achieve normalized IGF-I levels both during combination treatment with 
LA-SSA and during PEGV monotherapy and had a higher IGF-I level (xULN) before 
the addition of PEGV. Other descriptive data and measurements such as weight, 
height, and biochemical data are depicted in Table 1, as well as comparisons 
between the combination treatment group and the PEGV monotherapy group. 
No significant differences were observed in the combination treatment cohort 
between excluded (all originated from the LAS database) and included patients, 
except for the percentage of performed surgeries, radiotherapy and height, the 
excluded patients were smaller in stature. No significant differences were observed 
in the PEGV monotherapy cohort between excluded and included patients. 
Predictors of PEGV dosing required for disease control in 
combination treatment with LA-SSA 
All univariate analyses of the candidate predictors are depicted in Figure 1. A 
positive linear association was observed between IGF-I (xULN) and the PEGV dosage 
required for disease control. There was a positive non-linear association of weight 
with PEGV normalization dosage, suggesting an effect threshold from approximately 
100 kg (Figure 1), results were similar after adjustment for age and height (data not 
shown). There was a negative linear association of age with PEGV normalization 
dosage and a positive linear association of height with PEGV normalization dosage. In 
multivariable analyses, the association of age and height were no longer statistically 
significant after adjustment for weight, yet age did meet the pre-specified criteria of 
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Com
binati
on treatm
ent LA
-SSA
 + PEG
V
p-value
a
PEG
V
 m
onotherapy
p-value
b
Total cohort
Rott
erdam
LAS
LAS
N
o. of pati
ents
188
112
76
83
Pati
ent characteristi
cs: 
A
ge at diagnosis – yrs
42.0 [33.0 – 53.0]
45.5 [36.0 – 56.0]
39.0 [29.5 – 47.0]
 0.000
41.0 [29.0 – 51.0]
 0.001
Sex – m
ale %
58.0
58.0
57.9
1.000
53.0
0.000
W
eight before additi
on of PEG
V – kg
90.0 [77.0 – 104.0]
91.5 [79.0 – 104.0]
89.0 [74.5 – 105.0]
0.107
83.0 [71.0 – 93.0]
0.000
H
eight before additi
on of PEG
V – cm
175.0 [168.0 – 182.0]
178.0 [170.0 – 184.0]
170.0 [166.0 – 180.0]
0.000
170.0 [163.0 – 180.0]
0.000
Tum
or size – m
acro %
85.1
81.3
90.8
0.000
83.9
0.276
D
iabetes m
ellitus type II – %
39.4
36.6
43.4
0.025
34.9
0.050
IG
F-I xU
LN
 before additi
on of PEG
V
2.0 [1.5 – 2.7]
1.9 [1.5 – 2.6]
2.1 [1.6 – 2.8]
0.000
2.1 [1.5 – 3.2]
0.001
G
H
 before additi
on of PEG
V – µ
g/l
7.9 [3.1 – 17.8]
8.4 [3.2 – 17.5]
7.5 [2.2 – 18.6]
0.617
5.9 [2.0 – 11.0]
0.000
Previous treatm
ent:
  Surgery – total %
51.0
28.6
84.2
0.000
81.9
0.000
     O
nce debulked – %
48.6
28.6
78.1
71.1
     Tw
ice debulked – %
2.4
N/A
6.1
8.4
     ˃T
w
ice debulked – % 
N/A
N/A
N/A
2.4
  R
Tx – %
16.0
10.7
23.7
0.000
40.2
0.000
D
urati
on of LA
-SSA
 before additi
on of 
PEGV – m
onths
16.0 [8.3 – 39.0]
12.0 [7.2 – 26.8]
25.0 [11.5 – 62.0]
0.000
34.4 [13.4 – 86.4]
0.000
O
utcom
e: 
Required PEG
V
 dose  – m
g/w
eek
105.0 [65.0-200]
80.0 [60.0-120.0]
210.0 [105.0-280.0]
0.000
105.0 [105-140]
0.000
D
escripti
ve characteristi
cs of the three cohorts: Rott
erdam
 cohort using LA
-SSA
 + PEG
V, LA
S cohort using LA
-SSA
 + PEG
V
 and the LA
S cohort using PEG
V
 m
onotherapy. M
issing data w
ere im
puted in the 
original datasets by m
ulti
ple im
putati
on. Conti
nues variables are expressed in m
edian [interquarti
le range] and categorical variables in percentages. LA
-SSA
: long-acti
ng som
atostati
n analogues, PEG
V: 
pegvisom
ant, LA
S: Liège acrom
egaly survey, kg: kilogram
, cm
: centi
m
eter, M
acro: m
acroadenom
a, IG
F-I: insulin-like grow
th factor I, G
H
: grow
th horm
one, RTx: radiotherapy,m
g: m
illigram
, N
/A
: not 
applicable.
a. Com
binati
on treatm
ent (Rott
erdam
) vs. com
binati
on treatm
ent (LA
S)
b. Com
binati
on treatm
ent (Rott
erdam
 and LA
S) vs. PEG
V
 m
onotherapy (LA
S)
Table 1. D
escripti
ve characteristi
cs of the com
binati
on treatm
ent and PEG
V
 m
onotherapy cohorts
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being added in the final model. Other potential predictors were not associated with 
the PEGV normalization dosage (Figure 1).
Figure 2 depicts the performance of the standard prediction model (x-axis) as 
compared to the true PEGV normalization dosage (y-axis) and the difference between 
the predicted and true normalization PEGV-dose for each individual (colored dots 
are corresponding to the table colors; Figure 2). The standard prediction formula 
for PEGV normalization dosage based on multivariable models (EXP^(5.5994 + 
Figure 1. Identification of potential predictors during combination treatment
Univariate analyses of multiple determinants potential for the prediction of the PEGV dose needed to achieve 
normalization of IGF-I levels during combination treatment. IGF-I xULN, age at diagnosis, weight and height were 
significantly associated with PEGV dosing during PEGV treatment in combination with LA-SSA. 
PEGV: pegvisomant, IGF-I: insulin-like growth factor I, ULN: upper limit of normal, GH: growth hormone, micro: 
microadenoma, macro: macroadenoma. 
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Potential overtreatment Correct treatment Potential undertreatment
Model type over 60
mg/week
20 to 60
mg/week
between 20 and -20
mg/week
-20 to -60
mg/week
below -60
mg/week
Conservative
(decrease overtreatment)
6 (3.2%) 20 (10.6%) 64 (34.0%) 41 (21.8%) 57 (30.3%)
Standard 27 (14.4%) 63 (33.5%) 40 (21.3%) 16 (8.5%) 42 (22.3%)
Progressive
(decrease undertreatment)
90 (47.9%) 41 (21.8%) 16 (8.5%) 14 (7.4%) 27 (14.4%)
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Figure 2. Association of combined predictive values with the PEGV dose needed 
for IGF-I normalization
This Figure shows the association of the combined predictive values (X-axis, the model) with the PEGV dose needed 
for IGF-I normalization as obtained in clinical practice (Y-axis). The regression line is represented by the dashed line 
(grey). The individual data-points are colored according to the distance from the regression line (red: distance = 60 
mg/week, orange 20-60 mg/week, green <20 mg/week). Data-points in the Figure depict the standard model. The 
conservative and progressive model were defined as the normal model minus or plus 40 mg/week, respectively. 
The table below depicts the n (%) of the different model groups and also display the potential shift between the 
models.
PEGV: pegvisomant, IGF-I: insulin-like growth factor I.
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IGF-I ULN*0.2585 + weight*-0.0365 + weight2*0.00025 + age*-0.0045)) (Table 2) 
predicted the final PEGV normalization dose correctly in 63.3% of all patients within 
a range of +/- 60 mg/week and in 21.3% of all patients within a range of +/- 20 mg/
week (Figure 2). In addition, a more conservative model (standard prediction model 
minus 40 mg/week) correctly predicted the PEGV normalization dosage in 66.4% of 
all patients within a range of +/- 60 mg/week, and in 34.0% of all patients within a 
range of +/- 20 mg/week (Figure 2). For a more progressive model (standard model 
plus 40 mg/week), these numbers were 37.7 and 8.5%, respectively (Figure 2).
Predictors of PEGV dosing required for disease control during PEGV 
monotherapy 
A positive linear association was observed between weight and the PEGV dosage 
required for disease control (p≤0.001; Figure 3 and Figure 4). None of the other 
potential predictors were associated with the PEGV normalization dosage (Figure 
3). Figure 4 depicts the performance of weight (x-axis) as a predictor for PEGV 
normalization dosage as compared to the true normalization dosage (y-axis) and the 
difference between the predicted and true normalization dosage for each individual 
(colored dots are corresponding to the table colors; Figure 4). The standard 
prediction formula for PEGV normalization dosage based on weight (EXP^(4.092 + 
weight*0.00868)) predicted the final PEGV normalization dose correctly in 77.1% of 
all patients within a range of +/- 60 mg/week and in 31.3% of all patients within a 
range of +/- 20 mg/week (Figure 4). In addition, a more conservative model correctly 
predicted the PEGV normalization dosage in 67.4% of all patients within a range 
+/- 60 mg/week, and in 32.5% of all patients within a range of +/- 20 mg/week. For a 
more progressive model, these numbers were 56.6 and 14.5%, respectively.
Variable Estimate SE p-value
Intercept 5.5994 0.9382 <0.0001
IGF-I – xULN* 0.2585 0.0459 <0.0001
Weight – kg* -0.0365 0.0192 0.0830
Weight2 – kg* 0.0002 0.0001 0.0038
Age at diagnosis – years -0.0045 0.0033 0.1700
As the outcome is not normally distributed, the model should be calculated as: е(final model).
PEGV: pegvisomant, SE: standard error, IGF-I: insulin-like growth hormone I, ULN: upper limit of normal.
*before the addition of PEGV to LA-SSA. 
Table 2. Multivariable analysis of the final model to predict optimal PEGV dosing
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Figure 3. Identification of potential predictors during PEGV monotherapy
Univariate analyses of multiple determinants potential for the prediction of the PEGV dose needed to achieve 
normalization of IGF-I levels during PEGV monotherapy. Only weight was significantly associated with PEGV dosing 
during PEGV monotherapy. 
PEGV: pegvisomant, IGF-I: insulin-like growth factor I, ULN: upper limit of normal, GH: growth hormone, micro: 
microadenoma, macro: macroadenoma. 
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DISCUSSION
The PEGV dose required for normalization of IGF-I levels in acromegaly is highly 
variable and a wide inter-individual variation in PEGV serum levels is observed 
despite identical PEGV dosage (28,29). Previous studies suggest that this variability 
depends on disease activity and individual response to the drug (8,16). Therefore, 
PEGV titration is a process that requires a tailored approach for each individual. 
This is the first study that focuses on identifying predictors for PEGV dosing and 
Figure 4. Association of weight with the PEGV dose needed for IGF-I normalization
This Figure shows the association of the patient’s weight (X-axis) with the PEGV dose needed for disease control 
during PEGV monotherapy as obtained in clinical practice (Y-axis). The regression line is represented by the 
dashed line (grey). The individual data-points are colored according to the distance from the regression line (red: 
distance=60 mg/week, orange 20-60 mg/week, green <20 mg/week). Data-points in the Figure depict the standard 
model. The conservative and progressive model were defined as the normal model minus or plus 40 mg/week, 
respectively. The table below depicts the n (%) of the different model groups and also displays the potential shift 
between the models.
PEGV: pegvisomant, IGF-I: insulin-like growth factor I.
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developing a multivariable model in order to predict the required PEGV dose to 
achieve normalization of IGF-I levels in acromegaly patients. The main findings of 
this study are; 1) IGF-I, weight, height and age at diagnosis are associated with the 
PEGV dose required for normalization of IGF-I levels in patients treated with LA-SSA 
combined with PEGV and; 2) that weight is associated with the PEGV dose required 
for normalization of IGF-I levels in patients treated with PEGV monotherapy. 
 To the best of our knowledge, only one previous study has investigated 
determinants of the PEGV dose needed for IGF-I normalization. Parkinson et al. 
observed that GH and IGF-I levels, sex, weight and previous radiotherapy were 
associated with the PEGV dose required for disease control in patients treated with 
PEGV monotherapy (n=118) (20). In our study, IGF-I xULN was the best predictor for 
PEGV dosing, yet GH levels were not associated with the required PEGV dose. The 
most likely explanation for this difference is the variability of the GH-assays. The 
study by Parkinson et al. used a single assay for the measurement of all GH levels, 
while GH levels in our study were measured in several local hospitals and thereby 
consequently measured by different GH-assays. This can lead to measurement 
errors and a bias. Moreover, single GH has a limited clinical usefulness as it has a 
short half-life and is pulsatile excreted into the bloodstream. Therefore, random 
single measurements of GH are less suitable as a biochemical marker for acromegaly 
in clinical practice. These aspects are less prominent for IGF-I measurements, as 
they are expressed as the upper limit of normal and are less sensitive to daily 
variations as compared to GH. Despite, the limitations of GH-measurement, we 
chose to include and analyze these GH levels, because of its biological plausibility 
as a candidate predictor and the intension that our prediction model is going to be 
used in multiple hospitals and consequently GH-measurements will be performed 
with several different assays. 
The best predictor during combination treatment, besides IGF-I, is the patients 
weight before the start of PEGV. Patients with a higher bodyweight, require a higher 
PEGV dosage, which is a logical and expected phenomenon. However in our study 
a positive non-linear association was observed, suggesting a threshold effect from 
approximately 100 kg body weight which remained similar after correction for 
sex, age and IGF-I levels. A possible explanation for this effect threshold could be 
that these patients have different disease activity and therefore have a different 
body composition, possibly more fat mass. Former studies already reported an 
association between weight and PEGV dose titration (19,20,30). Future studies 
should investigate whether a clinical assessment of body composition (ratios of lean 
vs. fat mass percentages) may improve the prediction of the PEGV dose required for 
biochemical normalization. 
Female gender is reported to have a better PEGV response with similar PEGV 
doses during PEGV monotherapy, however this gender-difference was not statically 
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significant anymore when PEGV doses were expressed per kg body weight (19). 
Another study did observe that women needed a higher average PEGV dose of 
0.04 mg/kg/day during PEGV monotherapy (20). It has been speculated that sex 
differences in PEGV pharmacokinetics may influence absorption, distribution and/
or clearance of the drug as well as the modulation of GH sensitivity by estrogens 
and fat (31-33). However, regardless of weight differences, we could not confirm a 
sex difference in relation to the PEGV normalization dose during our study both in 
patients treated with PEGV monotherapy and in combination with LA-SSA. 
Opposite to patients treated with the combination therapy, we found that 
IGF-I was not a predictor of PEGV dosing during PEGV monotherapy, despite its 
biological plausibility. This may be explained by differences in the disease severity 
of patients in the combination versus monotherapy groups, given that the LAS 
combination cohort requires a median PEGV dose of 210 mg/week on top of the 
maximum LA-SSA dosage, while the LAS cohort treated with PEGV monotherapy 
required a median dose of 105 mg/week. According to the literature, to achieve 
efficacy rates of more than 90% during PEGV monotherapy, the average expected 
weekly dose is above 120-130 mg (12,34). Studies about the combination treatment 
reported PEGV doses that range between 60-140 mg/week in addition to LA-SSA 
[normalization rates range between 67-97%] (8,10,35). These data show that the 
LAS-monotherapy group contains less severe acromegaly patients, while the LAS-
combination treatment group contains more severe acromegaly patients relative 
to data from the literature, presumed that the PEGV dose represents disease 
severity. On the other hand, LA-SSA has a direct and an indirect effect, which results 
in GH-independent decrease of IGF-I secretion (36,37). A Danish group observed 
that PEGV serum levels increase by 20% when combined with LA-SSA (38). Besides 
dosing difference, it may be expected that the use of two drug modalities is naturally 
more given to patients with more disease severity. Additionally, IGF-I (xULN) levels 
before the addition of PEGV in both LAS cohorts treated with monotherapy and 
combination treatment are higher. On the other hand, it should take into account 
the differences between the various IGF-I-assays which were used in the different 
cohorts. 
The PEGV doses of the LAS cohort required for IGF-I normalization were 
strikingly high compared to the Rotterdam cohort. The distribution of normalization 
PEGV dosage were right skewed as opposed to the normally distributed Rotterdam 
cohort. This most likely reflects the fact that the LAS cohort represents the more 
severe cases in Europe, while the experience with PEGV in Rotterdam has led to 
a relatively low threshold for prescribing PEGV in addition to LA-SSA. This may 
not directly be linked to a difference in IGF-I levels before the addition of PEGV 
in our study, however, LAS patients are younger and are having more diabetes 
mellitus type II, which are characteristics of more severe acromegaly. Another 
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possible explanation could be the interest of the research group in Liège for genetic 
disorders causing acromegaly, taking into account that the possible prevalence of a 
mutation in the aryl hydrocarbon receptor interacting protein (AIP) gene, X-linked 
acrogigantism (X-LAG) and/or familial isolated pituitary adenoma (FIPA) patients 
could be higher in this cohort. Despite these differences, we found that a meta-
analysis of both cohorts (as a form of external replication) performed well and also 
the separate analyses per cohort showed the same effect directions. By combining 
both cohorts, the results of this study are widely generalizable as this approach has 
led to a study population that reflects a wide range of acromegaly patient that is 
eligible to start PEGV treatment. 
 This study was potentially limited by the retrospective design, which 
consequently led to missing data. In order to cope with both differentially and 
randomly missing data, we used multiple imputation. This study was also limited by 
the relative small sample size. However, this is expected given the low prevalence of 
acromegaly as well as the fact that only a subset of acromegaly patients is treated 
with LA-SSA in combination with PEGV. The Rotterdam cohort harbored exclusively 
patients that were normalized by LA-SSA in combination with PEGV, as PEGV doses 
were up-titrated until normalization of IGF-I levels were achieved. The exclusion 
of patients from the LAS cohort not normalized by LA-SSA in combination with 
PEGV (n=16, 8.5%) or PEGV alone (n=6, 7.2%) has remained limited. In order to 
overcome these limitations and to replicate our results, prospective studies utilizing 
a multicenter set-up are required. 
This model is designed for patients who are about to start PEGV treatment 
after failure of LA-SSA monotherapy. Furthermore, this study is not designed to 
predict PEGV overdosing, since PEGV doses were increased until IGF-I levels were 
normalized. But this prediction model should be considered as a useful clinical tool 
during PEGV dose titration, which can be time consuming over multiple outpatient 
clinic visits, especially when a high PEGV dose is needed to control the disease.
CONCLUSION
This is the first study that focuses on identifying predictors for the PEGV dose 
required for disease control in acromegaly and the development of a multivariate 
prediction model for the required PEGV dose. The model is designed for patients 
who are about to start PEGV after failure of LA-SSA monotherapy and could be used 
as a clinical guidance tool during the start of PEGV dose titration. In this study, the 
PEGV dose needed for normalization of IGF-I levels in addition to LA-SSA is associated 
with IGF-I levels, weight and age in a multivariate prediction model and predicted 
the final PEGV normalization dose correctly in 63.3% of all patients within a range of 
+/- 60 mg/week [21.3% within a range of +/- 20 mg/week]. The required PEGV dose 
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during monotherapy was associated with the patient’s weight and predicted the 
final PEGV normalization dose correctly in 77.1% of all patients within a range of +/- 
60 mg/week [31.3% within a range of +/- 20 mg/week]. For an acromegaly patient of 
60 years old, weight of 80 kilograms, height of 1.75 meters, and a IGF-I level of 1.6x 
the ULN using the maximum dose of LA-SSA, the standard model will calculate 83.3 
mg PEGV weekly. In this case, we will recommend to start with 80 mg weekly and 
titrate up or down guided by the IGF-I level (target 1.0x the ULN).
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INTRODUCTION 
More than a decade ago, pegvisomant (PEGV) became available as a treatment 
modality for acromegaly patients. Particularly, valuable for patients who were not 
successfully cured after transsphenoidal surgery, radiotherapy and/or achieved 
disease control after (adjuvant) long-acting somatostatin analogues (LA-SSA) 
treatment. In the beginning, PEGV was used as a single drug agent. Concerns were 
raised whether PEGV might induce growth of the pituitary adenoma. Most of the 
available experience was based on the treatment with LA-SSA and its success in 
tumor volume reduction. One of the advantages of the combination of PEGV with 
LA-SSA is that tumor size control or even tumor shrinkage can be expected, besides 
lowering the required PEGV dose and thereby induce possible cost reduction. 
Recently, one of the acromegaly consensus groups has recommended switching to 
combination treatment in patients with partial response to LA-SSAs (1). 
 This chapter will focus on the main discussion points of the previous 
chapters; efficacy and safety issues of the combination treatment in the Rotterdam 
cohort between 2004 and 2013 (chapter 2), somatostatin receptor (SSTR) expression 
during the combination treatment (chapter 3), the role of the polymorphism 
deletion 3 of the growth hormone receptor (d3-GHR) in PEGV-treated acromegaly 
(chapter 4 and 5) and the prediction of the required PEGV dose in order to normalize 
insulin-like growth factor I (IGF-I) levels during monotherapy and in combination 
with LA-SSA (chapter 6). The conclusion of this thesis and the future perspectives 
will be discussed at the end of this chapter. 
1. COMBINATION TREATMENT IN THE ROTTERDAM COHORT
Long-term data of the combination treatment is needed to confirm that efficacy rates 
and its safety profile retain over time. Chapter 2 of this thesis reports these aspects 
in currently the largest single-center cohort (Rotterdam cohort) using combination 
treatment from 2004 and 2013 (2). Here we discuss these efficacy rates, changes in 
tumor volume and other safety aspects of LA-SSA-treatment combined with PEGV. 
1.1 Efficacy and dose reduction 
PEGV monotherapy or combined with LA-SSA is highly effective in treating 
acromegaly, as pharmacology dictates that in principle in virtually every patient 
with acromegaly control of the disease should be possible. The appropriate PEGV 
dose varies among acromegaly patients, the Rotterdam cohort (n=112) reported 
that patients using the highest dose of LA-SSA needed a median weekly PEGV dose 
of 80 mg [range: 30 – 300] to achieve normal IGF-I levels in 97% of the patients (2). 
Monotherapy of PEGV requires a higher cumulative weekly dose of around 130-
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140 mg to achieve a similar normalization rate of 89-97% (3,4). In contrast to these 
reports, an Italian observational study reported no difference in median required 
PEGV dose to normalize IGF-I Levels in patients using PEGV monotherapy compared 
to patients treated with the combination therapy (5). However, these groups were 
not similar according to severity of the disease. The PEGV monotherapy group had 
significant lower growth hormone (GH) and IGF-I levels at baseline compared to 
the combination group in this Italian observational study (5). Large observational 
registries such as the ACROSTUDY™ and German pegvisomant observational 
Study (GPOS) (6,7), in which patients using PEGV are included regardless their 
concomitant medication, observed lower efficacy rates around 60%, compared with 
the clinical trials of PEGV monotherapy and combination treatment (3,4,8,9). In the 
ACROSTUDY™ PEGV was combined with LA-SSA in 23%, with a dopamine agonist 
in 6%, and a combination of the three agents in 4% of patients. After five years the 
mean weekly dose was 106 mg in patients with a normal IGF-I, and 113 mg in those 
with an elevated IGF-I (9). However, these studies were not designed to evaluate 
efficacy and dose titration, but aimed for the evaluation of safety aspects, such as 
rare side effects. The lower efficacy rates in the observational registration studies 
might be explained by the relative lower dose of PEGV. To achieve efficacy rates of 
more than 90% during PEGV monotherapy, the average expected weekly dose is 
probably above 130 mg (3,4).
Escape, defined as the need to increase the dose of PEGV because of an 
increase in IGF-I levels during PEGV treatment, was reported in 34% of a Spanish 
cohort (10). The majority of patients was easily controlled with either an increase 
in PEGV dose, additional medical treatment or both. Whether this increase in 
the necessary dose of PEGV should be called an escape is questionable, as most 
patients were easily controlled and remained controlled on a higher dose of PEGV. A 
significant number of these patients escaped from PEGV within the first six months 
after discontinuation of LA-SSA. Presumably during this period these patients were 
actually still receiving combination treatment, due to the long half-life of LA-SSAs. 
The Rotterdam cohort could not observe this phenomenon during combination 
treatment in acromegaly patients, except for one patient which case is described 
in chapter 2 (2).
1.2 Tumor volume 
While LA-SSA is successful in reducing tumor volume, previous concerns were raised 
whether PEGV might induce growth of the pituitary adenoma. Despite the fact that 
in a few cases an increase in tumor size during PEGV therapy was reported, there are 
no data suggesting that PEGV directly promotes tumor growth (11-13). In the GPOS 
study, changes in tumor size were systematically monitored in 307 patients, from 
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which 28 patients were treated with PEGV in combination with LA-SSA, however 
predominantly treated with PEGV monotherapy (14). In eight out of 307 patients 
(2.7%) an initial increase in tumor size was reported, while none of them were 
treated with PEGV in combination with LA-SSA. In only three of these eight patients a 
real, but minor, clinically irrelevant increase in tumor size after PEGV treatment was 
observed (14). In two of these patients a detectable rebound increase in tumor size 
after discontinuation of LA-SSA therapy was the probable reason for this increase 
in adenoma size. In the three remaining patients a steady increase of the tumor 
was already ongoing before the start of PEGV. In a Spanish study in 75 patients, five 
(6.7%) acromegaly patients were identified with an increase in pituitary tumor size 
(15). All of these patients were pre-treated with LA-SSA and then switched to PEGV 
monotherapy. Noteworthy in this study is that the reference magnetic resonance 
imaging (MRI) was made just after LA-SSA was discontinued (15). Therefore, the 
reported tumor size increases in this study may also be explained by the rebound 
phenomenon after cessation of LA-SSA treatment.
 In the Rotterdam cohort of acromegaly patients (n=141) treated with 
combination therapy, growth of the adenoma has been reported in only one patient, 
while this growth was already ongoing before the addition of PEGV (2). Moreover, 
during combined treatment tumor size shrinkage of more than 20% of the largest 
diameter before and during combination treatment was observed in 17% of the 
patients and the vast majority had a stable tumor volume. In previous studies of 
our group similar data was observed. We, therefore, conclude that PEGV apparently 
does not influence the natural course of tumor growth, and the observed tumor 
shrinkage is most likely effectuated by the continuation of the LA-SSAs, also in 
combination with PEGV. However, ongoing alertness is required to monitor tumor 
size by repetitive pituitary imaging.  
1.3 Safety aspects 
The large observational studies, ACROSTUDY™ and GPOS, designed to evaluate side 
effects of PEGV, reported lipohypertrophy in 2.2 and 7.4% respectively (6,7). In the 
Rotterdam cohort four patients (2.8%) developed lipohypertrophy which appeared 
to be reversible by a more frequent rotation of the injection-site (2). However, in 
one of these patients during combined treatment cosmetic surgery was necessary 
in order to reduce the significant lipohypertrophy. 
PEGV-induced elevations in hepatocellular enzymes are usually mild and self-
limiting, both during monotherapy PEGV as in combination with LA-SSA (5,16,17). 
These transient elevated transaminases (TET) of more than three times the upper 
limit of normal (>3 xULN) seem to occur more frequently during the combination 
treatment (7,9). Previous studies observed TET >3 xULN in 11.1 -15.3% of the patients 
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using LA-SSA combined with PEGV (5,9,17). One Italian study compared long-term 
treatment of PEGV alone with PEGV in combination with LA-SSA regarding to TET 
(5). Incidence of TET during monotherapy of PEGV was reported in 14.3% of the 
patients, while this incidence was 11.1% in the combined group. In the Rotterdam 
cohort (n=19/141, 13.5%) all cases were transient without PEGV dose adaptation 
or discontinuation of the drug, except for one patient (2). The development of TET 
was not PEGV dose-dependent (2). The ACROSTUDY™ and GPOS reported lower 
incidence rates of TET >3x ULN, 2.5 and 5.2% respectively. More frequent outpatient 
clinic visits and, thereby, more frequent assessments of ALT and AST might explain 
the observed differences in the incidence of TET, as the elevations in transaminases 
are transient and will pass unnoticed when follow-up intervals are wider.
  A Spanish study (n=36) previously described an association between TET 
and Gilbert’s polymorphism (UGT1A1*28) (18). This is an autosomal recessive 
inherited benign condition and causes mild unconjugated hyperbilirubinemia, which 
is associated with a higher risk of hepatotoxicity during treatment with drugs that 
are metabolized by the liver. We did not confirm this association between TET and 
this polymorphism in the Rotterdam cohort. A Danish randomized controlled trial 
(n=18) demonstrated that during co-treatment of LA-SSA and PEGV, the intrahepatic 
lipid content of the liver increased significantly compared to the group treated with 
LA-SSA alone (19). Moreover, the intrahepatic lipid content was positively correlated 
with the PEGV dose, which is in contrast to the finding in the Rotterdam cohort. The 
authors of the Danish study stated that the clinical impact of this phenomenon 
remains unclear, however the increase in intrahepatic fat might causally be linked 
to TET in PEGV-treated acromegaly. More studies are needed to confirm or disprove 
this possible explanation for the development of TET. 
2. SOMATOSTATIN RECEPTOR EXPRESSION 
One of the most common and likely explanations for the need of the combination 
treatment in patients for which LA-SSA alone was not sufficient enough to normalize 
IGF-I levels, is less expression of somatostatin receptor subtype 2 (SSTR2) on the 
cell surface of GH-secreting pituitary adenomas. A previous study reported that 
full-responders to LA-SSA showed significant higher SSTR2 expression compared to 
partial-LA-SSA-responders (20). This study was solely performed in patients using 
LA-SSA monotherapy, we were the first to assess the expression of SSTR2 and 
SSTR5 in patients that needed the addition of PEGV to LA-SSA in order to control 
disease activity, chapter 3 of this thesis (21). The Rotterdam cohort, therefore, most 
likely represents severe acromegaly patients, who were referred to our tertiary 
referral center. A previous Norwegian study, also performed in a tertiary referral 
university hospital, used comparable techniques and scoring systems for the SSTR 
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expression (22). In this study treatment naive GH adenomas seems to have a lower 
SSTR2 expression (median immunoreactivity score (IRS) 9) compared to the SSTR2 
expression of our treatment-naive group (median IRS 6), suggesting that the receptor 
pattern in the Rotterdam cohort is already relatively low at baseline (21,22). Since all 
patients included in the Rotterdam cohort received PEGV in addition to LA-SSA, we 
were able to perform a correlation analysis. The SSTR2 IRS was inversely correlated 
with the required PEGV dose in treatment naive adenoma tissues.  
The other underlying hypothesis of chapter 3 was whether various medical 
pre-treatment modalities differently affect the SSTR2 and SSTR5 expression on 
GH-secreting pituitary adenomas. Therefore, we assessed the SSTR2 and SSTR5 
expression on GH adenomas in three pre-treatment groups: drug-naive, treated with 
LA-SSA monotherapy, or LA-SSA and PEGV combination therapy before surgery. We 
observed that the SSTR2 expression on GH adenomas is lower in patients treated 
with LA-SSAs in combination with PEGV, compared to drug-naive patients. Which 
could be explained by the presence of more severe acromegaly in this group as 
stated in the previous paragraph, however, down-regulation of cell surface SSTR2 
by LA-SSA treatment should not be neglected (22-24). The previously described 
Norwegian study demonstrated down-regulation of SSTR2 by LA-SSA treatment in a 
randomized subset of acromegaly patients (n=13 mono LA-SSA, n=13 direct surgery)
(22), possibly through ligand-induced receptor internalization. In the Rotterdam 
cohort, the median duration of LA-SSA before surgery was 20 months in the group 
of patients that was pre-treated with LA-SSA and PEGV. 
Some limitations of the study in chapter 3 have to be taken into account during 
data interpretation, which are; 1) a rather small sample size; 2) the retrospective 
design of the study, including missing data; 3) the majority of the cohort represents 
severe acromegaly patients, as PEGV was needed to control IGF-I levels. However, 
these limitations are unavoidable as acromegaly is a rare disease and the combination 
of LA-SSA and PEGV is not the first-line treatment modality. 
3. EFFECT OF THE EXON 3-DELETED GH-RECEPTOR 
Transfection studies have shown that the lack of exon 3 in the GHR enhances GH signal 
transduction in vitro (25), and clinical data in the field of GH-deficiency suggested 
that this polymorphism confers a better response to recombinant GH replacement 
in GH deficient children (26). However, genome-wide association studies in the 
general population did not report any association with the GHR locus in healthy 
individuals concerning GH-targets such as final height and metabolic state (27-29). 
Studies evaluating the influence of d3-GHR on clinical and biochemical severity of 
acromegaly, produced contradictory evidence (30,31). Since GH-deficient children 
carrying d3-GHR have benefitted more from their recombinant GH treatment, this 
143
General discussion 
7
pharmacogenetic phenomenon could be of importance in PEGV-treated acromegaly. 
The results in chapter 4 and 5, reflecting the Rotterdam cohort and a meta-analysis 
of several European cohorts, both did not show a significant effect on the response 
of PEGV treatment nor on the required PEGV dose between fl/fl-GHR and d3-GHR 
carriers (32,33). 
The first two published studies reporting the effect of d3-GHR genotype on 
PEGV-pharmacodynamics in acromegaly observed beneficial effects regarding 
d3-GHR carriers, which was performed in a cohort of 19 and 44 patients (34,35). 
Hereafter, two larger acromegaly cohorts (n=104 and n=127) were published 
regarding this topic, which could not confirm these previous findings (33,36). These 
later findings were additionally confirmed, as the PEGV dose and PEGV serum levels 
in the circulation were not significantly different between carriers of the d3-GHR 
genotype and the fl/fl-GHR genotype in the Rotterdam cohort (33). It could be 
argued that the effect of the first two studies have been founded by coincidence as 
the sample size is limited. Moreover, publication bias can be present in the beginning 
of this publication series about the effect of d3-GHR in PEGV-treated acromegaly. 
On the other hand, the sample sizes of the two cohorts in the last negative studies, 
though with reasonably more patients, could also be too small to observe an effect. 
However, these phenomena always lurk whenever investigating a rare disease such 
as acromegaly. 
To strengthen the evidence, we conducted a meta-analysis in which these 
acromegaly cohorts were pooled together. The results of this study demonstrated 
that the response of PEGV treatment and the required PEGV dose, when tested 
in 324 acromegaly patients, was not affected by the d3-GHR genotype. A recent 
Brazilian study confirmed these findings in a large multiethnic cohort (n=121) 
addressing several aspects; clinical/biochemical data and treatment outcomes 
(37). No significant differences were observed between patients harboring at least 
one d3-GHR allele and those harboring the fl/fl-GHR genotype regarding medical 
treatment response (LA-SSA monotherapy, LA-SSA combined with cabergoline and 
PEGV monotherapy). More specific, the median IGF-I reduction during PEGV in this 
study (n=14, not included in the meta-analysis of chapter 5) was not significantly 
different between the two genotypes (p=0.829). Another possibility is that the effect 
of the d3-GHR isoforms are very slight, and cannot be objectified. We, therefore, 
state that the effect of d3-GHR is at least not clinically relevant during PEGV-dosing. 
4. PREDICTION OF THE REQUIRED PEGV DOSE COMBINED 
WITH LA-SSA
The required dose of PEGV to achieve disease control is highly variable between 
individual acromegaly patients, likewise is the variation in inter-individual PEGV 
Chapter 7
144
serum levels despite identical PEGV doses (38,39). A tailored approach for each 
individual is therefore required during PEGV dose titration. As previously described 
in chapter 4 and 5, the common polymorphism d3-GHR did not have an influence 
on PEGV response and dosing. Chapter 6 of this thesis did identify predictors for 
PEGV dosing, which we used to develop a multivariable model in order to predict 
the required PEGV dose to achieve disease control in acromegaly patients. IGF-I, 
weight, height and age at diagnosis are associated with the PEGV dose required for 
normalization of IGF-I levels in patients treated with LA-SSA combined with PEGV. In 
patients treated with PEGV monotherapy only weight is associated with the PEGV 
dose required for normalization of IGF-I levels. 
GH levels reported in chapter 6 were not associated with the required PEGV 
dose, despite their biological plausibility as a candidate predictor. This is most likely 
caused by the variability of the GH-assays included in our study. GH measurements 
included in the study were performed in several local hospitals and therefore by 
different GH-assays, which can lead to measurement errors and a bias during the 
analysis. Besides, GH has a short half-life and is excreted by the pituitary in a pulsatile 
manner, which makes it as a biomarker less suitable in clinical practice. Analyses can 
be improved with GH measurements performed with one single assay and a blood 
sample that is withdrawn on a standard time point in the morning or, even more 
reliable an average of several standardized measurements during one day. 
Disease severity differs between acromegaly patients using the combination 
treatment in our study. The cohort contains patients from the Rotterdam cohort 
(n=112) and the Liège Acromegaly Survey cohort (LAS, n=76). The LAS cohort is 
created by a software tool which enables hospitals throughout Europe to include 
data reporting patient characteristics and treatment modalities. PEGV doses in 
combination with LA-SSA required for IGF-I normalization of the LAS cohort are 
strikingly higher (median 210 mg/week) compared to the Rotterdam cohort (median 
80 mg/week). Additionally, IGF-I levels expressed as ULN before the addition 
of PEGV are significantly higher in the LAS patients compared to the Rotterdam 
cohort. Although, differences between the various IGF-I-assays which were used 
in the different cohorts should be taken into account. The LAS cohort probably 
reflects the presence of the more severe cases of Europe, while in Rotterdam the 
threshold for prescribing PEGV in addition to LA-SSA is relatively lower and thereby 
the Rotterdam cohort contains less severe acromegaly patients. However, we 
believe that by combining these two acromegaly cohorts treated with LA-SSA and 
PEGV a wide range of acromegaly patients is represented in this study, and that 
the results therefore are widely generalizable in clinical practice during the start of 
PEGV treatment in addition to LA-SSA. 
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5. CONCLUSION
In this thesis we have confirmed that LA-SSA in combination with PEGV as a 
treatment modality for acromegaly appears to be highly effective after experience 
for almost a decade in the Rotterdam cohort, provided that the required PEGV dose 
is used in order to control IGF-I levels. Side effects as lipohypertrophy and elevated 
transaminases were mild and transient. Tumor size control or even tumor shrinkage 
is observed in a vast majority of patients. 
Normalization of IGF-I levels in acromegaly patients is associated with the 
expression of SSTR2 on somatotroph adenomas. In the Rotterdam cohort, the SSTR2 
expression was lower in patients pre-treated with LA-SSA and PEGV compared to 
drug-naive acromegaly patients after transsphenoidal surgery. Moreover, a higher 
required PEGV dose in combination with LA-SSA was needed in patients with a lower 
SSTR2 expression on drug-naive somatotroph adenomas to achieve normalized 
IGF-I levels. (Partial) resistance for LA-SSA alone could be one of the reasons why 
these patients with a lower SSTR2 expression necessitate LA-SSA in combination 
with PEGV. 
The common polymorphism d3-GHR is associated with disease severity and it 
has been reported to be more responsive to PEGV treatment in acromegaly patients. 
Clinical data of the Rotterdam cohort do not support a role for GHR genotype in 
treatment response or PEGV dosing in patients treated with LA-SSA in combination 
with PEGV. A meta-analysis obtained from four separated study cohorts including 
the Rotterdam cohort (n=324), confirmed that the presence of the d3-GHR in 
acromegaly patients has no impact on clinical practice. 
Finally, the last study of this thesis did identify predictors for PEGV dosing. IGF-I 
levels, weight, height and age are associated with the optimal PEGV dose in order to 
normalize IGF-I levels in addition to LA-SSA. The IGF-I normalization dosage during 
PEGV monotherapy is only associated with the patient’s weight. A multivariate 
prediction model which can be used as a clinical guidance tool for PEGV dosing in 
addition to LA-SSA can be found in chapter 6. 
6. FUTURE PERSPECTIVES
Long-term data of the combination treatment in acromegaly presented in this thesis, 
confirm the high efficacy rates and generally well tolerated side effects reported by 
the first clinical PEGV-trials, more than a decade ago (3,4). However, acromegaly 
progresses slowly, therefore, long periods of follow-up data remain mandatory to 
assess more accurately the long-term outcome of its efficacy and safety profile but 
also data on morbidity and mortality, as we do already know from LA-SSAs alone 
which are on the market since 1988. A challenge for the future is to optimize the 
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quality of data. The studies performed in this thesis contain two main limitation; 
1) the retrospective study design and; 2) the small sample sizes. However, these 
limitations are not unexpected and are a common issue during the investigation 
of a rare disease such as acromegaly, especially as only a subset of the patients is 
treated with a combination of LA-SSA and PEGV. Although, we here present the 
largest single center cohort to date that uses PEGV in combination with LA-SSA. In 
order to overcome these limitations and to replicate our results, prospective studies 
utilizing a multicenter set-up are required, which is particularly the case for the next 
study focusing on the SSTR expression during combination treatment. 
Physicians tend to be mainly focused on biochemical parameters as GH and 
IGF-I levels during treatment of acromegaly. These parameters are definitely linked 
to a better outcome and a lower risk of morbidity and mortality (40,41). However, 
normalized serum GH and IGF-I levels do not necessarily result in complete 
resolution of signs and symptoms (42,43). A prospective, double blind, placebo 
controlled, crossover study demonstrated improved quality of life (QoL) in patients 
using LA-SSA combined with low-dose PEGV (43). Improved QoL was observed 
without significant changes in IGF-I levels after addition of PEGV to LA-SSA therapy 
in patients with normalized IGF-I levels during monotherapy of LA-SSA. Two things 
can be derived from this study; 1) new parameters are needed in the future for 
monitoring patients with acromegaly and; 2) less severe acromegaly patients can 
also benefit from the addition of pegvisomant to LA-SSA, not only the patients with 
partial response to LA-SSAs. Especially, since side effects remain mild and transient 
over time, as reported in chapter 2. 
New medical treatment modalities for clinical practice are being examined. A 
phase III study recently demonstrated that oral octreotide, designed for absorption 
in the gut, is able to decrease GH and IGF-I levels with a favorable safety profile in 
patients previously controlled by LA-SSA injections. This is particularly appropriate 
for patients with injection site reactions besides its practical comfort, given that 
injects are unnecessary. (44). For the nearby future, when this drug is on the market, 
studies can be done to investigate a combination of oral octreotide and PEGV. 
Another agent which might be suitable for combining with PEGV is pasireotide, a 
multireceptor ligand with high affinity for SSTR5. Striking in chapter 3 of this thesis, 
is the overall high expression profile of SSTR5 in the patients selected from the 
Rotterdam cohort after surgery. Other studies reported that the drug provides 
biochemical control in naive patients as well as patients that were controlled by 
LA-SSA and were switched to pasireotide (45,46). However, the drug is associated 
with high rates of hyperglycemia, which limits its usefulness as this is already one 
of the problems to overcome in acromegaly patients (47). An attractive option in 
the future for patients that do not tolerate the diabetic effects of pasireotide might 
be DG3173 (somatoprim). This is a ligand with a pharmacokinetic profile similar to 
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LA-SSA but highly selective for GH suppression and has less inhibitory effects on 
insulin secretion (48). However, it is still unknown how the mechanism behind this 
pancreatic protection works. Currently, DG3173 is being tested in a phase II trial 
in acromegaly patients (49). The above sentences present alternative agents that 
directly target the GH-secreting adenoma, but not an alternative for PEGV, which 
acts on the peripheral tissues. Another approach to reduce peripheral GH-activity 
is via ATL1103, an antisense oligonucleotide which targets the GHR synthesis (50). 
This agent knocks down the gene in the liver that encodes the GHR, and thereby 
reduces GHR expression on the hepatocyte surface (51). This agent is still in an early 
stage of development, as a phase II study recently showed decreased levels of IGF-I 
after ALT1103 injection treatment (52). The future will show whether DG3173 and 
ATL1103 are suitable for clinical practice after later stage clinical trials. 
PEGV dose prediction remains a challenge in the future, although chapter 6 
of this thesis presents a real step forward by describing a clinical guidance tool for 
the start of PEGV dose titration. This clinical tool can be improved by the inclusion 
of more acromegaly patients in a multi-center prospective study design. Although, 
I personally believe that a real breakthrough will rise when the mode of PEGV-
clearance is understood. Nowadays, we still do not know whether the drug is 
completely metabolized in the liver or if the kidney is playing a role during this 
process. One study demonstrated that PEGV together with the GHR, is internalized 
into GHR-expressing cells (53). A possibility is that during trafficking of this ligand, 
degradation occurs with loss of PEGylated moieties, which might be a clue for the 
final answer, which hopefully will be found in the nearby future.
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LIST OF ABBREVIATIONS
AcroQoL Acromegaly quality of life questionnaire
AE  Adverse event
AGT1A1*28 Gilberts polymorphism
AIP  Aryl hydrocarbon receptor-interacting protein
Alk Phos Alkaline phosphatase
ALT  Alanine aminotransferase 
AST  Aspartate aminotransferase
BBB  Blood brain barrier
Bili  Total bilirubin
CAB  Cabergoline
CON  Control
D3-GHR Growth hormone receptor polymorphism lacking exon 3
DA  Dopamine agonist
DM  Diabetes mellitus type II 
FIPA  Familial isolated pituitary adenoma
Fl-GHR  Full-length growth hormone receptor
GH  Growth hormone
GHrH  Growth hormone releasing hormone
GHR  Growth hormone receptor
GPOS  German pegvisomant observational study
HE  Haematoxylin eosin
HPRT  Hypoxanthine phosporibosyltransferase  
HWE   Hardy-Weinberg equilibrium
IGF-I   Insulin-like growth factor I
IQR  Interquartile range
IRS  Immunoreactivity score
JAK2  Janus kinase 2
LAS  Liège acromegaly survey
LA-SSA  Long-acting somatostatin analogue
MONO  Monotherapy
MRCP  Magnetic resonance cholangiopancreatography
MRI  Magnetic resonance imaging
NA  Not applicable
ND  Not determined
OCT  Octreotide
PASQ  Patient-assessed acromegaly symptom questionnaire
PCR  Polymerase chain reaction
PEGV  Pegvisomant
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PRL  Prolactin
QoL  Quality of life
Q-PCR  Quantitative polymerase chain reaction
rhGH   Recombinant growth hormone
SDS  Standard deviation score
SE   Standard error
SRIF  Somatotropin releasing-inhibiting factor
SSTR  Somatostatin receptor
STAT  Signal transducer and activator of transcription
TET  Transient elevated transaminases
TSS  Transsphenoidal surgery
ULN  Upper limit of normal 
X-LAG  X-linked acrogigantism
γ-GT  γ-glutamyl transpeptidase
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SUMMARY
In chapter 2 of this thesis we have confirmed that LA-SSA in combination with PEGV 
as a treatment modality for acromegaly still appears to be highly effective, after 
almost a decade of experience in the Rotterdam cohort (n=112). Normalization of 
IGF-I levels occurred in 97% of the patients, provided that the required PEGV dose 
was used. The median PEGV dose to achieve this efficacy rate was 80 mg/week 
[interquartile range: 60 – 120 mg]. Side effects such as lipohypertrophy (2.8%) and 
elevated transaminases of more than three times the upper limit of normal (13.5%) 
were mild and transient (n=141). Tumor size control and even tumor shrinkage is 
observed in a vast majority of patients. Pituitary tumor size increase was observed 
in one patient.
Normalization of IGF-I levels in acromegaly patients is associated with the 
expression of SSTR2 on somatotroph adenomas. In the Rotterdam cohort (n=39), 
the SSTR2 expression was lower in patients pre-treated with LA-SSA and PEGV 
compared to drug-naive acromegaly patients after transsphenoidal surgery, which 
is described in chapter 3. Moreover, a higher required PEGV dose in combination 
with LA-SSA was needed in patients with a lower SSTR2 expression on drug-naive 
somatotroph adenomas to achieve normalized IGF-I levels. (Partial) resistance for 
LA-SSA alone could be one of the reasons why these patients with a lower SSTR2 
expression necessitate LA-SSA in combination with PEGV. 
Chapter 4 and 5 focus on the common growth hormone polymorphism lacking 
exon 3, which is associated with disease severity and has been reported to be 
more responsive to PEGV treatment in acromegaly patients. Clinical data from the 
Rotterdam cohort (n=112) does not support a role for GHR genotype in treatment 
response or PEGV dosing nor PEGV serum levels in patients treated with LA-SSA in 
combination with PEGV. A meta-analysis obtained from four separate study cohorts 
including the Rotterdam cohort (n=324), confirmed that the presence of the d3-
GHR in acromegaly patients has no impact on clinical practice. The polymorphism 
was not of added value for either the determination of the required PEGV dose or 
the prediction of PEGV responsiveness.  
Finally, the last study of this thesis did identify predictors for PEGV dosing. 
IGF-I levels, weight, height and age are associated with the required PEGV dose in 
order to normalize IGF-I levels in addition to LA-SSA. The IGF-I normalization dosage 
during PEGV monotherapy is only associated with patients weight. A multivariate 
prediction model which can be used as a clinical guidance tool for PEGV dosing in 
addition to LA-SSA can be found in chapter 6. 
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SAMENVATTING
In hoofdstuk 2 van dit proefschrift hebben we aangetoond dat somatostatine 
analoga met gereguleerde afgifte in combinatie met pegvisomant een zeer 
effectieve behandeling is voor acromegalie patiënten na bijna tien jaar ervaring 
binnen het Rotterdam cohort (n=112). In 97% van de patiënten normaliseerden 
de IGF-I waarden, mits zij de juiste dosering pegvisomant kregen toegediend. De 
mediane pegvisomant dosering om het IGF-I te normaliseren is 80 mg per week. 
Bijwerkingen als lipohypertrofie (2.8%) en verhoogde transaminasen van meer dan 
drie keer de bovengrens van normaal (13.5%) bleken mild en van voorbijgaande 
aard te zijn (n=141). In de overgrote meerderheid van de patiënten is het volume 
van de tumor niet toegenomen, in een gedeelte van de patiënten is de tumor zelfs 
afgenomen. Bij slechts een patiënt was het volume van de tumor toegenomen 
tijdens de combinatie-therapie. 
 Normalisatie van IGF-I waarden in acromegalie patiënten is geassocieerd 
met de expressie van de somatostatine receptor subtype 2 (SSTR2) op het oppervlak 
van groeihormoon producerende adenomen. Binnen het Rotterdam cohort was de 
SSTR2 expressie lager in patiënten die waren voorbehandeld met somatostatine 
analoga in combinatie met pegvisomant dan bij patiënten die nog geen medicatie 
hadden gekregen na transsfenoïdale chirurgie, zoals beschreven staat in hoofdstuk 
3 van dit proefschrift. Bovendien hadden patiënten met een lagere SSTR2 expressie 
een hogere dosering pegvisomant nodig in combinatie met een somatostatine 
analoog. (Partiële) resistentie voor monotherapie met een somatostatine analoog 
kan een van de redenen zijn waarom patiënten met een lager SSTR2 expressie een 
combinatie van somatotatine en pegvisomant nodig hebben om de ziekte onder 
controle te krijgen. 
 Hoofdstuk 4 en 5 gaan over een veel voorkomend groeihormoonreceptor 
polymorfisme waarbij exon 3 ontbreekt (d3-GHR), dat geassocieerd is met de ernst 
van de ziekte en wordt beschreven als effectiever reagerend op pegvisomant in 
acromegalie patiënten. Klinische data van het Rotterdam cohort (n=112) wijzen uit 
dat de pegvisomant dosering en de spiegel pegvisomant in het bloed niet worden 
beïnvloed door d3-GHR in patiënten die behandeld worden met pegvisomant 
in combinatie met somatostatine analoga. Een meta-analyse, verkregen door 
vier aparte cohorten inclusief het Rotterdam cohort (n=324), samen te voegen, 
bevestigde dat het voorkomen van d3-GHR in acromegalie patiënten geen invloed 
heeft op de klinische praktijk. Het polymorfisme had geen invloed op de pegvisomant 
dosering noch, op het kunnen voorspellen van de effectiviteit van pegvisomant. 
 De laatste studie die is opgenomen in dit proefschrift identificeerde factoren 
om de pegvisomant dosering te voorspellen. IGF-I waarden, gewicht, lengte en 
leeftijd waren geassocieerd met de uiteindelijke dosering pegvisomant die nodig 
was om de IGF-I waarden te normaliseren, in combinatie met een somatostatine 
analoog. De dosering die nodig was voor het onderdrukken van de ziekte tijdens 
monotherapie pegvisomant was alleen geassocieerd met het gewicht. Een 
multivariaat predictie model dat gebruikt kan worden als een hulpmiddel tijdens 
het doseren van pegvisomant in combinatie met een somatostatine analoog, is te 
vinden in hoofdstuk 6. 
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naam Vat. Lieve Marijk, wat is het leuk als een van je beste vriendinnen hetzelfde 
pad bewandeld, als je zelf doet. Zelfs onze verdediging valt in dezelfde maand. Ik 
heb met plezier alle vreugden en frustraties met je kunnen delen de afgelopen jaren 
en dat zetten we voort tijdens onze opleiding binnen de interne geneeskunde. Youri 
en Nien, jullie ook bedankt voor de gezelligheid, relativering en support. Ik ben 
zeer benieuwd naar jullie uiteindelijke proefschriften. Voor tips weten jullie me te 
vinden. 
Lieve Mam, vaak maakte je je zorgen om mij met al je lieve bedoelingen. 
Gelukkig, zag je ook dat het goed met mij ging en ik me ontwikkeld heb. Zodoende 
heb je mij altijd gesteund en kon ik mijn verhaal bij je kwijt. Zonder jouw steun en 
die van pap, was ik nooit zover gekomen. 
Lieve Pap, maar enkele dochters kunnen zeggen dat hun vader een inhoudelijk 
aandeel heeft kunnen leveren aan de vorming van hun proefschrift. Je dacht mee 
en gaf me advies ten aanzien van de IGF-I en GH assays. Zodoende had je altijd een 
bovengemiddelde interesse, niet alleen als vader, maar ook als onderzoeker. Succes 
met je laatste artikelen die je nog wil schrijven voordat je met je welverdiende 
pensioen gaat. 
Lieve Louk, wat ben ik gezegend met een zus als jij. Je hebt er voor gezorgd dat 
veel stress me gespaard is gebleven, het mooiste cadeau is dat je mijn boekje een 
mooi design hebt gegeven en dat met een persoonlijke en zeer professionele touch. 
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Ik ben trots op je en werk in de toekomst graag nog meer met je samen! Twan, 
bedankt dat je nadat Louk klaar was met de vormgeving, alles nog inhoudelijk een 
keer hebt gecontroleerd voor me. Je weet het, ik sta bij je in het krijt, dus denk aan 
me op het moment dat jouw boekje klaar is voor de drukker.  
Lieve Tim, mijn grootste fan, zelfs als ik kribbig was op de momenten dat 
meerdere dingen tegelijk af moesten zijn en vele avonden en weekenden vol 
gepland stonden met promotie gerelateerde activiteiten. Bedankt, voor je begrip 
en support van de afgelopen jaren. Daarnaast heb je ook wezenlijk bijgedragen aan 
mijn promotie traject. Zo heb je Roxanne, Kimberly en ik voorzien van een goeie 
laptop. Heb je mij in het begin direct opgevoed wat betreft veiligheid van data en 
heb je mij geholpen met het vormgeven van meerdere figuren en het nakijken van 
enkele teksten. In tijden van drukte zorg jij nog altijd voor een rustige basis waar ik 
op terug kan vallen.
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